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Summary of Thesis
In the adult, changes in free ionized plasma calcium concentration ([Ca2+]0) are 
monitored by the G-protein-coupled, extracellular calcium-sensing receptor, CaR, 
but whether CaR plays a role in lung development is unknown. CaR has the 
potential to be a key regulator of Ca2+ dependent cell fate during development. It is 
hypothesized that extracellular calcium is an important extrinsic factor that 
modulates the intrinsic lung developmental programme, through activation of the 
CaR. CaR is expressed in the developing mouse lung in the pseudoglandular phase, 
from embryonic day 10.5 (E l0.5), with a peak of expression at E l2.5 and a 
subsequent decrease by E l8 , after which the receptor is absent. Lung branching 
morphogenesis in vitro is sensitive to [Ca2+]0, being negatively modulated by the 
higher, fetal (i.e., 1.7 mM) [Ca2+]0 yet optimal at physiological adult [Ca2+]c (i.e., 
1.05-1.2 mM). Administration of the specific CaR positive allosteric modulator, the 
calcimimetic R-568, mimics the suppressive effects of high Ca2+0 on branching 
morphogenesis while both phospholipase C and PI3 kinase inhibition reverse these 
effects. CaR activation suppresses cell proliferation while it enhances lung 
distension, fluid secretion and intracellular calcium signalling. Conditions which are 
restrictive to branching and fluid secretion can be rescued by manipulating [Ca2+]0 in 
the culture medium. Lung explant cultures from the current mouse model of CaR 
inactivation respond in a similar manner to [Ca2+]0 and the calcimimetic R-568. 
These results indicate the presence of expression of a functional CaR splice variant, 
which is detected at El 1.5, 12.5 and 15.5 in CaR knockout lungs. The observations 
presented here support a novel role for the CaR in preventing hyperplastic lung 
disease in utero and present two potential models for its mode of action within this 
system.
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GENERAL INTRODUCTION
13
1.1 Ionic Calcium
The observation by Sidney Ringer in 1883 showing that calcium (Ca2+) was 
necessary to maintain the contractions in isolated rat hearts (Ringer, 1883) moved 
Ca2+ from the realm of inert structural element to that of an active signalling 
molecule. Over time Ca2+ has been studied for its activity in muscle contraction 
(Weber et a l , 1964), eventually being recognised for its role throughout the body 
and cellular life. Several proteins were characterised for their ability to bind Ca2+ and 
modulate its activity within the cell; including EF hand proteins which change 
conformation upon binding to Ca2+, as well as Ca2+ channels which do not directly 
process the Ca2+ signal, but can be targets of Ca2+ regulation (Carafoli, 2002).
Ca2+ waves that spread from a point within the cell throughout its cytoplasm 
were first observed in fertilized oocytes (Ridgway et a l ,  1977) followed by 
repetitive oscillations, initially seen in hepatocytes (Woods et a l ,  1987). Ca2+ wave 
oscillations of several different kinds have now been observed in almost every cell 
type tested. The variation in the type and shape of the oscillations is a way in which 
the Ca2+ signal can be deciphered. Ca2+ can act as a first messenger, initiating 
increases in intracellular Ca2+concentration ([Ca2+]j) and as a second messenger 
within a signalling pathway (Carafoli, 2002). For instance, Ca2+ can both protect 
cells from, or promote cells into, undergoing apoptosis, either of which require a 
different signalling pattern (Orrenius et a l ,  2003). For example, human tracheal 
epithelial cells have increased proliferation in high calcium conditions, whereas they 
differentiate with little proliferation in low calcium conditions (Chopra et a l ,  1990). 
However, sustained increases or decreases in Ca2+ levels can interfere with Ca2+ 
signalling and are detrimental to cellular health and functioning. Therefore the
14
concentration of extracellular Ca2+ ([Ca2+]0) must be globally and locally controlled 
within the body.
1.2 Evidence for a Membrane-bound Calcium Sensing Receptor
In the systemic context, Ca2+0 levels regulate the secretion of parathyroid 
hormone (PTH) from the parathyroid glands. Initial studies found that in dissociated 
bovine parathyroid tissue, increasing [Ca2+]0 from 0.5 mM up to 2 mM increased 
[Ca2+]i concentrations while inhibiting PTH secretion, where PTH secretion was 
measured by radioimmunoassay (Shoback et al ,  1983). This suppression of PTH 
secretion was considered unusual in the context of other secretory systems where 
increases in [Ca2+]i normally promote secretion (Douglas, 1978). Further 
investigation into this phenomenon showed that the suppression of PTH secretion 
was accompanied by increases in [Ca2+]j, which could also be induced by the 
divalent cation ionophore ionomycin in the presence of 1 mM Ca2+0. This response 
was similar to changes produced with 1.5 mM Ca2+0 alone. The results of this study 
increased the evidence for parathyroid cells having an inverse relationship between 
[Ca2+]j and PTH release, leading to the hypothesis that the parathyroid cell contained 
a mechanism to detect small changes in [Ca2+]0 that could induce large changes in 
[Ca2+]j (Shoback et al ,  1984).
As stated in the previous section, Ca2+0 can initiate different types of [Ca2+]i 
responses which determine the type of cellular response (Carafoli, 2002). Nemeth 
and Scarpa (1987) detailed that there were two different types of [Ca2+]i response to 
Ca2+0 in bovine parathyroid cells. These responses were: 1. An increase in the steady 
state level of [Ca2+]i, and 2. A transient increase in [Ca2+]j. Each of these two 
responses occurs via a different mechanism for releasing Ca2+ into the cytoplasm, as
15
evidenced by their differential sensitivity. In bovine parathyroid cells, La3+ (10 pM) 
and high concentrations of Mg2+ (8  mM, above the concentration that evokes 
transient increases in [Ca2+]j) block transmembrane influx of extracellular Ca2+from 
raising the steady-state [Ca2+]i. The dynamics of the responses to La3+ and high 
concentrations of Mg2+ were not sensitive to nifedipine and were only partially 
sensitive to verapamil which indicated the presence of membrane-bound ion 
channels. The transient [Ca2+]i increases were elicited by various divalent cations, 
including Ca2+0, but could also be produced by certain membrane-impermeant 
cations in the absence of Ca2+0, indicating that the transient increases in [Ca2+]i were 
the result of Ca2+i release from within the cell itself. Therefore these do not 
necessarily enter the cell but react at the membrane, presumably at a receptor which 
is sensitive to physiological millimolar concentrations of cations (Nemeth & Scarpa, 
1987). Evidence that the interaction of cations, particularly Ca2+ and Mg2+, occur at a 
membrane-bound receptor came from studies again using dispersed bovine 
parathyroid cells. It was shown that Ca2+ and Mg2+ quickly instigate an increase in 
inositol 1,4,5-trisphosphate (IP3), with Ca2+ being more potent than Mg2+in 
producing a response. This change in IP3 was consistent with phospholipase C (PLC) 
activation, known in other cells to be coupled to G-protein activation (Brown et a l , 
1987).
1.3 Cloning of the Extracellular Calcium-Sensing Receptor
The receptor responsible for these responses was cloned by Brown et al. in 
1993 from mRNA isolated from calf parathyroid glands and was named bovine 
parathyroid calcium-sensing receptor (BoPCaRl). Hydropathy plots provided the 
potential structure of this receptor; 1085 total amino acids with 613 of these making
16
a large extracellular amino-terminus, 250 amino acids making up seven 
transmembrane domains and 222  amino acids constituting a cytoplasmic carboxy- 
terminus. This structure is characteristic of the G-protein-coupled receptor (GPCR) 
superfamily; specifically the Group C GPCRs which include y-aminobutyric acid 
(GABA) receptors, odorant and pheromone receptors as well as taste receptors 
(Chang & Shoback, 2004). BoPCaRl was found to have conserved regions similar to 
other Group C GPCRs, namely the metabotropic glutamate receptors (mGluRs), 
mGluRl and mGluR5. Transcripts of this receptor were also detected in bovine 
kidney, thyroid and some brain regions by Northern blot analysis (Brown et al., 
1993).
X. laevis oocytes injected with BoPCaRl cRNA were used for functional 
characterisation of this receptor because, when phosphatidylinositol (Ptdlns) coupled 
receptors are expressed in this cell type, endogenous inward currents from Ca2+- 
activated Cl' channels are activated in response to agonists. These responses were 
instigated by release of Ca2+i from intracellular stores via activation of PLC (Brown 
et al., 1993). Oocytes expressing BoPCaRl responded with large inward currents in 
a dose dependent manner to application of Ca2+, Mg2+, Gd3+ and neomycin. The 
EC50 values in this system for Ca2+= 3 mM, Mg2+ = lOmM, Gd3+ = 20 pM and 
neomycin = 60 pM were nearly identical to values previously determined on isolated 
bovine parathyroid cells (Brown et al., 1993). Similar structural and functional 
results were also obtained from a homologous rat extracellular calcium-sensing 
receptor (RaKCaR) cloned shortly after BoPCaRl from a rat kidney cDNA library 
(Riccardi etal.,  1995).
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Receptors with significant homology to BoPCaRl have since been cloned 
from human parathyroid (Garrett et al., 1995a) and kidney (Aida et al., 1995), rat 
thyroid (Garrett et al., 1995b) and brain (Ruat et al., 1995), rabbit kidney (Butters et 
al., 1997), human and mouse bone marrow cells (House et al., 1997). Other 
homologous receptors have been cloned from non-mammalian species, including 
chicken (Diaz et al., 1997) and fish (Loretz et al., 2004), suggesting an 
evolutionary conserved role for this receptor as a part of the Ca2+0 homeostatic 
system. As it has widespread species and tissue distribution, this receptor is 
generally referred to as the extracellular calcium-sensing-receptor (CaR).
Immunoblotting of endosomal proteins from rat kidney with CaR-specific 
antisera revealed multiple CaR species with molecular weights of 121, 138-169 and 
240-310 kDa. When these proteins were solubilised and subjected to density gradient 
ultracentrifugation, CaR immunoreactivity detected a species of approximately 220 
kDa that was not associated with any complex-bound G-proteins, but consisted of a 
dimeric CaR that was only partially dissociated by standard denaturing and reducing 
conditions. Upon addition of Ca2+ or Gd3+ to solubilised CaR, detection of the 
monomeric (121, 138-169 kDa) CaR species decreased while detection of the 
dimeric (240-310 kDa) species increased; suggesting that the binding of di- and tri- 
valent cations to the CaR stabilises dimerization of the receptor (Ward et al., 1998).
Further studies using immunoprecipitation of Flag-tagged human CaR 
expressed in human embryonic kidney 293 (HEK293) cells showed that monomeric 
CaR protein was detected in the cell membrane. When non-reducing conditions were 
used (sample buffer lacking DTT) immunoprecipitation revealed that detection of the 
monomeric species was replaced with detection of the dimeric species. Cross-linking 
studies along with the detection of the dimeric CaR in non-reducing conditions
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further confirmed that the CaR resides at the cell membrane as di-sulfide bonded 
homodimers (Bai et al., 1998).
The Ca2+ homeostatic activity of the CaR in the parathyroid is then mediated 
by homodimers of CaR in the cell membrane that detect small changes in [Ca2+]0. 
Activation or inactivation of the CaR controls the secretion of PTH, that in 
conjunction with its effectors controls the excretion and absorption of Ca2+ 
throughout the body (Fig. 1.1). In the kidney, for example, reduction of PTH 
secretion during hypercalcemia allows for urinary excretion of excess Ca2+ thus 
contributing to the restoration of normal Ca2+ levels in the body (Ward & Riccardi, 
2002).
1.4 Differential Expression with Differential Activity
To date the CaR has been found to be expressed in at least 14 different tissue 
types, for a comprehensive review see Brown and MacLeod, 2001. Obviously, not 
all of these are involved with Ca2+ homeostasis and therefore, the fact that the CaR 
can perform different functions depending upon the type of tissue in which it is 
expressed should come as no surprise. A summary of some of the localities where 
the CaR is expressed and its biological responses to agonists in those areas is 
presented in Table 1.1. As the activity of the receptor in the parathyroid gland has 
already been detailed in Section 1.2 and 1.3, other tissues which may be relevant to 
the results of this study are detailed below.
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Figure 1.1: Schematic representation of Ca2+0 homeostasis. The CaR initiates its G- 
protein mediated signalling pathways when extracellular ionized Ca2+([Ca2+]0) levels 
are within physiological ranges (1.2 mM in adults). When there is a drop in [Ca2+]0 
CaR becomes inactive allowing for secretion of parathyroid hormone (PTH) from 
the parathyroid glands. This hormone affects the kidney, intestine and bone and 
causes them to reabsorb Ca2+0 feeding it back into circulation to raise extracellular 
ionized Ca2+ levels, reactivating the CaR and suppressing PTH secretion.
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Table 1.1: Localities of CaR expression and responses to CaR agonists.
Cell / Tissue Signalling Initiated Biological Responses Reference
Parathyroid gland PLC activation, increased 
[Ca2+]i, ERK1/2 activation
Inhibition of PTH secretion, gene expression 
changes, tonic suppression of proliferation
(Brown et al., 1993; Kifor 
et al ,  2 0 0 1 )
Keratinocytes Production of inositol 
triphosphate (IP3), interaction 
with PLOy, increased [Ca2+]i,
Cellular differentiation, E-cadherin mediated 
cell adhesion
(Oda et al ,  1998; Tu et 
al,  2001; Tu et al ,  2008)
Kidney
-Glomerular Mesangial 
cells
-Madin-Darby canine 
kidney cells
Production of IP3, inhibition 
of adenylate cyclase
PLC activation, biphasic 
increase in [Ca2+]j
Rho activation, PLD 
activation
'y  1
Urinary excretion/reabsorption of Ca 0, 
decreased Cl" reabsorption
Stimulation of proliferation
Possible implications for cellular structure
(Riccardi etal., 1995; 
Riccardi et a l ,  1998)
(Kwak e ta l ,  2005) 
(Huang et al ,  2004)
Bone -Osteoclasts 
Osteoblasts
PLC activation, IP3 
production, activation of 
NFkB
ERK 1/2 activation, Akt 
stimulation, phosphorylation 
of GSK3P
Cellular differentiation, apoptosis of mature 
osteoclasts
Stimulation of proliferation, gene expression 
changes, nodule formation
(Mentaverri et al ,  2006)
(Yamaguchi e ta l ,  1998; 
Yamaguchi et al ,  2000; 
Dvorak et a l ,  2004)
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-Bone Marrow, 
hematopoetic stem cells To be determined
Adherence to collagen 1, binding to 
extracellular matrix
(Adams et al ,  2006)
Chondrocytes Inositol phosphate (IP) 
production, decrease cAMP
Gene expression changes, modulation of 
differentiation
(Chang et al ,  1999b; 
Rodriguez et a l ,  2005)
Intestine Production of IP3, increase in 
[Ca2+]i, inhibition of PLA 
mediated production of 
arachidonic acid, cAMP 
accumulation
Modulation of fluid secretion, gene 
expression changes, inhibition of cell 
proliferation
(Kallay e ta l ,  1997; 
Kallay et a l ,  2003; 
Cheng et a l , 2004)
Pancreas Increase in [Ca2+]j Secretion of fluid and HCO3' (Bruce e ta l ,  1999)
Neonatal Ventricular 
Cardiomyocytes
Production of IP, ERK1/2 
activation
Decrease in proliferation (Tfelt-Hansen et al ,  
2006)
Adult Ventricular 
Cardiomyocytes
PLC activation, increase in 
[Ca2+]i, production of IPs
Control of apoptosis in response to injury (Wang et a l ,  2003; 
Zhang et a l ,  2006)
Mammary gland To be determined Decrease in PTHrP secretion, Cai+transport 
into milk, gene expression changes
(VanHouten et al ,  2004; 
VanHouten et al ,  2007)
Placenta Biphasic increase in [Caz+]j Control of fetal Ca2+-homeostasis, PTHrP 
secretion
(Bradbury et al ,  1998; 
Kovacs e t a l ,  1998)
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Lens epithelial cells To be determined Regulation of activation of Ca^-activated K+ 
channel
(Chattopadhyay et al ,  
1997)
Pituitary Gland Increase in [Ca2+]i, cAMP 
accumulation
Unknown (Shorte & Schofield, 
1996; Romoli et al ,  
1999)
Astrocytoma cells p38 activation Regulation of activation of Ca2+-activated K+ 
channel
(Ye et al ,  2004)
Embryonic Superior 
cervical ganglion
To be determined Increased axonal growth and arborisation (Vizard et al ,  2008)
23
1.4.1 Control o f Proliferation, Differentiation and Apoptosis
Patients with non-functioning CaR and mice who lack expression of CaR 
both have hyperplastic parathyroid glands (Ho et al., 1995). The interpretation of 
these findings is that the CaR tonically suppresses proliferation in the parathyroid 
glands (Ho et a l ,  1995). This role as a suppressor of cellular proliferation has also 
been noted in intestinal colonocytes where decreasing [Ca2+]0 increased proliferation 
due to inactivation of the CaR (Kallay et al., 2000). Keratinocytes, from both 
humans and mice, respond to increasing [Ca2+]0 with an increase in [Ca2+]i and an 
increase in IP3 production, similar to that seen in parathyroid cells (Bikle & Pillai, 
1993). CaR activity in keratinocytes from skin has a dual role because Ca2+0- 
mediated CaR activity both halts proliferation and drives differentiation. As the 
keratinocytes proliferate and reach confluency in the culture system, the Ca2+i 
responses diminish along with expression of CaR (Oda et al., 1998; Oda et al., 
2000). These results indicate that CaR drives differentiation, but is not required for 
the maintenance of terminally differentiated keratinocytes.
CaR activation has been shown to be a regulator of proliferation in a positive 
fashion as well. In organ cultures of rat metatarsal bones, CaR activation using both 
Ca2+ and the CaR specific allosteric agonist NPS-R-568 increased metatarsal length 
by inducing proliferation and hypertrophy of chondrocytes (Wu et al., 2003). This 
positive effect is also seen in ovarian surface epithelial cells (OSEs). These cells 
respond to increasing [Ca2+] with an increase in [Ca2+]i, and the phosphorylation of 
extracellular signal related kinases 1/2 (ERK1/2) causing proliferation (Hobson et 
al., 2000). Proliferation is also induced by 1.8-2.5 mM Ca2+0 in fetal rat calvarial 
(FRC) cells, a model for osteoblasts, possibly occurring via CaR activation of 
ERK1/2 (Dvorak et al., 2004).
24
Complicating matters are results that demonstrate that both proliferative and 
pro-apoptotic signals are induced by CaR activation in opossum kidney (OK) cells. 
Proliferative signals are induced by acute treatment with the aminoglycoside 
antibiotic, gentamicin (an activator of the CaR, see section 1.5.2). However if 
applied chronically, gentamicin induces apoptosis in OK and HEK293 cells stably 
expressing the CaR (Ward et al., 2005)
1.4.2 Control o f Secretion and Gene Expression
The role of the CaR in controlling the secretion of PTH is well-known; 
however it has also been shown to regulate secretion in tissues such as the intestine 
and the pancreas. In the pancreas, where the composition of pancreatic juice 
containing bicarbonate and free-ionised Ca2+0 is balanced to prevent the formation of 
calcium carbonate stones, the CaR was localised with immunohistochemistry in the 
ducts, acini and certain cells in the islets of Langerhans (Bruce et al., 1999). 
Measurements of ductal secretion showed that Gd3+ application caused secretion of 
fluid and HCO3" similar to a known secretion stimulator, forskolin. Based on both 
the localisation and functional observations, Bruce and colleagues hypothesised that 
in the pancreas the CaR is involved in controlling fluid secretion ensuring that 
luminal [Ca2+] remains too low for pancreatic stones to precipitate in the high 
concentrations of bicarbonate within pancreatic juice.
The CaR has been detected along the length of the gastrointestinal tract from 
the stomach (Cheng et al., 1999) through the small and large intestine, mostly in 
epithelial cells (Chattopadhyay et al., 1998). Isolated colonic epithelial crypt cells 
express the CaR on both apical and basolateral membranes. Experimentation using 
these crypts show that CaR modulates fluid secretion in response to Ca2+ (Cheng et 
al., 2 0 0 2 ) by enhancing the destruction of cyclic nucleotides, inhibiting a sodium and
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chloride co-transporter and activating of fluid absorption (Geibel et a l ,  2006) thus 
preventing secretory diarrhoea.
Additionally in the intestine, dietary Ca2+ has been shown to be a 
chemoprotective agent against colon cancer formation (Peterlik & Cross, 2005) 
through mechanisms that could be mediated by Ca2+ -dependent activation of the 
CaR. CaR activation can inhibit defective canonical Wnt signalling in APC 
truncated-adenocarcinoma cells by inducing secretion of Wnt5a, a non-canonical 
inhibitor of canonical Wnt signalling, which has also been associated with longer 
survival in Dukes B colon cancer patients (MacLeod et a l ,  2007). In colon 
carcinoma cells activation of the CaR promotes the expression of E-cadherin, a 
glycoprotein responsible for calcium-dependent, cell-to-cell adhesion that also 
interacts with p-catenin, a canonical Wnt-signalling pathway component. In the same 
study, CaR activation suppressed the ability of P-catenin to bind to its target 
transcription factors. Thus, the malignant behaviour of these cells was prevented by 
CaR-mediated inhibition of gene transcription and activation, as well as CaR- 
mediated inhibition of anchorage-independent growth (Chakrabarty et a l ,  2003).
E-cadherin mediated cellular adhesion is vital for maintaining the structural 
integrity of the skin and correct differentiation of epidermal keratinocytes (Xie & 
Bikle, 2007). It has been previously discussed in Section 1.4.1 that CaR activation is 
also vital for the differentiation of epidermal keratinocytes (Oda et a l ,  2000). 
Recently it has been determined that there is a link between CaR activation and E- 
cadherin in epidermal keratinocytes (Tu et al ,  2008). Using CaR anti-sense cDNA 
which blocked expression of the native CaR, this group showed that not only does 
CaR activation play a role in calcium signalling, cell survival and differentiation, but 
also in E-cadherin-mediated cell adhesion and signalling. Reduction of CaR
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expression also blocks the activation and association of phosphatidylinositol 3- 
kinase (PI3K) with E-cadherin via a mechanism involving Src-family tyrosine kinase 
signalling (Tu et a l ,  2008).
CaR activation mediates gene expression in several tissues including 
chondrocytes (Chang et a l ,  1999a), osteoblasts (Dvorak et a l ,  2004) and the 
parathyroid gland (Yamamoto et a l ,  1989). Chondrocytes are cells which form 
cartilage and the putative skeleton. A cell line commonly used as a chondrocyte 
model, C5.18 respond to increasing [Ca2+]0 with CaR activation which in turn 
suppresses nodule formation and expression of the genes encoding aggrecan, type II 
collagen and type X collagen (Chang et a l ,  1999a). In osteoblasts, CaR activation 
increases the mRNA for type 1 collagen, core binding factor 1, osteocalcin and 
osteopontin possibly in order to regulate the mineralisation process (Dvorak et al ,  
2004). In the parathyroid glands, sustained exposure to high Ca2+0, not only inhibits 
PTH secretion, but also the gene expression for PTH (Yamamoto et a l ,  1989).
1.5 Ligands for the CaR
The above detailed effects of CaR activation can be instigated by a variety of 
ligands. The CaR is distinctive amongst GPCRs in its ability to bind inorganic 
molecules, Ca2+ and Mg2+ being just two of these. Although the CaR takes its name 
from its primary physiological ligand, Ca2+, this receptor also responds to other 
polyvalent cations such as Gd3+, as well as polyvalent peptides (i.e. amyloid-p 
peptides and glutathione), polyamines such as spermine, aminoglycoside antibiotics 
and amino acids (Steddon & Cunningham, 2005). Ligands are divided into two 
categories, Type I or Type II calcimimetics. Type I calcimimetics are conventional 
receptor agonists (like Ca2+ and Gd3+) while Type II calcimimetics are positive 
allosteric modulators of the CaR. Positive allosteric modulators bind to the receptor
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at a site separate to endogenous receptor agonists and require the presence of an 
endogenous agonist in order to modulate receptor activity (Schwartz & Holst, 2006). 
Both types of ligands are discussed in detail in the following sections.
1.5.1 Type I Calcimimetics
Ca2+0 binding occurs in the extracellular domain (ECD) of the CaR involving 
residues Ser-170 and, to a lesser extent, Ser-147 (Brauner-Osbome etal., 1999) 
shown by producing chimeric receptors containing the ECD of the CaR with the 
transmembrane domain (TMD) and C- terminal tail of mGluRl. The Hill coefficient 
(indicates cooperativity in ligand-protein interaction) for the CaR with Ca2+ is 
approximately 3 (Bai etal., 1996), which implies that there are several additional 
Ca2+0 binding sites within the CaR (Brown & MacLeod, 2001). The EC50 for Ca2+0 
varies depending upon the cell type and system in which the CaR is expressed; 
however it is generally in the low millimolar range. The following list contains 
examples of different cell types and their respective EC50:
Colonic epithelial cells -  EC50 = 0.759 + 0.1 mM (Cheng et al., 2004);
Parafollicular cells of thyroid gland -  E C 5 0  = 1.2 -  2.4 mM (McGehee et a l ,  1997); 
Oligodendrocytes -  E C 5 0  =1.4  mM (Ferry et al., 2000);
AT-3 prostate carcinoma cells -  E C 5 0  = 6.1 mM (Lin et al., 1998).
While the primary physiological ligand for the CaR is Ca2+, this receptor also 
responds to other inorganic cations. Their potency depends on the charge and radius 
of the cation. Therefore Gd3+ and La3+, are stronger agonists than Ca2+ and Ba2+, 
which are stronger than Mg2+ and Na+ (Chang & Shoback, 2004). In a similar 
fashion the CaR responds, at concentrations which are present in some tissues like 
the brain, to polyamines (spermine and spermidine) based on the net positive charge 
of the molecules at physiological pH (Quinn et al., 1997).
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1.5.2 Type II Calcimimetics
Amino acids are positive modulators of the CaR, meaning they are 
ineffective at promoting signalling activities in the absence of Ca2+0. The modulation 
of the CaR by amino acids is stereoselective with L-amino acids more potent than D- 
amino acids (Conigrave et a l ,  2000). It is thought that amino acid sensing by the 
CaR contributes to physiological Ca2+-homeostasis because at physiological [Ca2+]0 
(1.1 mM), application of several L-amino acids at the physiological concentration of 
1 mM suppressed PTH secretion to levels normally seen in the presence of 1.2 mM 
Ca2+0 (Conigrave et a l ,  2004). The amino acid sensitivity of the CaR could also have 
effects in the intestine where the CaR is expressed in epithelial cells and amino acids 
are released from food (Chang & Shoback, 2004).
Several pharmacological compounds have been produced to modulate the 
CaR, including the clinically available Cinacalcet (AMG-073). Two earlier 
calcimimetic compounds are NPS-R-467 and Amgen R-568. All of these compounds 
are small, organic, phenylalkylamine compounds without polycationic structure 
(Fig.l.2A) that have been structurally modified from fendiline, a calcium channel 
blocker (Nemeth et a l ,  1998). These calcimimetics are also stereoselective, which 
means that a stereoisomer of the compound is less active than its counterpart (Ferry 
et al., 2000; Quarles et al., 2003); these are generally used as negative controls for 
the activity of the calcimimetics. R-568 (3 pM) shifted the EC50 for the [Ca2+]0 
response of oocytes (Fig.l.2B) from 7.6+1.7 mM to 3.4+0.7 mM (Hammerland et 
a l,  1998). Both NPS-R-467 and R-568 (100 nM) shifted the EC50for the [Ca2+]0 
response of bovine parathyroid cells to Ca2+0 to the left, moving the EC50 from 
1.66+0.34 mM to 0.61+0.04 mM (Nemeth et a l ,  1998). The same study also 
determined that these calcimimetics only affected stimulation of the CaR when in the
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presence of Ca2+0 at a concentration of at least 0.5 mM and did not produce any 
additional stimulation when Ca2+0 was raised above 1.5 mM. The range of [Ca2+]0 in 
which these calcimimetics are active is 0.1 mM -  3 mM (Nemeth, 2004). 
Additionally, in both HEK293 cells stably expressing human CaR and bovine 
parathyroid cells, R-568 was approximately twice as potent at inducing CaR 
activation as NPS-R-467 (Nemeth et a l , 1998). It should also be noted that 
regardless of their respective EC50S, these compounds are the same, they both inhibit 
secretion of PTH and elicit increases in [Ca2+]j.
Zhang et a l  (2002) looked at the effect of NPS-R-467 on HEK293 cells, 
transiently transfected with either wildtype (WT) CaR or mutated CaR. Treatment 
with 1 pM NPS-R-467 decreased the EC50 for Ca2+0 of the WT receptor by 39%. 
This concentration also significantly decreased the EC50 for Ca2+0 of many of the 
mutant receptors produced for this study. Additionally, this study looked at another 
allosteric modulator of the CaR, L-phenylalanine, which in some cases did not shift 
the EC50 for Ca2+0 in several of the mutant CaRs. It can therefore be deduced that 
there are separate sites for allosteric binding in the CaR (Zhang et a l ,  2002). NPS- 
R-467 also helps to potentiate secretion of insulin from cells in the pancreas via 
interaction of the CaR with a nonspecific cation channel (Straub et a l ,  2000).
Studies with R-568 have shown its effectiveness at modulating the response 
of the CaR when applied to bovine parathyroid cells (Nemeth et a l ,  1998) and when 
administered subcutaneously to adult rats. In adult rats it reduces levels of 
parathyroid hormone and calcium in the serum after nephrectomy, thus implying that 
its actions are mediated via CaR located in the parathyroid and not in the kidney 
(Fox et a l ,  1999b). R-568 also reduces the parathyroid cell proliferation normally 
seen after this procedure (Wada et a l ,  1997). However R-568 can also cause
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hypocalcemia in normal rats by inhibiting PTH secretion and stimulating calcitonin 
secretion (Fox et al ,  1999a).
It has also been shown that R-568 not only modulates the responsiveness of 
the CaR, but can also influence receptor expression. Treatment of transiently 
transfected HEK293 cells with R-568 (10 pM) increased the expression of CaR 
protein after 12 h in culture (Huang & Breitwieser, 2007). Interestingly, this 
treatment also rescued the expression of several loss-of-function CaR mutants. 
HEK293 cells transiently transfected with these mutants initially showed very little 
cell surface expression, while after 12 h of R-568 treatment, there was an increase in 
the plasma membrane expression of the CaR mutants. These mutants also showed an 
increase in ERK1/2 phosphorylation, indicating functional signalling responses once 
the receptor was located in the membrane (Huang & Breitwieser, 2007). These 
results indicate that R-568 not only modulates the response of wildtype CaR, but can 
also modulate the responses of several mutant CaR configurations by increasing their 
movement to the plasma membrane.
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Figure 1.2: Type II calcimimetic structure and effect on [Ca2*]0 concentration response 
of oocytes. A). NPS-R-467 and R-568 are structurally similar compounds derived 
from the structure of the calcium channel blocker fendiline. Figure taken from 
Nemeth et al,  1998. B). Application of 3 |lM R-568 (closed circles) to oocytes in
the presence of increasing [Ca2+]0 shifts the response to the left making the CaR
more sensitive to lower [Ca2+]0. Figure taken from Hammerland et al,  1998.
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Aminoglycoside antibiotics such as neomycin and gentamicin are also 
activators of the CaR in some tissues. Neomycin has been shown to be a 
concentration-dependent activator of [Ca2+]i increases in oocytes expressing the 
bovine parathyroid CaR (Brown et a l ,  1993). In HEK293 cells stably expressing the 
CaR; neomycin, tobramycin and gentamicin all produced dose-dependent CaR 
signalling responses (McLamon et al., 2002). This activation of the CaR by these 
antibiotics is thought to contribute to the renal toxicity effects sometimes seen when 
these antibiotics are taken (McLamon & Riccardi, 2002).
Table 1.1 demonstrates the point that the CaR has phenotypic pharmacology, 
that is, the pharmacological phenotype will change dependent upon the cellular 
locality in which CaR is expressed (Nemeth, 2004). Therefore aminoglycoside 
antibiotics, and indeed other CaR agonists, may not elicit responses in all tissues and 
cell types to which they are applied. For example, the calcimimetic AMG-073 
induces relaxation of contraction in isolated rat aortas, but this is not mimicked by 
application of neomycin (Smajilovic et a l ,  2007). Human aortic endothelial cells, 
presumably also part of the isolated aortas in the previous example, exhibit a similar 
lack of response to neomycin (Ziegelstein et a l ,  2006).
1.6 CaR Signalling
Activation of the CaR is linked to a diverse range of signalling pathways.
This is due to the fact that the CaR is a pleiotropic G-protein coupled receptor, 
meaning that upon binding by its associated ligands, it can produce diverse effects by 
changing its interactions with several different G-proteins or other associated 
proteins like filamin (Huang & Miller, 2007). G-proteins interact with GPCRs, like 
the CaR, and upon receptor activation release the biologically active subunits a-GTP 
and py (Albert & Robillard, 2002). CaR activation can result in the stimulation of
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both pertussis toxin sensitive and insensitive G-protein mediated responses (Brown 
& MacLeod, 2001). Different combinations of subunits designate different G-protein 
subfamilies and the CaR has been shown to interact with Gs Gq, Gj and G12/13 (Ward, 
2004; Mamillapalli et a l ,  2008). Again, the cellular context of CaR expression 
seems to determine the predominant signalling pathway that is initiated. This has 
been elegantly demonstrated in experiments using breast epithelial cells. In normal 
mammary epithelial cells CaR activation is linked to Gi signalling. When mammary 
cells become malignant, the CaR switches from Gi-coupled to Gs-coupled signalling. 
The underlying reason for this change is currently unknown, but this process could 
be contributing to the malignancy of breast cancer (Mamillapalli et a l ,  2008). This 
ablity to change G-protein partners is one reason for the ability of the CaR to affect 
so many different cellular processes. A summary of CaR ligands and signalling 
pathways is shown in Figure 1.3.
1.6.1 Phospholipase Activation and Interactions with Rho by CaR
In parathyroid cells, Ca2+0 induces PLC mediated increases in IP3 and 
attendant release of Ca2\  which are indicative of Gq activation (Brown et a l ,  1987). 
Activation of PLC via Gq in parathyroid cells and transfected HEK293 cells is 
pertussis toxin insensitive (Brown & MacLeod, 2001). The evidence for interaction 
of CaR with Gq in the parathyroid is further strengthened by the phenotype of mice 
lacking expression of Gq in their parathyroid glands. These mice have symptoms 
very similar to CaR knockout mice (see Section 1.8.1) with increased serum [Ca2+] 
and [PTH], hyperplastic PTH glands and early post-natal lethality (Wettschureck et 
al,  2007). CaR may influence Gq signalling elsewhere in the body, implied by Gd3+ 
stimulated activation of the CaR increasing Gq protein in Madin-Darby Canine 
Kidney (MDCK) cells (Arthur et a l ,  1997). PLC activation via CaR interaction with
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Gq has been identified in the majority of systems where CaR has been found to be 
expressed including; kidney (Riccardi et al., 1995), pancreas (Bruce et al., 1999), 
placenta (Bradbury et al., 1998), intestine (Gama et al., 1997), ovarian epithelial 
cells and fibroblasts (McNeil et al., 1998a; McNeil et al., 1998b).
Phospholipase D (PLD) is also activated by high Ca2+ in CaR transfected 
MDCK cells. Activation of PLD is pertussis toxin insenstitive, but can be inhibited , 
by disruption of Rho, indicating the involvement of G12/13 (Huang et al., 2004). 
However, the interaction with Rho may also be dependent on CaR interaction with 
filamin, as well as G12/13, due to the lack of response seen when dominant-negative 
Rho is applied to CaR transfected HEK293 cells (Pi et al., 2002). CaR demonstrates 
ligand specific pharmacology, as well as differentially timed responses in HEK293 
cells stably expressing the CaR. In these cells, Ca2+ and NPS-R-467 can initiate Gq 
mediated PLC signalling, initiating Ca2+i mobilisation and ERK 1/2 activation within 
minutes of treatment. It can also initiate G 12/13 and Rho resulting in actin stress fiber 
assembly and changes in cell morphology after several hours of treatment. In these 
same cells, L-amino acids initiated Ca2+i mobilisation, but no detectable activation of 
ERK 1/2 or changes in cell morphology (Davies et al., 2006).
1.6.2 Protein Kinase Activation by CaR
Mitogen activated protein (MAP) kinases are a family of protein kinases that 
includes extracellular signal-regulated kinases (ERK), c-Jun N kinases (JNK) and 
p38. All have been shown to be activated by the CaR, although in several different 
systems. ERK activation is by far the most common form of MAP kinase activation 
by CaR reported. In CaR transfected HEK293 cells and bovine parathyroid cells 
ERK 1/2 activation has been induced by CaR activation, both by high Ca2+0 and 
calcimimetic NPS-R-467. This ERK 1/2 activation was blocked by addition of
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U73122, a PLC inhibitor, and by GF109203X, a protein kinase C (PKC) inhibitor, 
indicating the involvement of Gq (Kifor et a l , 2001). Inhibition of PI3K also 
inhibited ERK activation in CaR transfected HEK293 cells (Hobson et a l ,  2003). 
Inactivation of PI3K has also been used in other native CaR expressing systems to 
inhibit ERK activation including: ovarian surface epithelial cells (Hobson et a l ,  
2 0 0 0 ), opossum kidney cells (Ward et al ,  2 0 0 2 ) and hyperplastic human parathyroid 
cells (Corbetta et a l ,  2002).
JNK is a stress activated MAP kinase family member that is phosphorylated 
in MDCK cells responding Gd3+ or high Ca2+ exposure (Arthur et a l ,  2000). H-500 
Leydig cancer cells are a model for humoral hypercalcemia that is associated with 
malignancy of cancer. They have been used to investigate CaR signalling that 
induces parathyroid hormone-related peptide (PTHrP) release. The release of PTHrP 
in these cells is abolished when JNK or PKC is inhibited and potentiated upon 
application of a PKC activator (Tfelt-Hansen et a l ,  2003).
PTHrP secretion by H-500 Leydig cells is attenuated when p38 MAPK is 
inhibited (Tfelt-Hansen et al ,  2003). Further studies with these cells showed that 
p38 activation by the CaR was responsible for an increase in proliferation and 
protection from apoptosis when exposed to high Ca2+0 or NPS-R-467 (Tfelt-Hansen 
et a l ,  2004). Activation of p38 by the CaR is also involved in the CaR-mediated 
activation of a Ca2+-activated K+ channel in U87 astrocytoma cells (Ye et a l ,  2004).
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Figure 1.3: Schematic diagram of extracellular calcium-sensing receptor signalling.
The CaR is present in the cell membrane as a constitutive homodimer with a large 
extracellular domain. This receptor can be activated not only by Ca2+0, but also by 
polyamines, Gd3+, calcimimetic compounds, Mg2+, amino acids (AA), amyloid-|3 
peptides (Ap), glutathione (GSH) and aminoglycoside antibiotics (AGA). Signalling 
cascades initiated by CaR include, but are not limited to: 1. Gi inhibition of adenylate 
cyclase (AC), reducing cAMP production; 2. G 12/13 and Rho mediated activation of 
phospholipase D (PLD); 3. activation of p38; 4. phosphatidylinositol 3-kinase (PI3 K) 
activation of MEK and ERK 1/2 and/or activation of Akt leading to the 
phosphorylation of glycogen synthase kinase 3p (GSK3p); 5. Gq mediated activation 
of phospholipase C (PLC), activating protein kinase C (PKC) and/or inositol 
trisphosphate (IP3) leading to release of Ca2+ from internal stores; 6 . CaR interaction 
with E-cadherin (through an as yet undetermined mechanism) which recruits and 
associates with PI3 K leading to activation of PLC and Ca2+, increase. Figure adapted 
from Ward 2004, Tfelt-Hansen et al., 2004 and Tu et a l, 2008.
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1.7 Mutations of the CaR
Mutations of the CaR can result in either a non-functioning or constitutively 
functioning receptor; both of these states cause difficulties in maintaining systemic 
calcium homeostasis. The severity of the symptoms experienced by patients with 
mutated CaR can vary based on the type and genetic dosage of the mutation.
1.7.1 Inactivating Mutations
Two pathologies in the handling of Ca homeostasis were identified prior to 
the cloning of the CaR. Patients with familial hypocalciuric hypercalcemia (FHH; 
also known as Familial benign hypercalcemia) have moderate elevations in serum 
Ca2+ levels and low excretion of Ca2+ in the urine, as the name suggests. They also 
have PTH levels that are not physiologically compatible with their level of serum 
Ca2+ (Attie et al., 1983). As FHH is an autosomal dominant disorder, offspring of 
these patients are also highly likely to have FHH, generally an asymptomatic 
condition, or a more severe condition, neonatal severe hyperparathyroidism 
(NSHPT) if the mutation is homozygous. NSHPT can be lethal unless diagnosed 
quickly and rectified with an immediate parathyroidectomy. This lethality is due to 
the severity of the Ca2+ and PTH elevation in the serum of these patients. In patients 
with either FHH or NSHPT there is a pathologic response to changes in Ca2+0 
(Steinmann et al., 1984).
After cloning of the CaR in 1993, screening was performed on patients 
suffering from either of these diseases. It was found that mutations in conserved 
regions of the CaR gene rendered the CaR of these patients less responsive to Ca2+, 
Gd3+ and neomycin application thus providing the link between the CaR, FHH and 
NSHPT (Poliak et al., 1993). NSHPT results from having two copies of FHH
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causing mutations, dramatically changing the set point at which the parathyroid 
responds to Ca2+0 (Poliak et al ,  1994b). Since the linkage of CaR mutations to FHH 
and NSHPT, many different mutations have been described which inactivate the 
CaR. Many of these mutations are in the extracellular and transmembrane domains, 
regions that are highly conserved across human, bovine and rat sequences (Pearce et 
al,  1995; Pearce et a l ,  1996c; Cole et a l ,  1997; Demedts et al ,  2008) and are listed 
on the CaR mutations database found on www.casrdb.mcgill.ca. Several mutations 
result in defective processing and trafficking of the receptor to the cellular 
membrane, thus explaining the decreased ability to respond to Ca2+ (Pidasheva et al ,  
2005; Pidasheva et a l ,  2006). Other mutations may truncate the protein, producing a 
non-functional CaR or interfere with the ligand-binding sites within the receptor 
(Cole et a l ,  1997). Another type of mutation resulting in a non-functioning CaR is 
the insertion of a repetitive Alu-sequence into exon 7 of the CaR gene which results 
in a protein without much of its intracellular carboxy terminus, impairing its 
trafficking and signal transduction capabilities (Janicic e ta l ,  1995; Bai e ta l ,  1997; 
Cole e ta l ,  1997).
1.7.2 Activating Mutations
Autosomal dominant hypocalcaemia (ADH) is caused by activating 
mutations in the CaR which result in inappropriate activation of the receptor. The 
first described mutation, Glul28Ala, resulted in an alanine substitution within exon 2 
in the ECD of the CaR protein. This substitution resulted in a mutant receptor that 
produced significantly more IP3 in response to both 0.5 and 5 mM Ca2+ than 
wildtype receptors. Therefore, the mutated receptor had a greater amount of activity 
regardless of [Ca2+]0 (Poliak et al ,  1994a).
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Many other mutations have since been described which produce a CaR with 
an increased sensitivity to Ca2+ (Pearce et al., 1996b; Watanabe et al., 1998; 
Lienhardt et al., 2000; Lienhardt et al., 2001). One of these mutations was found to 
be a large deletion in the cytoplasmic tail of the receptor and this mutated receptor 
had a greater cell surface expression than wildtype CaR, possibly accounting for the 
increase in CaR activity. Interestingly, ADH seems to be independent of any gene- 
dosage effect, as one male from this study was homozygous for this mutation, but 
had similar symptoms to other heterozygous family members (Lienhardt et al., 
2000).
1.7.3 Splice Variants of the CaR
In the course of sequencing the CaR in normal human keratinocytes a splice 
variant was detected (Oda et al., 1998). This splice variant lacks the 231 nucleotides 
which encode exon 5 of the full-length receptor, resulting in a protein reduced by 77 
amino acids. In the keratinocyte cultures used for this study, the exon-5-less splice 
variant (SPV) does not induce an IP3 response to Ca2+-stimulation and as the 
keratinocytes differentiated, full-length CaR expression decreased while SPV 
expression remained relatively constant. When co-expressed in HEK293 cells with 
the full-length CaR, the SPV reduces the normal IP3 response by about 30% (Oda et 
al., 1998). This SPV was also detected in mouse keratinocytes and kidney from 
animals in which wild-type CaR expression had been disrupted (Oda et al., 2000). 
Neither one of these studies was able to elicit normal CaR signalling responses from 
the SPV.
The SPV was later also detected in mouse growth plate chondrocytes 
(GPCs). In this instance the SPV was detected at the cell membrane of GPCs and 
produced normal responses to classic agonists of the CaR (Ca2+, Mg2+, Sr2+, Mn2+,
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and neomycin). The detection of the SPV at the membrane and signalling responses 
were only detected in the native GPC cell population. When expressed in 
heterologous systems, Chinese hamster ovary (CHO) cells and HEK293 cells, SPV 
protein is retained intracellularly and therefore is unable to provoke normal 
signalling responses. These results indicate that in native tissues there is a 
mechanism, lacking in heterologous expression systems, that allows trafficking of 
the SPV to the membrane where it can then signal and at least partially compensate 
for the loss of the full-length CaR (Rodriguez et al,  2005).
1.8 Animal models of CaR activity
1.8.1 Mutants with Inactivated CaR
The first mouse with an inactivation of the CaR was made by insertion of a 
neomycin resistance cassette into the then exon 4 (since re-designated exon 5) of the 
CaR gene (Ho et al ,  1995). This mouse mimicked symptoms of both FHH and 
NSHPT depending on the heterozygosity or homozygosity of the mutation (Fig. 1.4). 
Heterozygotes (HET) were viable and physically indistinguishable from their 
wildtype (WT) littermates. They did however, have elevated serum Ca2+ and 
elevated PTH levels with hypocalciuria, similar to human patients with FHH. 
Homozygotes null (NULL) for the CaR were indistinguishable from their WT 
littermates at birth. However they failed to develop normally and remained much 
smaller. These mice died between post-natal day 3 and 30 with substantially elevated 
serum Ca2+ and PTH levels, as well as enlarged parathyroid glands and skeletal 
abnormalities, making them a model for patients with NSHPT (Ho et a l ,  1995).
However severe their phenotype, mice NULL for the CaR do naturally 
express the exon-5 less splice variant of the CaR in some tissues, including 
keratinocytes (Oda et al ,  2000), kidney (Oda et al ,  2000) and chondrocytes
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(Rodriguez et al ,  2005), but not in others like the superior cervical ganglia (Vizard 
et a l ,  2008). This variable expression makes them an incomplete knockout model.
Many of the symptoms seen in the NULL mouse are thought to be the effects 
of severe up-regulation of PTH secretion and the attendant hypercalcemia (Kos et 
al,  2003). Due to the varied distribution of the CaR in tissues not responsible for 
Ca2+0 homeostasis, two modifications to the original CaR knockout mouse have been 
made. The first modification was done by crossing the original CaR knockout with a 
PTH knockout resulting in CaR/PTH NULL mice that were viable. Mice which were 
CaR/PTH NULL still had hyperplastic parathyroid glands with a trend towards 
hypercalciuria and hypercalcemia. This trend was characterised by greater variability 
in the range of values seen for serum Ca2+ and urine Ca2+in CaR/PTH NULL mice 
than in mice null for PTH alone. While this cross prevented the major effects of over 
secretion of PTH, it still demonstrates that CaR has a role in Ca2+ homeostasis 
without PTH and provides a model to look at the non-PTH related roles of the CaR 
(Kos e ta l ,  2003).
The second mouse model removed the effects of PTH excess by crossing the 
original CaR mice with glial cells missing 2 (Gcm2) deficient mice (Tu et a l ,  2003). 
Gcm2 is the master gene responsible for development of the parathyroid gland. 
Therefore these mice lack a parathyroid gland and display normal skeletal 
development. Their serum Ca2+ and PTH levels are similar to their Gcm2 deficient 
littermates, although their hypocalciuria is maintained confirming the role of the CaR 
at least in renal excretion of Ca2+ (Tu et al ,  2003). However, regardless of the 
reduced severity of their phenotypes, these two mouse models retain the limitation of 
the original CaR knockout. This limitation is the result of the expression and activity
42
of the exon-5-less SPV in several cell types and tissues which would not be affected 
by cross-breeding with PTH NULL and Gcm2 mice.
Recently, a floxed CaR mouse has been described with the insertion of LoxP 
sites flanking exon 7 of the CaR gene (Chang et a l ,  2008). This mouse can be used 
to produce tissue-specific knockouts of the CaR when bred with other transgenic 
mice expressing Cre-recombinase under the control of tissue-specific promoter 
sequences. It also means that the problem with possible SPV expression is solved, as 
removing exon 7 disrupts expression of both full-length and SPV CaR.
This mouse has been used to produce knockout of CaR expression in 
parathyroid cells, osteoblasts and chondrocytes. Regardless of the promoter sequence 
used, offspring presented with gene-dosage specific phenotypes, with the 
heterozygous phenotype being less severe than the homozygous. For brevity, only 
the homozygous phenotypes will be detailed below. As in the original CaR knockout 
(Ho et al ,  1995), when CaR expression is removed from parathyroid cells 
specifically, there is a 45% reduction in overall post-natal growth with an 
undermineralised skeleton. However, the hyperparathyroidism in homozygous 
parathyroid cell knockouts was 7.5-fold more severe than in the original CaR NULL 
mouse. This implies that the SPV is indeed partially compensating for the lack of 
full-length CaR expression in the original CaR NULL mouse (Chang et a l ,  2008).
Two different promoter sequences were used to remove CaR expression from 
osteoblasts. Both promoters, which blocked CaR expression at the late, post-natal 
stage of osteoblast lineage and embryonic/early postnatal stage independently, 
blocked post-natal growth and resulted in undermineralised skeletons. Therefore, 
CaR modulates the growth and differentiation of osteoblasts which is an essential 
part of post-natal skeletal development.
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When CaR expression was initially ablated from chondrocytes using a CART 
promoter, the phenotype was embryonically lethal, with embryos dying between E l2 
and El 3. The use of this promoter for CaR removal inhibits early cartilage and bone 
mineralisation. As these embryos were non-viable, a tamoxifen-inducible CART 
promoter was used for CaR ablation at El 6-El 7. The offspring produced from this 
strategy had 10% decreased skeletal length as well as delayed chondrocyte 
maturation and terminal differentiation, due in part to reduced insulin-like growth 
factor 1 signalling. Therefore, there is a role for Ca2+ sensing by the CaR in 
chondrocytes. The culmination of the results from all three of these tissues show that 
signalling by the CaR is directly involved in the differentiation and development of 
the skeleton and that this involvement, in some tissues, begins in the embryo.
1.8.2 Mutants with Activated CaR
As stated earlier activating mutations of the CaR result in ADH (Pearce et al,  
1996a), and while mice with inactivated CaR have been characterised for some time, 
the mouse line which possesses an activating mutation of the CaR is relatively newly 
described. This mouse line was found to have a homozygous missense mutation to 
the fourth TMD of the CaR which results in a significant shift in the concentration 
response curve, with the mutant CaR responding to a lower [Ca2+]0 than wildtype 
receptors (Hough et al., 2004).
This mouse line has been designated Nuf for the “nuclear flecks” which are 
present in the lens of the eye. The mutation is also autosomal dominant with the 
resulting heterozygous (Nuf/+) mouse phenotype similar to that experienced by 
human ADH patients who are heterozygous for CaR mutations. These symptoms 
include, low plasma PTH concentrations, hypocalcaemia and hyperphosphatemia. 
Homozygotes (Nuf/Nuj) and heterozygotes (Nuf/+ ) have additional pathology to that
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presented by human ADH patients. Nuf/Nuf and Nuf/+ have ectopic calcification in 
various tissues including the tongue, jaws, kidneys, heart and lungs as well as the 
cataracts for which they were named (Hough et al ,  2004).
A second mouse model was produced by directing a constitutively active 
CaR to the osteoblasts by using a human osteocalcin promoter (Dvorak et al., 2007). 
These mice do not have any of the metabolic disturbances normally associated with 
global expression of a constitutively active CaR. They do have significantly lower 
amounts of cancellous bone than their wildtype littermates by 12-weeks of age 
regardless of gender, and this decrease becomes more pronounced as they age.
Within their bones they also have increased production and activity of osteoclasts 
concomitant with increased RANK-L expression, a stimulator of osteoclast 
differentiation and activity. Therefore the phenotype of these mice indicates that CaR 
signalling in osteoblasts is vital for osteoclastic maintenance and turnover, locally 
regulating bone remodelling (Dvorak et a l ,  2007).
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Figure 1.4: The phenotype of CaR knockout mice. CaR knockout mice were created 
by inserting a neomycin cassette into exon 5 of the CaR gene. This resulted in mice 
which have gene-dose dependent phenotypes similar to human phenotypes; the mice 
shown are 23 days old. A). Topmost white mouse is wildtype with no abnormalities. 
B). The middle black mouse is a heterozygote which has no gross abnormalities, but 
is a model of Familial Hypocalciuric Hypercalcemia with elevated levels of Ca2+ and 
PTH. C). The small black mouse is a homozygote, with obvious growth retardation, 
is a model for Neonatal Severe Hyperparathyroidism. Other symptoms this mouse 
displays are lethargy, enlarged parathyroid gland, severely elevated Ca2+ and PTH. 
Figure reproduced from Ho et al., 1995.
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1.9 Ca2+, CaR and the fetus
Prior to the cloning of the CaR, experiments by LeBoff et a l  (1985) 
determined that parathyroid cells from neonatal calves required exposure to a higher 
[Ca2+]0 than adult bovine parathyroid cells in order to inhibit the secretion of PTH. 
Neonatal bovine parathyroid cells required 1.27+0.11 mM Ca2+0 in order to half- 
maximally inhibit PTH secretion, while adult bovine parathyroid cells produced a 
similar response when exposed to 1.06+0.11 mM Ca2+0 (LeBoff et a l , 1985). 
Therefore neonatal calves are hypercalcaemic with a reduced sensitivity to [Ca2+] 
than their adult counterparts. This fetal hypercalcemia has been documented in 
several different species including humans, rodents and sheep at stages fairly early in 
pregnancy; 35 days in sheep and 15 weeks in humans (Kovacs & Kronenberg, 1997).
In a pivotal study for understanding the phenomenon of hypercalcemia in the 
fetus, Kovacs et al,  (1998) demonstrated that [Ca2+]0 in the fetus is maintained 
independently of the maternal [Ca2+]0 by the CaR. This was shown in studies using 
CaR knockout mice which showed that HET or NULL embryos had increased 
[Ca2+]0 levels and decreased placental Ca2+0 transport in comparison to their WT 
littermates regardless of the genotype and [Ca2+]0 of their mother. HET and NULL 
embryos also had significantly increased [Ca2+]0 in their amniotic fluid in 
comparison to their WT littermates indicating that renal handling of Ca2+0 is not vital 
to maintaining the hypercalcaemic status of the fetus. Double knockouts were 
produced by crossbreeding CaR knockouts to either PTHrP or PTH/PTHrP receptor 
knockout mice. Analysis of the embryonic [Ca2+]0 from these matings showed that 
the elevation of [Ca2+]0 in CaR HET and NULL embryos requires activation of the 
PTH/PTHrP receptor through binding of PTHrP.
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In WT mice, [Ca2+]0 is maintained at approximately 1.7 mM in E l8.5 mouse 
fetuses, significantly higher than the 1.2 mM maintained by their mothers. 
Therefore, in the developing fetus parathyroid CaR suppresses PTH secretion in 
response to this higher [Ca2+]0, and placental CaR through interactions with PTHrP 
influences the dynamics of placental Ca2+0 transport in order to maintain 
hypercalcemia (Kovacs et al., 1998). At birth this hypercalcemia begins to be 
resolved to post-natal normocalcaemia within 24 hours (Kovacs & Kronenberg,
1997) indicating that the control of [Ca2+]0 by the CaR is developmentally regulated.
Developmental regulation of CaR activity and expression has also been 
shown in tissues besides the placenta. Rat kidney expresses CaR in a 
developmentally regulated manner, with protein expression detected at E l8 in large 
tubules thought to be branching ureteric buds. Over the first week after birth 
expression of CaR mRNA greatly increases from pre-natal levels and reaches adult 
levels of expression by post-natal day 14. These increases presumably are linked 
with the need for increased renal function after birth excreting unnecessary Ca2+in 
the urine (Chattopadhyay et al., 1996).
Developmental regulation of the CaR has also been shown in cells not 
classically known for their expression of the CaR. Recently, Vizard et al., (2008) 
reported that CaR expression in the superior cervical ganglion (SCG) of embryonic 
mice is developmentally regulated, with low expression levels at embryonic day 
(E)16 that increase to a peak at E l8 and then falls back to E16 levels post-natally. In 
this developmental window, SCG neurons are growing and branching extensively to 
innervate their targets, a process that is susceptible to changes in [Ca2+]0, and 
treatment with calcimimetics. Growth of sympathetic neurons has also shown to be 
curtailed in CaR NULL mice indicating that the effect of CaR activation on growth
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in vitro is relevant in vivo for normal sympathetic innervation density (Vizard et al,  
2008). It is possible that other tissues developmentally regulate CaR expression and 
activity, but have yet to be investigated.
1.10 Lung Development
In the mouse, lung development begins at E9.5 when there is an evagination 
of the foregut endoderm forming the primordial trachea which quickly splits into two 
primordial lung buds (Hogan, 1999). This process of branching occurs in five stages 
(Fig. 1.5), ultimately resulting in mature lungs capable of gas exchange within 
minutes of birth (Warburton et a l ,  2005). Lung development begins in the 
embryonic phase (E9.5 -  El 1.5 in mice; 3-7 weeks in humans) with branching 
morphogenesis continues thorough the pseudoglandular stage (El 1.5-E16.5 in mice; 
5-17 weeks in humans) of lung development where there are robust interactions 
between two cell layers; epithelium/endoderm and mesenchyme/mesoderm (Whitsett 
et a l ,  2004). The budding pattern at these early stages is stereotypic and 
reproducible, producing lungs that have dorsal-ventral and medial-lateral axes, along 
with identity from left to right (Hogan, 1999). Recently this pattern has been mapped 
to take place with three different genetically encoded modes of branching (domain 
branching, planar bifurcation and orthogonal bifurcation) each resulting in a different 
branch arrangement that ultimately results in a lung with an intricate yet 
stereotypical pattern of branches (Metzger et a l ,  2008).
As stated earlier, this process of branching is genetically encoded, with the 
interaction of various intrinsic growth factors, transcription factors and proteins 
critical for the proper development of the lung. Mutations or disruptions to these 
intrinsic factors, as well as the influence of some extrinsic factors can alter the 
course of lung development resulting in hypo- or hyperplastic lungs with impaired
49
function (Warburton & Olver, 1997). A brief overview of the resulting phenotype 
from the inactivation or activation of several of the most robustly studied factors is 
presented in Table 1.2. Specific factors that are relevant to this study are detailed in 
sections 1.10.1 and 1.10.2.
1.10.1 Intrinsic Factors affecting Lung Development
Fibroblast Growth Factor (FGF) signalling has an evolutionarily conserved role 
in lung branching and morphogenesis; FGF homologues in Drosophila are critical to 
the development of the trachea, specifying the tracheal branching pattern and later 
controlling finer branching at the tips of the primary branches (Sutherland et al., 
1996). The mammalian counterpart to the drosophila FGF Branchless is FGF-10 
which is of particular importance to the mammalian developing lung (Park et al.,
1998). Using whole mount in situ hybridisation, it is detected in the mesenchyme 
surrounding the primitive tracheal tube at E9.5. By E l0.5 FGF-10 expression is 
restricted to the distal mesenchyme of the two main bronchi and remains in the distal 
mesenchyme until at least E l4.5. At this point, whole mount in situ hybridisation is 
not possible, but FGF-10 RNA was detected up until E l8.5 by Northern blot analysis 
(Bellusci et al., 1997b). Knockout of FGF-10 in mice results in pups lacking lungs, 
with the tracheas of the embryos being terminated without any bronchi at the level of 
the thymus, indicating that FGF-10 is critical for the initiation of the primary bronchi 
(Min et al., 1998).
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Stage 1: Embryonic
Mouse
E9 -  E l 1.5
Human
3 - 7  weeks
Stage 2: Pseudoglandular
El 1.5 -  E16.5 5 - 1 7  weeks
Stage 3: Canalicular
E16.5 -  E17.5 1 6 -2 6  weeks
E 17 .5 -P 5
P5 -  P28
Stage 4: Saccular
2 4 -3 8  weeks
Stage 5: Alveolar
£
38 weeks -  
maturity
Figure 1.5: Stages of embryonic lung development. Lung morphogenesis takes place 
in five stages. The initial budding from the foregut endoderm is the embryonic phase. 
This is followed by the pseudoglandular phase, when the majority of branching 
morphogenesis occurs. The canalicular phase is next when the vascular bed begins 
to be organised and the pulmonary acinus forms. The peripheral airspaces are dilated 
and their epithelium begins to differentiate in the saccular phase. The final process is 
the alveolar phase when the alveoli grow and separate. Figure adapted from:
Whitsett et al., 2004.
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Table 1.2 Overview of factors with mutations that affect lung development.
Factor Type Pathology Reference
Intrinsic
BMP4 Inhibition Impaired development of distal epithelium, lethal (Weaver et al ,  1999)
EGFR Inhibition Reduced branching morphogenesis, lethal failure of lungs to 
mature
(Miettinen etal., 1997)
FGF-10 Inhibition Lung agenesis (Min et al ,  1998)
FGFR2b Inhibition Inhibited branching morphogenesis (De Moerlooze et al ,  2000)
SHH Inhibition Inhibited branching morphogenesis, disrupted 
vasculogenesis
(Litingtung e ta l ,  1998; 
Pepicelli e t a l ,  1998)
TTF-1
TGFp
Inhibition
Inhibition
Defective lung formation, lack of oesophageal/tracheal 
septation
p l- Impaired development, p2- lethal respiratory failure, p3 
-  lethal lung dysplasia
(Minoo e ta l ,  1999)
(Kaartinen et al ,  1995; Zhou 
et a l ,  1996; Sanford et al,  
1997)
TGFp Overexpression pl - lung hypoplasia
(Serra e ta l ,  1994)
VEGF Inhibition Abnormal lung development -  decrease in acinar tubules 
and mesenchyme
(Miquerol et al ,  1999)
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Wnt
Wnt
Inhibition
Overexpression
Wnt5a -  overexpansion of airways, tracheal truncation 
Wnt5a - Reduced epithelial branching, dilated distal airways
(Li et al., 2002) 
(Li et a l ,  2005)
Extrinsic
Diaphragmatic
Hernia
Reduction of 
pleural space
Lung hypoplasia and inadequate lung development (DiFiore et al ,  1994)
Nicotine Exposure Receptor activation Hyperplasia, increased branching, premature differentiation (Wuenschell et al ,  1998)
Oxygen Hyperoxia Premature differentiation (Acarregui e ta l ,  1993)
Tracheal
Occlusion
Increased internal 
pressure
Increased branching morphogenesis & premature 
differentiation
(Quinn et al ,  1999)
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Not only is FGF-10 vital for the primary lung buds, it serves as a chemotactic 
stimulus to the developing lung epithelium. When isolated epithelia are cultured in 
matrigel near an acrylic bead soaked in FGF-10, there is an initial outgrowth of the 
epithelium towards the source of FGF-10 and then branching around it (Weaver et 
al,  2000). That the epithelium contains a receptor to detect the presence of FGF-10 
can be inferred from the aforementioned results, and indeed FGF receptor 2 (Fgfr2) 
is expressed in the developing lung epithelium (Peters et al ,  1992). When this 
receptor is inactivated specifically in the lung, 2 undifferentiated epithelial tubes 
extend from the trachea to the diaphragm, indicating that Fgfr2 is vital for branching 
and differentiation of the lung epithelium (Peters et al ,  1994). The specific isoform 
of the Fgfr2 receptor that responds to FGF-10 is understood to be Fgfr2b (Fig.
1.6A). This interaction has been inferred from the similarity of mice which lack 
Fgfr2b and mice lacking FGF-10 expression. Both mice are non-viable as their lungs 
do not extend beyond their trachea (De Moerlooze et a l ,  2000).
While FGF-10 is intimately involved in epithelial-mesenchymal interactions in 
branching morphogenesis, other FGFs also have roles within the lung. For instance, 
FGF-1 is present in the mesenchyme early in lung development and promotes 
multiple branched buds in isolated epithelial cultures, while FGF-7 is expressed from 
mid-gestation and induces proliferation and differentiation of isolated epithelial 
cultures (Cardoso et al ,  1997). FGF-9 is expressed in the lung epithelium and in the 
pleura or mesothelium covering the lung at the initiation of lung branching 
morphogenesis, but by E l2.5 its expression is restricted to the mesothelium. Mice 
lacking FGF-9 show it to be responsible for lung size by controlling the proliferation 
of the mesenchyme (Colvin et al ,  2001). However, it is generally accepted that there
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is a hierarchical ranking of importance in this family of growth factors, i.e. without 
FGF-10, none of the other FGFs would get a chance to be expressed.
As FGF-10 has such a marked chemotactic effect on the epithelial development 
of the lung, it is important to control the locality of its expression. Mice which are 
null for Sonic hedgehog (Shh) display a diffuse expression of FGF-10 throughout 
their lungs, which consist of epithelium from the two primary bronchi that are 
simply large cysts (Pepicelli et al., 1998). Indeed Shh acts as a negative regulator of 
FGF-10 with its expression localised at distal epithelial tips, where it diffuses to the 
mesenchyme and helps regulate bud size and shape by down regulating FGF-10 
expression (Bellusci et al., 1997a; Lebeche et al., 1999). Another factor that controls 
the activity of FGF-10 in the lung is sprouty 2 (Spry2; Fig. 1.6A). Spry2 expression 
is FGF-10 dependent and interferes with FGF-10 activity, inhibiting its signalling 
with Fgfr2b by interacting with parts of the MAP kinase signalling cascade and 
resulting in a net decrease in MAP kinase activation (Tefft et a l ,  2002).
Concomitantly expressed with Fgfr2b, Shh and Spry2 in the distal epithelium 
is Bone Morphogenic Protein 4 (Bmp4), another regulator of branching 
morphogenesis (Bellusci et al., 1996). With expression concentrated in the terminal 
buds at El 1.5 through E15.5 and some expression in the adjacent mesenchyme, 
Bmp4 has been implicated in differentiation and branching morphogenesis, as 
demonstrated using mice in which Bmp4 is overexpressed in the epithelium using a 
surfactant protein -  C (SP-C) promoter (Bellusci et a l ,  1996). By E l5.5 the lungs of 
these mice are dramatically smaller than their wildtype counterparts with fewer 
terminal branches that are enlarged and separated by thick mesenchyme. By E l8.5 
there are apparent defects in alveolarization with decreases in alveolar type II (ATII) 
cell number. While studies with the above mice implicate Bmp4 in later lung
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developmental events, there is conflicting information about its activity earlier in 
lung development. Exact actions are difficult to determine due to, on one hand the 
late expression of SP-C in the above mouse model and on the other, the lethality of 
the Bmp4 null mouse, which dies before the initiation of lung formation (Winnier et 
a l ,  1995). In addition, in vitro studies have presented conflicting results regarding its 
roles, which seem to depend on the method of culture (Weaver et a l ,  2000; Bragg et 
al., 2001). Mesenchyme-free epithelial cultures treated with exogenous Bmp4 
indicate that it has a negative modulatory effect on FGF-10 signalling (Weaver et a l ,  
2000), while in whole lung explants application of physiological levels of exogenous 
Bmp4, enhances branching (Bragg et a l ,  2001). The combination of these results 
implies that both the presence of mesenchyme, and the level of Bmp4 is expression, 
are vital to type of effects Bmp4 signalling has on lung branching morphogenesis 
(Fig. 1.6B). Gremlin is a negative modulator of Bmp4 activity during lung 
development. It is most highly expressed early in lung development (El 1.5-14.5) 
where it restricts Bmp4 activity to the distal buds thereby helping to coordinate the 
optimal number of branching epithelia (Shi et a l ,  2001).
Proteins from the Wnt family have been recently shown to be intrinsic factors 
which affect the expression of some of the above described growth factors during 
lung organogenesis. Members of this family fall into two different categories 
depending on their modes of action, canonical and non-canonical (Seto & Bellen,
2004). Canonical members stabilize (3-catenin and activate target genes through its 
binding with TCF/LEF transcription factors (Seto & Bellen, 2004), while non- 
canonical Wnts are p-catenin independent and can antagonise canonical Wnt 
signalling (Topol et a l ,  2003). Both canonical and non-canonical Wnts have been 
shown to be expressed during lung development (Cardoso & Lu, 2006).
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Canonical Wnt2a, Wnt2b and Wnt7b are expressed by the lung during 
development. Wnt2a is expressed in the distal lung mesenchyme, and disruption of 
this gene results in developmental defects, but not in the lung (Monkley et a l ,  1996). 
However this lack of a lung phenotype could be the result of redundancy as Wnt2b is 
also expressed in the mesenchyme (Katoh et al., 1996). Mutants with inactivation of 
Wnt7b, normally expressed in the distal epithelium, have lungs which are severely 
hypoplastic due to proliferation and smooth muscle cell defects (Shu et a l ,  2002).
In many cases however, the effects of canonical Wnt signalling are studied by 
interfering with p-catenin, rather than the Wnt proteins themselves, thereby 
providing an insight to the broader function of canonical Wnt signalling. Complete 
removal of p-catenin from the distal epithelium results in a lack of Bmp4 expression, 
as well as reduction of Fgfr2b with reduced FGF dependent ERK1/2 activity (Shu et 
a l,  2005). In addition, this study also showed that when Wnt signalling was 
inhibited by Dikkopf-1 (DKK1), SP-C, a marker for distal epithelial cells, was 
decreased in the distal epithelium while a marker for proximal epithelium, CC10, 
was increased (Shu et a l ,  2005). Taken together, these results point toward canonical 
Wnt signalling controlling the proximal-distal patterning of the lung by controlling 
the expression of Bmp4 and Fgfr2b (Fig. 1.7). Additionally it seems that canonical 
Wnt signalling plays a role in the cleft formation and resultant branch formation of 
early lung development. This conclusion was drawn from experiments where 
application of DKK1 to early (El 1.5) cultured lungs, which resulted in enlarged 
terminal buds, decreased fibronectin (FN) deposition and decreased a- smooth 
muscle actin (a-SMA) expression (De Langhe et a l ,  2005).
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Figure 1.6: Models of FGF-10 and Bmp4 activity in lung development. A). FGF-10 is 
expressed in the distal mesenchyme of the developing lung exerting chemotactic 
effects on Fgfr2b expressing epithelium resulting in cellular proliferation and bud 
outgrowth. These effects are tempered by both Shh, which reduces the expression of 
FGF-10 and Spry2, which interferes with FGF-10/Fgfr2b signalling. B). Bmp4 is 
expressed in the distal tips of the developing lung where it enhances branching 
morphogenesis. Overexpression of Bmp4 throughout the epithelium, as well as 
negative regulation by Gremlin, results in decreased branching morphogenesis. 
Figure adapted from Bellusci et a l, 1996, 1997a and b, De Moerlooze et a l, 2000, 
Tefft et a l, 2002 and Shi et a l, 2001.
58
Lumen
Epithelium
M esen ch y m e
Fgfr2b
Canonical
Non-
Canonical
-n
-n
Figure 1.7: Model of factors affected by Wnt proteins during lung development.
Canonical Wnt/p-catenin signalling in the distal epithelium has effects on 
Fibronectin (FN) deposition at the clefts formed for branching, Fgfr2b, a- smooth 
muscle actin (a-SMA) and Bmp4 expression. Non-canonical Wnt signalling by 
Wnt5a has antagonising effects on the signalling of FGF-10, as well as Shh and 
Bmp4. Figure adapted from De Langhe et a l, 2005 and Shu et a l, 2005.
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Non-canonical Wnt signalling effects have been mainly investigated using the 
protein Wnt5a. Wnt5a is expressed in both the mesenchyme and the branching distal 
epithelium of the developing lung, where it has been shown to affect expression of 
both Shh and FGF-10 (Li et al., 2002; Li et a l ,  2005). Embryos which are null for 
Wnt5a die shortly after birth from respiratory failure due to lungs which have 
shortened tracheas and highly branched, immature, over-expanded distal airways. 
These lungs show increased expression of Shh, FGF-10 and Bmp4, consistent with 
the state of the distal airways (Li et a l ,  2002). Conversely, embryos which 
overexpress Wnt5a in the epithelium have lungs which are smaller with a reduced 
number of dilated branches in spite of upregulation of FGF-10 expression and a 
decrease in Shh expression. The transgenic lungs from this study did not respond in 
the normal way to upregulation of FGF-10 expression, possibly due to reduced 
signalling between Shh and its receptor (Li et a l ,  2005), but more likely due to an as 
yet undetermined effect on FGF-10 signalling itself.
In order for the lung to function properly at birth, i.e. perform gas exchange, 
the vascular network within the mesenchyme must be adequate relative to the 
amount of epithelial surface generated during development. The main growth factor 
studied for its role in vasculogenesis is vascular endothelial growth factor (VEGF), 
along with its cognate receptor fetal liver kinase -  1 (Flk-1). VEGF activity is critical 
for embryonic development in general, as mice losing one or both alleles for VEGF 
die early in gestation between E9.5 and E l0.5 (Miquerol et al., 1999) and embryos 
null for its receptor, Flk-1, die even earlier at E8.5-E9.5 (Shalaby et al., 1995).
Expression of VEGF has been detected in the lung epithelium of human fetuses 
(Acarregui et al., 1999) and in cultured mouse lung epithelium expression is specific 
to the terminal branch points (Healy et al., 2000). There are several isoforms of
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VEGF in the mouse. The isoform VEGF164 is the most potent mitogenic factor for 
endothelial cells (Keyt et a l ,  1996), and is expressed in the epithelium and 
mesenchyme at E l2.5 where it maintains vascular structure and endothelial cell 
proliferation (Akeson et a l ,  2003). When a VEGF coated bead is placed within the 
cultured lung explant, a capillary bed is formed around it (Healy et al., 2000). This 
result suggests that VEGF is responsible for vascularisation in the developing lung. 
This idea is further supported by the fact that mice deficient in the VEGF receptor, 
Flk-1, have no blood vessel development (Shalaby et a l ,  1995).
VEGF signalling, by application of exogenous VEGF 164 to cultured lung 
explants, has also been shown to: a) affect proliferation of both mesenchyme (where 
Flk-1 is expressed) and epithelium; b) up-regulate Flk-1, SP-C and Bmp4 
expression; c) down-regulate Spry2 and Spry4 expression. In contrast, it does not 
affect FGF-10 expression. These effects are reversed when Flk-1 expression is 
inhibited with antisense oligodeoxynucleotide (ODN) treatment; i.e. Flk-1, SP-C and 
Bmp4 are down-regulated while Spry2 and Spry 4 are upregulated (Del Moral et a l ,  
2006b). The combination of these two sets of results shows that the effects of 
VEGF164 application are mediated through its interactions with Flk-1. Therefore 
VEGF signalling is a vital component of epithelial -  mesenchymal communication 
which mediates lung development.
1.10.2 Extrinsic Factors affecting Lung Development
All of the factors discussed in Section 1.9.1 are susceptible to under - and 
over -  expression as well as inappropriate timing of expression. These faults can be 
caused by an inherent genetic defect, or they can be influenced by factors which 
come from outside the developing lung or fetus. These extrinsic factors can alter the
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intrinsic programme of lung development resulting in impaired function after birth 
(Pinkerton & Joad, 2000).
Oxygen (O2) is one such extrinsic factor which can affect the intrinsic lung 
developmental programme. Development occurs in the relative hypoxic environment 
of the uterus (Lee et al., 2001) and the lung itself remains poorly vascularised until 
mid-gestation, with staining for vascular endothelial markers not appearing in the 
mouse lung until E l2.5 (Colen et al., 1999). Due to the lack of vascularisation, it is 
assumed that the developing lung has a lower O2 tension (P02) than its adult 
counterpart. This has been shown in developing sheep where the pulmonary P02 has 
been shown to be 16-18 mmHg. This P02 indicates a hypoxic environment as the 
ambient external environmental P02 is 140-150 mmHg (Acarregui et al., 1993).
A P02 greater than 71 mmHg causes spontaneous induction of surfactant 
protein -  A (SP-A) expression and morphological differentiation in cultured human 
fetal lungs while a P02 of approximately 7 mmHg keeps them in a state similar to 
that at the beginning of culture (Acarregui et al., 1993). Rat lung explants cultured at 
21 mmHg display increased branching morphogenesis and proliferation as well as 
the correct proximal-distal differentiation for their stage. When rat lung explants are 
cultured at 71 mmHg, the pattern of branching morphogenesis, proliferation and 
proximal-distal differentiation seen in response to 21 mmHg is disrupted. Mouse 
lung explants in hyperoxic conditions of 250 mmHg or greater did not branch or 
grow (Wilbom et a l ,  1996) setting an upper limit on the amount of O2 that a 
developing lung can tolerate. As for intrinsic factors which are modulated by O2 
concentration, VEGF, Flk-1 and platelet endothelial cell adhesion molecule -1, all of 
which are involved in vascular development, are more highly expressed in lungs 
cultured at 21 mmHg than in those at 140 mmHg. Expression of FGF-10, Fgfr2b and
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Bmp4 were unchanged between the two concentrations, however, SP-C expression 
increased as the lungs were maintained in culture, demonstrating an appropriate rate 
of epithelial differentiation in this low O2 concentration (van Tuyl et a l ,  2005).
Nicotine, which crosses the placental barrier and concentrates in the 
environment around the fetus (Luck et a l ,  1985), is another extrinsic factor that can 
affect lung development. Children bom to mothers who smoked throughout 
pregnancy have significantly decreased lung function (Cunningham et al., 1994) and 
predisposition to episodes of wheezing (Hanrahan et a l ,  1992). When lung explants 
are cultured in the presence of 1 pM nicotine, there is a 32% increase in the number 
of terminal airway branches when compared to culture conditions without nicotine. 
Following nicotine exposure there is also an increase in expression of mRNAs 
encoding SP-A and SP-C, which are used as markers of the lung’s stage of 
differentiation. The increase in these surfactant proteins indicates that the lung has 
prematurely developed (Wuenschell et a l ,  1998). Other studies have shown that 
nicotine exposure increases the proliferation of alveolar type II cells and increases 
surfactant protein synthesis in general (Rehan et a l ,  2007). These changes in the 
terminal sacs of the airways could later impede gas exchange. While there are 
currently no reports linking nicotine exposure to changes in intrinsic factors such as 
FGF-10 or Bmp4, there have been reports of it affecting components of the 
extracellular matrix. These components include factors such as collagen and elastin, 
which are vital to forming the correct structure of the lung (Pierce & Nguyen, 2002), 
and defects in their expression may negatively impact the ability of the lung to 
expand properly.
Another extrinsic factor that can affect intrinsic lung developmental 
mechanisms is a mechanical impediment to lung development. One naturally
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occurring mechanical change is the pathological state of congenital diaphragmatic 
hernia (CDH) where development of the lung is impeded by the presence of 
abdominal organs within the chest cavity. CDH results in lung hypoplasia with 
severe morbidity and mortality consequences (Stege et al., 2003). In neonates 
suffering from this abnormality, the degree of lung hypoplasia is associated with the 
severity of their symptoms and survival (Smith et a l ,  2005). At this time there is not 
linkage between a specific gene and the development of CDH, but it is linked with 
malfunctioning peristalsis in airway smooth muscle (Jesudason, 2006; Jesudason et 
al., 2006).
One of the current treatments for CDH is tracheal occlusion, which in itself 
can result in defective lung development. The lung develops as a fluid-filled organ, 
with fluid being secreted by the developing epithelium, and tracheal occlusion 
greatly increases intraluminal pressure due to the inability of the secreted fluid to 
evacuate from the lung. Tracheal ligation may occur pathologically, as in cases of 
congenital tracheal agenesis (Mori et al., 2001), or surgically, as in cases where it is 
used to treat CDH (Smith et al., 2005) and it can be experimentally accomplished 
within ex vivo lung cultures. In E14 mouse lung explants tracheal ligation increased 
both lung growth and maturation (Blewett et al., 1996), this was also true for the 
lungs of an infant which suffered from tracheal agenesis (Mori et al., 2001).
1.11 The Lung, Calcium and the CaR
There are several studies which point to a role for Ca2+ in lung development. 
In 1995 it was reported that contractions of the developing airway smooth muscle 
could be abolished by the application of an L-type calcium channel blocker, 
nifedipine, thereby blocking the influx of Ca2+0 into the lung smooth muscle cells 
within El 1 mouse lung explants. This treatment also affected the overall growth of
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the lung, producing a hypoplastic lung (Roman, 1995). Later experiments confirmed 
these observations and elaborated that the effect of nifedipine on lung growth could 
not be rescued by exogenous application of FGF-10, implicating that there was a link 
between FGF-10 signalling and the smooth muscle cell activity within the 
developing lung. Indeed, nifedipine abolished both lung smooth muscle contractions 
and the increases in lung growth normally mediated by FGF-10 (Jesudason et al,
2005). This study also demonstrated that the contractions of airway smooth muscle 
were peristaltic in nature and their frequency could be modulated by application of 
nicotine and FGF-10.
The above studies have shown that the peristaltic movement is reliant upon 
Ca2+0 influx, and that airway peristalsis is linked to normal development of the lung. 
Ca2+- imaging experiments revealed that regenerative, spontaneous Ca2+i waves 
travel via gap junctions through the smooth muscle. Generation of these waves 
required Ca2+0 entry and are dependent on Ca2+i release from the sarcoplasmic 
reticulum (Featherstone et a l ,  2005). It is interesting that this Ca2+- dependent 
phenomenon is developmentally regulated, related to the growth of the lung in 
normal conditions and yet this relationship can be broken when there is an 
underlying cause of lung hypoplasia, like CDH (Jesudason et a l ,  2006). While these 
studies have used nominally Ca2+0-free solutions on cultured lung buds to elucidate 
the nature of the Ca2+ activity in smooth muscle, there are no studies on any effects 
which [Ca2+]0 may have on lung development.
The lack of study in to the potential effects of Ca2+0 on lung development has 
possibly occurred because, prior to the experiments detailed in this thesis, there has 
been no evidence that the lung possessed a mechanism with which to respond to 
changes in Ca2+0. CaR transcripts have not been detected in adult lungs by Northern
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blot analysis (Brown et a l ,  1993; Riccardi et a l ,  1995). However, there is some 
circumstantial evidence pointing towards the possibility that CaR activity may 
influence lung development.
In the vast number of reports describing different CaR mutations resulting in 
NSHPT, one 3-month old patient presented with hypercalcemia, hyperparathyroid 
bone disease and difficulty breathing. He underwent an immediate 
parathyroidectomy, however despite this intervention and resolution of his 
hypercalcemia, he died from respiratory failure (Pidasheva et a l ,  2006). 
Unfortunately, there is no published information on the exact pathological status of 
his lungs. Another NSHPT patient was bom prematurely, and was diagnosed with 
lung hypoplasia, respiratory distress syndrome and early pulmonary interstitial 
emphysema on the day of her birth. Again, despite rapid and successful interventions 
to mitigate severe hyperparathyroidism, this patient died from severe chronic lung 
disease (Fox et a l ,  2007). Although these are two reports of lung symptoms within a 
larger body of published reports it is possible that other NSHPT patients have also 
had respiratory issues that were incidental to their other more severe symptoms. This 
supposition is supported by another publication which reported that in a family with 
a high occurrence of FHH, several children had died at the ages of 2-14 months from 
respiratory or gastro-intestinal disturbances or from sudden infant death (Auwerx et 
a l,  1985b).
Interstitial lung disease is one type of respiratory pathology that has been 
shown to have a high occurrence within FHH cohorts. It is part of a group of 
diseases broadly known as pulmonary fibrosis that result in respiratory deficiency 
due to scarring of the alveolar interstitium (Steele et a l ,  2005). It has been published 
that in a familial cohort of 43 members there was a positive correlation between
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inheritance of FHH and interstitial lung disease. This coexistence of pathology was 
regardless of patient’s smoking habits and generally involved malfunctioning 
granulocytes (Auwerx etal., 1985a; Auwerx et al., 1985b). The pathologies 
mentioned here could be the result of defective CaR function. Even though there is 
no evidence to suggest that CaR is present in the lung from birth onwards to 
adulthood, it is entirely possibly that maladjustment to Ca2+-dynamics during 
development due to defective CaR function results in defective lung physiology later 
in life.
1.12 Aims and Objectives
The division and expansion of branches in the developing lung is primarily a 
prenatal occurrence which occurs when the fetus is exposed to hypercalcaemic 
conditions compared to its adult life, with standard free ionized [Ca2+]0 of 1.7 mM . 
Given that calcium concentration has potential effects on the expression and control 
of vital developmental proteins in the lung; I hypothesize that extracellular calcium 
is an important extrinsic factor that modulates the intrinsic lung developmental 
programme. Furthermore, as preliminary data have shown CaR mRNA expression 
within the developing lung; I propose that the potential effects of calcium will be 
modulated via activation of the extracellular calcium-sensing receptor.
Specific aims of this project include:
1. To determine the effect of changing [Ca2+]0 on lung branching 
morphogenesis;
2. To determine the detailed ontogeny and cellular distribution of CaR in lung;
3. To establish the role of CaR in lung development;
4. To determine functional consequences of CaR activation in the lung;
5. To characterize the mechanism of action of CaR-dependent regulation of
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branching;
6. To characterize the lung phenotype of CaR knockout mice.
In order to accomplish these aims I will be using the established model of gas-fluid 
interface lung explant culture which is a robust tool due to the fact that the process of 
lung development is stereotypically retained when embryonic lungs are grown in 
culture (Jaskoll et a l ,  1986). This culture method was chosen over other methods, 
i.e. submersion cultures (McAteer et al., 1983) or Matrigel embedding, due to the 
desire to enable comparison of my results against other published studies using the 
interface culture method. Additionally, the interface method allows for 
uncomplicated counting of terminal branches which is the primary read-out of this 
study. I will also be using PCR, immunohistochemistry and transgenic mouse 
models to test my hypothesis.
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CHAPTER 2:
EFFECT OF EXTRACELLULAR 
CALCIUM ON LUNG BRANCHING 
MORPHOGENESIS
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2.1 Methods
2.1.1 Lung Explant Cultures
Embryos at day 12.5 of development (E l2.5) were removed from time-mated 
pregnant C57/BL6 females. The morning of plug was considered E0.5 and all 
pregnant female mice were humanely sacrificed in accordance with UK Home 
Office Schedule 1 procedures or Children’s Hospital Los Angeles Institutional 
Animal Care and Use Committee regulations by CO2 inhalation. Embryos were 
removed from dead, pregnant females in utero to cold Hank’s balanced saline 
solution (HBSS), gently dissected from their membranes with the aid of a 
stereomicroscope, decapitated and the lungs dissected from the body.
Lung explant culture experiments were based on the culture model developed 
by Jaskoll et al., (1986). The lungs were dissected from embryos in cold HBSS 
(Invitrogen, Paisley, UK) without Ca2+ or Mg2+. For individual lobe experiments, the 
lungs were divided mechanically using forceps to break off each lobe. The isolated 
lungs or lobes were placed on Nucleopore filters (8.0 |im pore size; Whatman Intl. 
Ltd., Maidstone, Kent, UK) floating on the surface of 1000 j l l I  of DMEM/F12 
medium (Invitrogen, Paisley, UK) in Nunclon 4-well dishes (De Langhe et al., 2005) 
with 1000 U/ml penicillin and 0.1 mg/ml streptomycin (Invitrogen, Paisley, UK). All 
explant culture experiments were performed in chemically defined, serumless 
conditions.
Once initial pictures were taken (t = 0 h), the cultures were placed in a cell 
culture incubator at 37°C, 5% C02/95% saturated air. Pictures were taken at 0, 24 
and 48 h in culture using a Leica MZ12s stereomicroscope, digital camera and 
software (Leica Microsystems (UK) Ltd., Milton Keynes, Buckinghamshire, UK) at 
2.5x magnification. The effect of different [Ca2+]0 on lung growth and branching
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morphogenesis was tested by altering the Ca 0 concentration of DMEM/F12. This 
medium contains a basal [Ca2+]0 of 1.05 mM and was adjusted by adding either 0.2 
M EGTA to reduce the Ca2+ present in the medium, or 0.5 M CaCh to increase the 
[Ca2+]0. [Ca2+]0 was measured, in 3 samples to ensure that calculated concentration 
and actual concentration were within a reasonable margin using a ABL 800 FLEX 
(Radiometer Limited, Sussex, UK) blood gas analyser. Results are presented in 
Table 2.1.
Branching morphogenesis was quantified by counting the number of terminal 
branches around the periphery of the lung explants at the time of removal, at 24 and 
48 h in culture. The percent change in branching was calculated as: (Branches24h 0r48h 
-  Branches^) / Branchesoh x 100.
Table 2.1: Predicted and measured [Ca2+]0 of lung explant culture medium. Predicted 
[Ca2+]0 and measured [Ca2+]0 of culture medium used for lung explant cultures at 
37°C , pH 7.4. 3 separate samples were measured for each [Ca2+]0, data presented are 
mean + standard deviation.
Predicted [Ca2+]0 Measured [Ca2+]0 0.2 mM EGTA 
added
0.5 mM CaCh 
added
0.5 mM 0.62+0.1 mM 2.75 pL n/a
1.05 mM 0.92+0 mM n/a n/a
1.2 mM 1.09+0.1 mM n/a 0.3 pL
1.7 mM 1.51+0.2 mM n/a 1.32 pL
2.5 mM 2.49±0.1 mM n/a 2.9 pL
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2.1.2 Area Measurements of Lung Explant Cultures
Photomicrographs taken at t = 48 h were imported into Adobe Photoshop 7.0 
to 100% their original size (20.43 x 27.62 cm). For all photomicrographs, brightness 
and contrast were increased (+43, +66) to enhance delineation between mesenchyme 
and lumen. Using the “lasso” tool the external edge of the lung was traced (Fig. 2.4 
A/ and ii), the “histogram” function was used to determine the number of pixels 
within the traced area, and this measurement was assumed to be the total lung area. 
The mean + standard error of the mean (s.e.m.) was then calculated using Microsoft 
Excel producing a value for the total area of lungs cultured in the presence of 1.05 
and 1.7 mM Ca2+0. Also using the “lasso” tool the internal lumen spaces were traced 
and again the “histogram” function used to determine the number of pixels contained 
within the traced area. This measurement was assumed to be the luminal area of the 
lung. The amount of mesenchyme within each lung was calculated by subtracting the 
luminal area from the total lung area. The percentage of lumen or mesenchyme 
within the total area of each lung was calculated by the following formula:
(Total area -  Lumen (or mesenchyme) area)/ Total area = x*100 = % lumen or % 
mesenchyme. The mean + standard error of the mean (s.e.m.) was then calculated for 
the % lumen or % mesenchyme within lungs cultured in the presence of 1.05 and 1.7 
mM Ca2+0.
2.1.3 Immunohistochemistry
Microdissected and cultured lungs were fixed in 4% paraformaldehyde (PFA) 
in phosphate buffered saline (PBS) at 4°C for 20 min. The specimens were 
subsequently washed twice with PBS, then dehydrated and stored in 70% ethanol at 
4°C. PFA-fixed tissue was then embedded in paraffin wax and 5 |im thick sections
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were cut for histology on a standard microtome. Sections were mounted on 
Superfrost Plus glass slides (Fisher Scientific, UK). Tissue sections prepared for 
histology were de-paraffinized with Histochoice (Sigma-Aldrich, Gillingham, 
Dorset, UK) and rehydrated through a series of graded alcohols. After rehydration, 
the slides were subjected to antigen retrieval by submerging in citrate buffer (2.1g 
Citric Acid Monohydrate in 1 L H2O brought to pH 6.0 with NaOH) heated to 
boiling in a 900 W microwave for 3 min. Once the buffer was boiling, the 
microwave setting was reduced to 300 W and the slides were boiled for a further 10 
min. The slides were left to cool to room temperature (RT) in the citrate buffer. 
When the buffer was at RT, the slides were rinsed in PBS and non-specific binding 
of the primary antibody was prevented by incubating slides in 3% bovine serum 
albumin (BSA) in PBS (Sigma-Aldrich, Gillingham, Dorset, UK) containing 0.1% 
Triton-XlOO (Sigma-Aldrich, Gillingham, Dorset, UK) for 1 h at room temperature. 
For proliferation studies, immunohistochemistry was performed using a rabbit 
polyclonal antibody against phosphorylated histone H3 (Upstate, Lake Placid, NY, 
USA), a marker of mitosis. The slides were incubated with this antibody at 1:200 
dilution in antibody dilution fluid (AbDF; 1% BSA, 3% Seablock (EastCoast Bio, 
Soham, Cambridgeshire, UK) in PBS with 0.1% Triton-XlOO) overnight at 4°C.
The primary antibody was removed by washing in several changes of PBS. 
The secondary antibody (supplied in the Dako Envision Kit mentioned below) was 
applied for 30 min at RT, and then removed in several washes of PBS. Visualization 
of the detected proteins was performed using an Envision Diaminobenzidine kit 
(DAB; Dako, Ely, Cambridgeshire, UK) according to the manufacturer’s 
instructions. Once the DAB was developed to an adequate level, with nuclear 
staining and minimal background, the slides were counterstained with Harris’s
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haematoxylin, dehydrated and mounted with Clarion mounting medium (Sigma- 
Aldrich, Gillingham, Dorset, UK). For staining of apoptotic cells in paraffin 
sections, an ApopTag Plus Peroxidase In Situ apoptosis detection kit 
(Chemicon/Millipore, Watford, UK) was used according to manufacturer’s 
instructions.
For both proliferation and apoptosis quantification, three lungs were stained 
for each 1.05 mM and 1.7 or 2.5 mM Ca2+0. Once stained, 5 photomicrographs were 
taken at lOOx magnification of two sections (5 sections apart to minimise risk of 
double counting cells) per lung. The number of stained cells (proliferating or 
apoptotic), as well as the total cell number within each photomicrograph was 
counted and the number of stained cells expressed as a percentage of total cell 
number.
2.1.4 Trans-epithelial Potential Difference
This protocol was developed, performed and kindly provided by William 
Wilkinson Ph.D. Lung trans-epithelial potential difference (TPD) was recorded using 
the current clamp technique. After 48 h in culture, individually mounted lung 
explants attached to filters were removed from growth medium, placed in the bottom 
of recording chamber and held down with a platinum ring that did not touch the lung 
explant. The recording chamber was then carefully filled with a solution containing 
(in mM); 135 NaCl, 5 KC1, 1.2 MgCl2, 1 CaCl2, 5 HEPES, 10 Glucose, pH 7.4 with 
NaOH. Borosilicate glass electrodes (World Precision Instruments, Stevenage, UK), 
were filled with 0.4 % trypan blue solution in 0.85% saline (Invitrogen, Paisley, UK) 
and had a resistance of 4-5 MG. Electrodes were carefully pushed into a random 
lumen terminal, whilst maintaining positive pressure on the electrode, when access 
was achieved (blue dye in lumen), positive pressure on the electrode was removed,
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and equilibrium was allowed to be reached over a 5 min period before being 
removed. The trans-epithelial potential difference was taken as the difference 
between the inside and outside at the end of the 5 min. Recordings were made using 
an Axon Multiclamp 700A amplifier (Axon Instruments) and analysed using pClamp 
9 software. Ag-AgCl reference electrode was placed in the bath approximately 5 mm 
from the lung explant.
2.1.5 Statistics
Graphic representations and statistics of the data were prepared with Origin 7 
software. Data are presented as the mean (from multiple pooled experiments where 
indicated) + s.e.m. Significance was determined using one-way ANOVA with 
Tukey post-hoc test and a p-value of <0.05 was deemed significant.
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2.2 Philosophy of work
Previous studies carried out on isolated embryonic rat lung explants have 
indicated that altered Ca2+i dynamics influence lung growth. These studies have 
investigated the phenomenon of spontaneous airway contractions observed in rats, 
mice and humans (See section 1.11 for review), showing that [Ca2+]0 is involved in 
the generation of Ca2+ waves in airway smooth muscle (ASM) in the developing 
lung (Featherstone et a l ,  2005). Although these studies have shown that [Ca2+]0 is 
required for the propagation of ASM Ca2+-waves; the effects on branching 
morphogenesis of altering the [Ca2+]0 of the culture medium in which mouse lung 
explants are cultured has not been assessed. The series of experiments presented 
within this chapter were designed to investigate the potential effects of free-ionized 
Ca2+0 on the branching morphogenesis programme of the lung.
2.3 Branching morphogenesis is sensitive to [Ca2+]c .
Using an established model of mouse lung explant cultures (Jaskoll et al., 
1986), E l2.5 lungs were cultured for 48 h in chemically defined, serum-free medium 
conditions. E l2.5 embryos were used for these studies because, at this point the 
lungs are at the beginning of the pseudoglandular stage of lung development and 
branching morphogenesis is easily quantifiable. A range of different [Ca2+]0, from
1.05 to 2.5 mM Ca2+0 (Fig 2.1), was chosen to correspond with previously published 
lung culture studies, and to reflect physiological levels. [Ca2+]0 of approximately 1.2 
and 1.7 mM correspond to the adult and foetal serum free ionized [Ca2+]0, 
respectively (Kovacs & Kronenberg, 1997). Additionally, we considered the range 
at which the CaR responds to Ca2+, normally between 0.5 and 3.5 mM, as it is
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responsible for maintaining physiological systemic [Ca2+]0 levels (Brown & 
MacLeod, 2001).
Lung branching morphogenesis was sensitive to Ca2+0, with differences in the 
amount of branching morphogenesis quantified after 48 h, depending upon the 
[Ca2+]0 to which the lung explant was exposed (Fig 2.2). Figure 2.2A shows that the 
most permissive conditions for branching morphogenesis occurred when the [Ca2+]0 
was in the range of adult physiological levels of 1 .0 5 -1 .2  mM Ca2+c. At these 
concentrations, branching was increased by 123+4.5% (n=54) and 109.7+3.1% 
(n=88) after 48 h respectively. Lung explants cultured in the presence of [Ca2+]0 
similar to fetal [Ca2+]0i 1.7 mM, were restricted in the amount of branching 
morphogenesis after 48 h. Branching morphogenesis in these explants was halved to 
62.2+4.4% (n=45) in comparison to branching morphogenesis levels in 1.05 mM 
Ca2+0, and continued to be suppressed in 2mM Ca2+0 (37.1+8.8%) and 2.5 mM Ca2+0 
(54.7+4.2%). Representative pictures of lung explants cultured in either permissive 
or restrictive conditions at 0, 24 and 48 h in culture can be seen in Figure 2.2B.
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[Ca2+]0 (mM) 1.05 1.2 1.7 2.5
t = 0 h
t = 48 h
Figure 2.1: Initial determination of the effects of the [Ca2+]0 of culture medium on lung branching morphogenesis. A preliminary 
experiment was performed to determine if El 2.5 mouse lung explant cultures are sensitive to changes in the [Ca2 + ] 0  of culture medium. 
The upper panel of pictures represents the lungs at the time of dissection (E l2.5, t = 0 h) and placement onto floating filters. The lower 
panel of pictures represents the same lungs after 48 h (t = 48 h) in culture in the presence of culture medium containing the [Ca2 + ] 0  
(mM) designated above the panels. Scale bars = 600 pm.
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Figure 2.2: Lung branching morphogenesis is affected by incubating E12.5 mouse 
lungs in the presence of different [Ca2+]0. Lungs from El 2.5 mouse embryos were 
cultured for 48 h in serum-free DMEM/F12 with [Ca2+]0 adjusted using 0.5M CaCh 
to increase or 0.2M EGTA to decrease [Ca2+]0 • A). Total number of terminal 
branches was counted at 0, 24 and 48 h, normalized to 0 h, and the change expressed 
graphically as a percentage increase over 24 or 48 h. Data shown are the mean ± 
s.e.m., n numbers shown above each condition in parentheses from > 4 pooled 
experiments B). Representative pictures of lungs cultured in the presence of 1.05 
mM Ca2 + 0 (top row) or 1.7 mM Ca2+0 (bottom row) at 0, 24 and 48 h. Scale bars = 
700 pm.
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Next, the permanence of [Ca ]0-induced, branching morphogenesis effects 
was tested after 24 h in culture, by changing the [Ca2+]0 to which the lung explants 
were exposed for a further 24 h in culture. Thus, lung explants initially cultured with 
medium containing 1.05 mM Ca2+0 for 24 h, were subsequently cultured in medium 
containing 1.7 mM Ca2+0 for another 24 h or vice versa. Experimental controls 
consisted of lung explants maintained within either 1.05 mM or 1.7 mM Ca2+0for the 
duration of the experiment, although for consistency new medium was added after 
24 h.
The results of the “switching” experiments show that the reduced amount of 
branching morphogenesis in lung explants cultured in the presence of 1.7 mM Ca2+0 
can be rescued when lungs are removed from these suppressive conditions after 24 h. 
Removing the lung explants from the presence of 1.7 mM Ca2+0 after 24 h into the 
presence of 1.05 mM Ca2+0 for a further 24 h, results in a recovery of branching 
morphogenesis to 154+19.6%, versus a branching increase of only 80.8+20.7% when 
lungs were kept in the presence of 1.7 mM Ca2+0 for 48 h (Fig. 3.3A, D and E, n=5). 
Conversely, removing the lung explants from the presence of 1.05 mM after 24 h 
into the presence of 1.7 mM Ca2+0 for a further 24 h does not affect the rate of 
branching morphogenesis with branching increased by 171.8+22.4%, which is not 
different from the 172.6+30.7% in lungs maintained in the presence of 1.05 mM 
Ca2+0 for 48 h (Fig. 2.3A, B and C, n=5).
Lung explants cultured in 1.05 mM Ca2+0 appeared to be larger than lung 
explants grown in 1.7 mM Ca2+0 (Fig. 2.1). Therefore the total area and the luminal 
areas were measured by tracing both the external circumference and internal luminal 
area (Fig. 2.4A) and calculating the number of pixels contained within each area. 
There was a significant difference in the total area between lungs cultured in the
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presence of 1.05 mM Ca2+0 and 1.7 mM Ca2+0. The total area measured for lungs 
cultured in the presence of 1.05 mM Ca2+0 was 1.22xl05±4.2xl03 pixels (n=15), 
while the total area of lungs cultured in the presence of 1.7 mM Ca2+0 was 
significantly decreased to 1.03x10 ±4.3x10 pixels (n=14 from 4 separate isolations, 
p=0.003, Fig. 2.4B). The luminal space within lungs grown in the presence of 1.7 
mM Ca2+0 was also significantly smaller than the luminal space within lungs cultured 
in the presence of 1.05 mM Ca2+0. Lung explants cultured in the presence of 1.05 
mM Ca2+0 contained 61.04+1.04% lumen, while lungs cultured in the presence of 1.7 
mM Ca2+0 contained 57.95+0.87% lumen (p=0.033, Fig. 2.4C). The opposite was 
true for the percentage of mesenchyme making up the total lung area. Lungs cultured 
in the presence of 1.7 mM Ca2+0 had a greater percentage of mesenchyme with 
42.05+0.87% which was reduced to 38.97+1.04% in lungs cultured in the presence 
of 1.05 mM Ca2+0 (p=0.033, Fig. 2.4C). Therefore, there was a 3% increase in the 
percentage of mesenchyme component within lungs cultured in the presence of 1.7 
mM Ca2+0.
81
A. i
I 124 h 
^ 4 8 h
200 -
WD
*1 150-
wccsS
—
•S 100-
CJC
CC3
t  50-
1.05 1.05 to 1.7 1.7 1.7 to 1.05
[Ca2+]o (mM)
Figure 2.3: Lung branching morphogenesis can be rescued by manipulating [Ca2+]0.
E l2.5 mouse lungs were cultured for the first 24 h in the presence of 1.05 mM or 1.7 
mM Ca2+0. At 24 h the culture medium was changed from 1.05 mM to 1.7 mM, 1.7 
mM to 1.05 mM or replaced with medium containing the same [Ca2 + ] 0  as the original 
medium. Lung explants were then cultured for another 24 h. A). Representative 
pictures of explants: u 1.05 mM Ca2 + 0  for 48 h, ii. 1.05 mM Ca2 + 0  for 24 h then 
changed to 1.7 mM Ca2 + 0  for a further 24 h, iii. 1.7 mM Ca2 + 0  for 48 h, iv. 1.7 mM 
Ca2+0 for 24 h then changed to 1.05 mM Ca2 + 0 for a further 24 h. Inset pictures show 
each lung at 0  h showing a comparable number of initial terminal branches for each 
condition. B). Changing the [Ca2+]0 from 1.05mM to 1.7mM Ca2 + 0  after 24 h had no 
effect on the amount of branching morphogenesis at 48 h. Changing the [Ca2 + ] 0 from 
1.7 mM to 1.05 mM Ca2 + 0 after 24 h significantly increased the amount of terminal 
branching in the lung explants at 48 h. Data shown are mean± s.e.m. (n=5 lungs per 
condition from a single isolation), *** = p<0.036, in comparison to time-matched 
lung explants cultured in the presence of 1.7mM Ca2+0. Scale bars = 700 pm.
82
■ ■  1.05 mM Ca 
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Figure 2.4: Total, luminal and mesenchymal area are affected by manipulating [Ca2+ ]0 
of culture medium. Total lung area was measured by tracing the outside of (A, blue 
lines), and luminal area was measured by tracing the airways within, the lung (A, 
white dashed lines). A). Representative pictures of explants: i. 1.05 mM Ca2 + 0  for 48 
h, iL 1.7 mM Ca2 + 0  for 48 h. B). Total lung area is decreased when lungs are cultured 
in the presence of 1.7 mM Ca2+0for 48 h when compared to time-matched lungs 
cultured in the presence of 1.05 mM Ca2+0. C). Lungs cultured in the presence of 1.7 
mM Ca2 + 0  have a reduced percentage of lumen and an increased percentage of 
mesenchyme after 48 h when compared to time-matched lungs cultured in the 
presence of 1.05 mM Ca2+0. Data shown are mean± s.e.m. (n=15 for 1.05 mM Ca2 + 0  
and n=14 for 1.7 mM Ca2 + 0  from 4 isolations), ***= p<0.033 calculated by ANOVA 
with Tukey post-hoc test. Scale bars = 650 pm.
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2.4 Sensitivity to [Ca2+]0 is abolished when lung lobes are cultured 
individually.
At one point in this study, it was thought that it may be more accurate to have 
different [Ca2+]0 applied to the same lung, as this would allow for a single lung to be 
the control and experimental sample at the same time. This was tested by separating 
individual lobes from the lungs at the time of dissection and growing them in 
separate wells with different [Ca2+]0 in the culture medium. However, when this was 
done the sensitivity of branching morphogenesis to the differing [Ca2+]0 was 
completely abolished (Fig. 2.5).
There was no significant difference between lobes cultured in the presence of
1.2 mM (Fig. 2.5Ai, n = 8 lobes) or 1.7 mM (Fig. 2.5Aii, n = 5 lobes) Ca2+c, at either 
24 or 48 h (p>0.05). Branch numbers almost doubled within 24 h for both conditions 
resulting in 90+8.6% and 96+16.3% in 1.2 mM and 1.7 mM Ca2+0, respectively. At 
48 h branching had increased by 318.5+34.2% in 1.2 mM [Ca2+]0 and by 
357.3+53.7% in 1.7 mM [Ca2+]0. These results indicate that it is necessary to 
maintain the structural integrity of the lung explant as a whole for [Ca2+]0 sensitivity.
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Figure 2.5: [Ca2+]0 sensitivity is requires an intact lung explant. Lungs from E l2.5 
mouse embryos were separated into individual lobes and cultured for 48 h in serum- 
free DMEM/F12 containing 1.2 or 1.7 mM Ca2+0. A). Representative pictures of lung 
lobes cultured in the presence of: i. 1.05 mM Ca2 + 0  for 48 h, i t  1.7 mM Ca2 + 0  for 48 
h. Inset pictures show each lung at 0 h (post-dissection) showing a comparable 
number of initial terminal branches for each condition. B). Total number of terminal 
branches was counted at 0, 24 and 48 h, normalized to 0 h, and the change expressed 
graphically as a percentage increase over 24 or 48 h. Data shown are the mean ± 
s.e.m. (n = 8  lobes for 1.2 mM Ca2 + 0  and n = 5 lobes for 1.7 mM Ca2 + 0  from a single 
isolation). Scale bars = 300 pm.
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2.5 Cellular consequences of changing [Ca2+]0 on the developing lung.
The observed changes in the amount of lung branching morphogenesis in 
response to [Ca2+]0 could be due to a decrease in proliferation, and increase in 
apoptosis or a combination of the two. In order to determine which of these cellular 
responses occurred in response to [Ca2+]0, the levels of proliferation and apoptosis 
were quantified in both low (1.05 mM Ca2+0) and high (1 .7 -2  mM Ca2+0).
Proliferating cells were detected using immunohistochemistry of 
phosphorylated histone H3 as in Section 2.1.3. For lung explants cultured in the 
presence of 1.05 mM Ca2+0> the level of proliferation was 11.49+0.42% of the total 
cell number counted (Fig. 2.6A/ and B, n=3). In Lungs that were cultured for 48 h in 
the higher [Ca2+]0 conditions, 1.7 to 2mM Ca2+0, the level proliferation was 
significantly decreased to 5.37+0.89% of the cells counted (Fig. 2.6 A/i and B, n=3, 
p<0.004).
Apoptotic cells were detected using an in situ TUNEL detection kit as in 
Section 2.1.3. In lung explants cultured in the presence of low [Ca2+]0 (1.05 mM) the 
percentage of apoptotic cells detected in the total cell number counted was 
9.99+1.4% (Fig. 2.7 A/, Bi and C). There was no significant difference in the number 
of apoptotic cells between lung explants cultured in the presence of either low or 
high [Ca2+]0. Indeed, lung explants cultured in the presence of high [Ca2+]0 (1.7-2 
mM) had 12.15+3.04% apoptotic cells (Fig. 2.7 Aii, B ii and C).
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2.6 Functional characterisation of lung explants.
Adequate lung growth requires fluid-dependent distension in the developing 
tissue (Harding & Hooper, 1996). The fluid causing this distension is secreted from 
the lung epithelium by secondary active Cl' transport resulting in a negative trans- 
epithelial potential difference (TPD), the magnitude of which reflects the rate of Cl' 
driven fluid secretion (Olver & Strang, 1974). Measurement of TPD has not been 
reported previously in a mouse lung culture model. Therefore, a protocol was 
developed and optimised for such measurements. Time lapse images from E l2.5 
mouse lungs cultured in low (1.05 mM) and high (1.7 mM) [Ca2+]0 illustrate that the 
rate and extent of branching are both significantly reduced in high [Ca2+]0 culture 
conditions (Figure 2.8). Additionally this figure shows that the terminal buds of 
lungs cultured in the presence of 1.7 mM Ca2+0 appear to be more distended (Fig. 
2.8B), with a higher luminal volume at each branch terminus, possibly indicative of 
fluid secretion which is visible after 24 h in culture.
The mean TPD of terminal branches from lungs incubated for 48 h in in the 
presence of 1.05 mM [Ca2+]0 was -1.24+0.15 mV. The mean TPD increased 
significantly to -1.68+0.16 mV when the lungs were cultured for 48 h in the presence 
of 1.7mM [Ca2+]0 (Fig.2.9A, n > 17 per condition, p<0.05). The increase in 
branching seen when lungs are switched from 1.7 mM Ca2+0 to 1.05 mM Ca2+0 after 
24 h is not accompanied by similar changes in the TPD (Fig. 2.9 B). Once the TPD 
becomes more negatively charged after 24 h, from -1.07+0.1 mV in 1.05 mM Ca2+0 
to -1.49+0.23 mV in 1.7 mM Ca2+0, it remains at this level regardless of the [Ca2+]0 
to which the lung is exposed for the next 24 h (n=5 for each condition).
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Figure 2.6: Proliferation of cells in lung explant cultures is [Ca2+]0 sensitive.
A). Representative detection of proliferating cells (brown pigment) in a 5pm section 
of an E12.5 mouse lung explant cultured in the presence of: u 1.05 mM Ca2+0for 48 
h or ii. 1.7 mM Ca2+0. B). Proliferation, measured as the number of cells positive for 
anti-phosphorylated Histone H3 immunoreactivity is Ca2+0-sensitive and is greater 
when lungs are cultured in the presence of 1.05 mM Ca2 + 0  when compared to the 
number of proliferating cells in lungs cultured in the presence of 1.7 mM Ca2+0. Data 
shown are the mean ± s.e.m, n=3 lungs per condition, *** = p<0.004. E designates 
an area of epithelium, M designates an area of mesenchyme, Scale bars = 100 pm.
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Figure 2.7: Apoptosis of cells in lung explant cultures is not [Ca2+]0 sensitive. A).
Representative TUNEL detection of apoptotic cells (brown pigment) in a 5pm 
section of an E l2.5 mouse lung explant cultured in the presence of: i. 1.05 mM 
Ca2+0or ii. 1.7 mM Ca2 + 0  for 48 h, scale bars = 100 pm. B). Higher magnification of 
apoptosis detection in lungs cultured in the presence of i. 1.05 mM Ca2+0or ii. 1.7 mM 
Ca2 + 0 for 48 h. E designates an area of epithelium, M designates an area of 
mesenchyme, Scale bars =10 pm. C). Apoptosis measured as the number of cells 
detected by a TUNEL assay, is not Ca2+0 -sensitive. Data shown are mean + s.e.m., 
n=3 lungs for each condition.
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Figure 2.8: The rate of branching and the size of the luminal areas are affected by [Ca2+]0. El 2.5 mouse lungs were dissected and cultured 
on Transwells for 48 h in an Incucyte cell imager within a cell culture incubator, and pictures were taken once every hour for a total of 
48 h. El 2.5 mouse lungs cultured in 1.05mM Ca2 + 0 for 48 h branch more quickly and have smaller luminal spaces in their terminal 
branches (Panel A) than lung explants grown in 1.7 mM Ca2 + 0  (Panel B). Scale bars = 100 pm.
90
- 2. 0- (20)
Figure 2.9: Trans-epithelial potential difference in lung explant cultures is [Ca2+]0- 
sensitive. TPD recordings were taken from E l2.5 mouse lungs after 48 h in the 
culture conditions listed. A). TPD increases when lungs are cultured in the presence 
of 1.7 mM Ca2+0 (** = p<0.05) for 48 h. B). TPD is augmented when lungs are 
cultured in the presence of 1.7 mM Ca2+0 conditions which unlike branching 
morphogenesis, cannot be reversed by culturing explants in the presence of 1.05 mM 
Ca2+0 for 24 h after an initial 24 h in the presence of 1.7 mM Ca +0. Data shown are 
mean + s.e.m, n= shown in parentheses under each data point. (Data kindly provided 
by William Wilkinson, PhD)
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2.7 Chapter Discussion
For the purpose of this discussion and the remainder of this report the term 
“low” refers to [Ca2+]0 in the range of 1.05 -  1.2 mM and “high” refers to [Ca2+]0 in 
the range of 1.7 -  2 mM.
This chapter shows that, lung branching morphogenesis and lung size are 
sensitive to changing [Ca2+]0 via a mechanism(s) that involves changes in 
proliferation levels and Cl' secretion. These observations are completely novel. Also 
novel is the ability to reverse the suppression of branching morphogenesis observed 
in the presence of high Ca2+0 after 24 h by reducing the Ca2+0 to 1.05 mM. A 
summary chart of the results presented in this chapter is presented in Figure 2.10.
Interestingly, conditions which seem to be the most permissive for branching 
morphogenesis (1 .0 5 -1 .2  mM Ca2+c) correspond to physiological adult [Ca2+]0; 
while concentrations of 0.5 mM and 1 .7 -2  mM Ca2+0 seem to suppress the maximal 
response. The manner in which 0.5 mM Ca2+c suppresses branching morphogenesis 
has not been investigated in depth within this study. However this result suggests 
that there is both a minimum and maximum [Ca2+]0 required for optimal branching. 
This is supported by a preliminary experiment culturing lung explants in the 
presence of 0.1 mM Ca2+0 that resulted in the death of the explants within 48 h. 
However, it is also possible that the mode of achieving reductions in [Ca2+]0, i.e. the 
introduction of 0.2 M EGTA into the culture medium, is in itself causing the 
suppression of branching morphogenesis and death of the explants.
Therefore, much of the experimentation has focused rather on 1.7 mM Ca2+0 
as this corresponds to [Ca2+]0 reported for the developing mouse fetus (Kovacs et al., 
1998). The results showing branching suppression at this [Ca2+]c prompted the
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question, why would conditions thought to be normal for the developing fetus be 
restrictive in this manner?
There is a need for the lung to maintain a balance in its final branch number 
for optimal development of alveoli. Many adverse factors, including oxygen 
exposure, abnormal growth factor signalling and regulation, can all cause the 
alveolar epithelial surface to be hypoplastic and deficient in its ability to perform gas 
exchange (Warburton et a l ,  2006). However, there is also a danger of hyperplasia, 
with too many branches/alveoli, as seen in cultured lung explants that have been 
exposed to nicotine (Wuenschell et al., 1998). In fact, children exposed to nicotine in 
utero also have trouble with efficient gas exchange (Cunningham et a l, 1994). 
Perhaps [Ca2+]0 is a factor that acts as a controller to ensure that the optimal number 
of branches is achieved.
It is unsurprising that the structural integrity of the lung explants needs to be 
maintained in order to retain the [Ca2+]c sensitivity. It has been previously published 
that tracheal occlusion results accelerated lung growth, in part due to up-regulation 
of TGF-p (Quinn et a l ,  1999). Breaking the lungs into individual lobes may provoke 
similar stimuli to that of tracheal occlusions. The bronchiole of E l2.5 mouse lung 
explants contains smooth muscle, which will constrict upon breaking the lobe away 
from the rest of the lung, thereby shutting off any open lumen and increasing the 
pressure within the lobe. It is also possible that by dissociating the lung lobes there is 
an alteration in the activity of the peristaltic pacemaker (Jesudason et a l, 2005) 
within the smooth muscle of the lung airway that causes the increased branching 
morphogenesis noted in dissociated lung lobes.
What is the underlying cause of the branching differences that are seen in 
high vs low [Ca2+]0 cultures? Apoptosis levels in this study (9-12%) are greater than
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the published approximated values for apoptosis occurring during the 
pseudoglandular stage of development of 1-2% (Wongtrakool & Roman, 2008). This 
increased apoptosis could be due to difference in the culturing conditions from those 
used in the Wongtrakool and Roman study, which cultured explants in DMEM with 
10% bovine calf serum, which was not used in this study. Additional discrepancy 
could be produced by the differences in the sample sizes and modes of counting. 
However, apoptosis levels do not significantly differ in the low versus high [Ca2+]0 
cultures indicating that increased apoptosis is not necessarily the cause for the 
reduced branching morphogenesis and lung size observed in high [Ca ]0 cultures.
Proliferation levels detected in this study (6-12%) are lower than those 
previously published for proliferating epithelial cells in El 1.5 lung explants grown 
for 4 days in BGJb medium, 35% (Chen et al., 2005). This difference could be due 
to a difference in culturing conditions, or indeed in counting method as the Chen et. 
a l  study did not detail the photomicrograph size used. However, as an assay for 
differences between high and low [Ca2+]c cultures, the 50% difference in 
proliferation may be an indication of an attenuation of the amount of proliferating 
cells present in the developing lung by high [Ca2+]0> or conversely, an increase in 
proliferation mediated by lower [Ca2+]0. Proliferation levels are known to be affected 
by other manipulations of the lung developmental programme. Disruption of Bmp 
signalling, for example, decreases lung epithelial cell proliferation (Eblaghie et a l , 
2006). There is also evidence for proliferation being regulated by [Ca2+]0. For 
example, Capan-1 cells, a model for human pancreatic exocrine cells, show a 
significant decrease in proliferation, when exposed to 4 mM Ca2+0 (Racz et a l,
2002).
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The ability to determine the TPD of lung explants provides another layer of 
information on the lung explant’s response to [Ca2+]0. The lung explants cultured in 
the presence of high [Ca2+]0 branch less and remain smaller, but their luminal volume 
at the terminus of each bud appears greater. However, measurements of the total 
luminal area show that there is a decrease in the amount of luminal space in 1.7 mM 
Ca2+0 indicating that although the terminal buds appear larger, overall, more 
branches translates into a larger luminal volume regardless of the bud size at the 
terminus. The TPD of lungs cultured in the presence of high [Ca2+]0 is more 
negative, possibly indicating an increase in Cl' dependent fluid secretion; or it is 
possible that this increase in negativity could be due to an increase in Na+ 
absorption. However, there is no published evidence for sodium absorption or the 
expression of epithelial sodium channels (ENACs) at this stage of development for 
review see : (Wilson et al., 2007). Therefore in this study, it is assumed that TPD is a 
measure of Cl' secretion and there appears to be no link between branch number and 
this measure. This is supported by a report which inhibited Cl' secretion in rat lung 
explants by the application of bumetanide, which decreased overall lung growth, but 
did not affect branching morphogenesis (Souza et al., 1995).
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Figure 2.10 Diagrammatic summary of Chapter 2 results. Extracellular [Ca2+] has 
effects on the development of the fetal lung effecting various aspects of development 
such as branching morphogenesis, lung size and proliferation.
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The lack of a link between branching and secretion (or increase in TPD) is 
shown when the increase in negativity is not rescued in the same manner as 
branching when [Ca2+]0 are switched after 24 h in culture. These results, in 
conjunction with the ability to rescue branching suppression by changing the [Ca2+]0 
after 24 h, would imply that it is not the accumulation of lung lumen fluid that is 
disrupting branching morphogenesis as has been previously suggested from 
experiments using sucrose to increase osmotic pressure (Nogawa & Hasegawa, 
2002).
It has been previously shown that luminal fluid plays a vital role in the 
stereotypic branching pattern of the lung through viscous fingering. This is a process 
whereby a given fluid infiltrates a more viscous fluid. Vincent Fleury discusses the 
physics behind and implication of this process in the development of branching 
organs where he states that, branching epithelial tubes (like those in the developing 
lung) contain a fluid of low viscosity in comparison to the mesenchymal matrix in 
which they are embedded. This difference in viscosity is the reason behind the 
increase in branching resulting from an increase in mechanical pressure (Fleury, 
2001). That is, increasing the pressure of the less viscous fluid allows it easier 
movement through the higher viscosity fluid. If the pressure were to remain 
unchanged, then there would be less movement (i.e. branching) of the less viscous 
fluid. This process is also reliant on the cellular structure around the fluid space and 
the cells must maintain connectivity as a solid sheet. As this sheet, they help create 
osmotic pressure with high pressure in the lumen and the cells must proliferate in 
order for the tube to continue to grow and branch (Fleury & Watanabe, 2002). It is
• • 9 -4-possible that high [Ca ]0 is affecting two parts of this process. Greater Cl' secretion 
may not lead to an increase in pressure, but to a reduction of viscosity, and therefore
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there is no pressure dependent increase in branching. Or there is the possibility that 
the pressure is increased in conjunction with Cl' secretion in high [Ca2+]0, but the 
cellular structure and interactions surrounding the lumen have changed so that fluid 
fingering does not occur, possibly due to stretching of, or an increase in the viscosity 
of, the mesenchyme.
By determining the mechanism that is controlling the branching response, 
lung development may eventually be susceptible to pharmacological manipulation to 
help rescue defective branching in vivo. Indeed, the results showing that the 
inhibition of the branching programme by high [Ca2+]0 can be reversed by low 
[Ca2+]0 would imply just this. It seems that the branching process once started cannot 
be halted, but if suppressed, it can be “jump-started” by making the conditions to 
which the lung is exposed more favourable to branching. However the maturity of 
the lung also needs to be taken into account, i.e. are the branches supported by a 
vascular network that will eventually be capable of gas exchange? Therefore it is 
important to understand the underlying mechanism(s) by which the response to 
[Ca2+]0 is controlled in the normal developing lung.
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CHAPTER 3: 
EXPRESSION OF THE 
EXTRACELLULAR CALCIUM- 
SENSING RECEPTOR DURING 
LUNG DEVELOPMENT
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3.1 Methods
3.1.1 RNA Isolation and Reverse Transcriptase Polymerase Chain Reaction 
(RT-PCR)
RNA was isolated from pooled samples of mouse embryonic lungs using 
either Trizol reagent (Invitrogen, Paisley, UK) or RNeasy mini isolation kit (Qiagen, 
Crawley, West Sussex, UK). Both were used according to the manufacturer’s 
instructions. After purification RNA was quantified and quality checked using 
spectrophotometry readings at 260 nm and 280 nm. cDNA was synthesised using 
Superscript first strand synthesis system for reverse transcriptase PCR (Invitrogen, 
Paisley, UK) according to manufacturer’s instructions. PCR was performed using 
“intron-spanning” primer sequences designed against published CaR mouse 
sequences (NCBI Accession # NM_13803), at an annealing temperature of 55°C: 
forward primer 5’ - ACCTGCTTACCCGGAAGAGGGCTTT, 
reverse primer 5’ -  GCACAAAGGCGGTCAGGAAAATGCC. 
fl-actin primers were used to amplify the housekeeping gene from all samples at an 
annealing temperature of 50 °C: 
forward primer 5’ -  TCCTAGCACCATGAAGAT, 
reverse primer 5’ - AAACGCAGCTCAGTAACA.
PCR reactions were performed using the following PCR regime: an initial denaturing 
step of 95°C x 5 min; denaturing of 95°C x 1 min, annealing as specified above x 30 
s, elongation 72°C x 1 min repeated for 35 cycles; final elongation of 72°C x 8 min.
The following method was developed and kindly provided by Pierre 
DelMoral, PhD. For quantitative PCR, RNA was purified from pooled samples of 
lungs (3 for each time point) aged between El 1.5-El8.5 using RNeasy kits from 
Qiagen (Crawley, West Sussex, UK). After purification the RNA was quantified and
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quality checked using a Nanodrop Spectrophotometer (Bio-Rad). Reverse 
transcription was carried out using ljug RNA using the iScript select cDNA kit (Bio- 
Rad) according to manufacturer’s instructions. The resulting cDNA was used for 
quantitative PCR in a Roche Light cycler (Roche, California, USA). Primers specific 
for CaR (NM_13803.2) and 18S (NR_003278.1) were designed using the Roche 
Assay Design Center (www.roche-applied-science.com) to be used in conjunction 
with PCR probes from the Roche Universal Probe Library. Both sets of primers 
were used in reactions with cycling conditions as follows: initial incubation of 95 °C 
x 5 min, then denaturation at 95 °C x 20 s, annealing at 60°C x 20 s, and elongation 
at 72 °C x 10 s which was repeated for 40 cycles. The Universal probes and primer 
sequences used were:
18S amplification; probe #55 ,
forward primer 5’ -AAATCAGTTATGGTTCCTTTGGTC, 
reverse primer 5 ’ -GCTCTAGAATTACCACAGTTATCCAA.
CaR amplification; probe # 32, intron-spanning, 
forward primer 5 ’ -GGTCCTGTGCAGACATCAAG, 
reverse primer 5’- CCGCACTCATCGAAGGTC.
3.1.2 In Situ Hybridization (ISH)
Microdissected lungs were fixed in 4% PFA in PBS at 4 °C (fixation times 
were dependent on developmental stage and varied between 10 min to 1 h). The 
lungs were subsequently washed twice with PBS, dehydrated and stored in 70% 
ethanol at 4°C. The CaR antisense and sense probes (Method for production in 
Appendix A) were used along with RNase-free solutions, tubes and pipettes, in an 
attempt to prevent RNA degradation in the samples. The whole mount protocol was
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based on a previously described method (Winnier et al., 1995). The lungs were 
transferred to 2 ml tubes and bleached in a 4:1 mix of 100% EtOH and 30% H2O2 
then washed with PBS containing 0.1% Tween-20. The lungs were then briefly 
digested with Proteinase K (Roche Applied Sciences, Burgess Hill, UK) then post­
fixed in 0.2% glutaraldehyde mixed with 4% PFA. Pre-hybridisation was performed 
for 2 h at 68 °C in hybridisation buffer (Containing: deionised formamide, SSC, 
tRNA, SDS and heparin) after which the buffer was replaced with hybridisation 
buffer containing lpg/ml DIG-labelled RNA-probe and left to hybridise overnight at 
68 °C with shaking. The following morning the lungs were washed and treated with 
RNase A to remove any non-specific binding or un-hybridised RNA probe. The 
lungs were then treated to prevent any non-specific binding of the primary antibody 
for 1 h at room temperature while the anti-DIG antibody was pre-absorbed at 4 °C. 
After adding the pre-absorbed antibody to the samples, the complexes were 
incubated overnight at 4 °C with shaking. The following morning the antibody was 
removed and the samples washed for at least 24 h with hourly solution changes 
throughout the day. On the final day after washing, the samples were developed with 
BM purple at 37 °C to reveal hybridised probe and the samples were post-fixed in 
4% PFA to preserve the colour for analysis.
3.1.3 Immunohistochemistry
Whole embryos or microdissected lungs were fixed in 4% PFA in PBS at 4 
°C (fixation times dependent on developmental stage and varied from 10 min - 
overnight). The specimens were subsequently washed twice with PBS, then 
dehydrated and stored in 70% ethanol at 4°C. PFA fixed tissue was then embedded 
in paraffin wax and 5 pm thick sections were cut for histology on a standard 
microtome. Sections were mounted on Superfrost Plus glass sildes (Fisher Scientific,
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UK) and once dry were de-paraffinized with Histochoice (Sigma-Aldrich, 
Gillingham, Dorset, UK) and re-hydrated through a series of graded alcohols. After 
rehydration, the slides were treated using citrate buffer antigen retrieval as in Section 
2.1.3.
The slides were treated with 3% BSA in PBS (Sigma-Aldrich, Gillingham, 
Dorset, UK) containing 0.1% Triton-XlOO (Sigma-Aldrich, Gillingham, Dorset, UK) 
for 1 h at room temperature to prevent non-specific binding of the primary antibody. 
Several primary antibodies were tested in order to determine and confirm the 
specificity of CaR staining. The 733 primary antibody was a rabbit polyclonal 
directed against a peptide corresponding to residues 215-237 in the extracellular 
domain of the bovine CaR protein (Riccardi et al., 1998) diluted 1:200 and 1:400 in 
antibody dilution fluid (AbDF; 1% BSA, 3% Seablock (EastCoast Bio, Soham, 
Cambridgeshire, UK) in PBS with 0.1% Triton-XlOO). Negative controls for this 
antibody were omission of the primary antibody from the AbDF, and use of the pre­
immunisation serum from the same rabbit that produced the 733 antibody (PIS;
1:400 in AbDF). Several commercially available antibodies were also tested for the 
immuno-detection of the CaR in mouse lungs. IMG-71169 and IMG-71168 
(Imgenex, San Diego, CA, USA) were both used at a 1:400 dilution. Although the 
exact peptide sequences are proprietary of Imgenex, IMG-71169 is in the region of 
370-420 residues and IMG-71168 is in the region of 200-250 amino acid residues of 
the human parathyroid CaR sequence. An antibody detecting amino acids 12-27 at 
the very end of the CaR N-terminus was also tested (PA1-934A; Affinity 
BioReagents, Colorado, USA) at 1:50 and an antibody to 20 amino acids near the C- 
terminus of the protein (designated USB) was used at 1:200 dilution (COl 17-15, US 
Biologicals, Massachusetts, USA). Negative controls for these antibodies were
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performed by omitting the primary antibody and by using irrelevant Rabbit IgG 
complexes (Abeam pic., Cambridge, UK) diluted to the same extent as the primary 
antibody.
Primary antibodies were incubated overnight at 4°C, and then washed several 
times in PBS. The secondary antibody (supplied in the Dako Envision Kit mentioned 
below) was applied for 30 min at RT, and then removed in several washes of PBS. 
Visualization of the detected proteins was performed using an Envision 
Diaminobenzidine kit (DAB; Dako, Ely, Cambridgeshire, UK) according to the 
manufacturer’s instructions. Once the DAB was developed to an adequate level, the 
slides were counterstained with Harris’s haematoxylin, dehydrated and mounted with 
Clarion mounting medium (Sigma-Aldrich, Gillingham, Dorset, UK).
Photomicrographs were taken on a standard light microscope, attempting to 
maintain the same conditions for each set of pictures at each magnification. 
Photomicrographs were processed in Adobe Photoshop and subjected to a curves 
adjustment to remove background by selecting a reference area to be set as the white 
background for the picture. The pictures were then adjusted for brightness, contrast 
and size as needed. It was attempted to maintain the same image capture parameters 
for photomicrographs that were to be presented together.
3.2 Philosophy of Work
As stated in the previous chapter, activation of the CaR could be responsible 
for the differential sensitivity of mouse lungs to changes in [Ca2+]0 of the culture 
media. However, neither CaR protein nor RNA has been previously detected in the 
lung (Brown et al., 1993; Riccardi et al., 1995). In those studies, only adult lungs 
were investigated, no attempt to detect CaR in the developing lung has ever been 
published. The results in this chapter show that the both CaR RNA and protein are
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expressed in a developmentally controlled manner for a period in the embryonic 
mouse lung, coinciding with the pseudoglandular phase of lung development during 
which the majority of branching morphogenesis occurs.
3.3 CaR RNA expression
3.3.1 RT-PCR
Initial RT-PCR experiments were performed using CD1 mouse embryos; as 
this strain produces large litters, less mice needed to be sacrificed to obtain adequate 
samples for each time point. The results from these mice indicated that CaR RNA 
was expressed at El 1.5, E12.5 and E16.5, with no expression at E18.5 (Fig. 3.1A). 
Each sample was also used for a -RT negative control to determine if there was any 
DNA contamination in the RNA, and for amplification of P-actin as a positive 
control for each sample (Fig. 3 .IB). All primers were intron-spanning as an 
additional control for any genomic DNA contamination in the samples.
3.3.2 Quantitative PCR
Quantitative PCR was performed on RNA which was extracted from 3 
C57/B16 mouse lungs pooled for each time point. CaR specific and 18S 
(housekeeping gene) primers were used in conjunction with probes from the 
Universal Probe Library (Roche, California, USA) for detection of mRNA 
expression and relative quantification of CaR in these samples. Resulting PCR 
measurements were initially normalised to 18S expression levels to ensure that there 
was no initial difference in the amount of RNA. Following this normalisation, the 
amount of CaR mRNA expression was calculated relative to its expression level at 
El 1.5, which was set to a value of 100%, as it was the earliest time point tested.
105
A.
W E 11.5 12.5  16 18.5 584 bp
B.
W E 11.5 12.5  16 18.5
180 bp
Figure 3.1: Initial RT-PCR amplification of CaR and P-actin. Total RNA was isolated 
from pooled CD1 strain embryonic mouse lung samples and reverse transcribed. The 
PCR reaction was performed using CaR specific primers resulting in a 584 bp 
product (red arrow, A) and p- actin primers resulting in a 180 bp product (blue 
arrow, B). As a negative control, water (W) was substituted for RNA, and as a 
positive control, total RNA from an E l0.5 embryo (E) was used. Embryonic lungs at 
El 1.5, E12.5, E16 and El 8.5 were tested for their expression of CaR RNA. A DNA 
ladder in 1 0 0  bp increments from 1 0 0  -  1 0 0 0  bp is the first lane on the left of each 
panel and indicates the size of amplicons. Panel B also shows in the lane to the left 
of each p-actin band the additional negative control of the samples where the reverse 
transcriptase was omitted from the 1 st strand synthesis.
Table 3.1: CaR Expression levels determined by quantitative PCR. Total RNA was 
isolated from pooled lung samples (n=3 lungs for each time point). Complementary 
DNA was produced and used in PCR reactions for 18S and CaR mRNA detection. 
Data shown are the average of 2 reactions on the same cDNA samples. Data kindly
Lung Sample Normalized expression level 
(% of E11.5)
E l 1.5 1 0 0
E12.5 261
E13.5 56
E14.5 7
E15.5 109
E16.5 30
E17.5 33
E18.5 27.5
P10 0
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Expression of CaR was detected throughout the embryonic development of 
C57/B16 mouse lungs (Table 3.1) with a peak of expression at El 2.5, which was an 
161% increase over expression levels at El 1.5. This peak tapers off through the 
remainder of development back down to El 1.5 levels at E l5.5, where expression is 
109+14%. By El 8.5 the expression decreases to 27.5+1% of expression at El 1.5 and 
in a single sample tested at P10 there was no detectable CaR expression.
3.3.3 Whole Mount In Situ Hybridisation
Whole mount in situ hybridisation is a widely used method in developmental 
biology to detect and visualise the expression pattern of mRNA in early 
developmental stage tissues (Bellusci et a l,  1997b; Shi et al., 2001; De Langhe et 
a l,  2005). A probe was made from a previously amplified segment of the human 
CaR corresponding to the nucleotide sequence 2332 -  2975 from human parathyroid 
CaR (Accession number U20759) to detect the expression of CaR mRNA in 
developing lung tissue (See Appendix A). As a negative control, the reverse 
complement of this sequence showed that there was no non-specific binding of 
probes within the lung tissue. Figure 3.2A shows that an E l0.5 lung subjected to the 
sense probe and processed at the same time as the lung in Figure 3.2B shows no 
detection of CaR mRNA within the lung tissue. The E10.5 lung in Figure 3.2B 
shows detection of CaR mRNA expression in the epithelium lining the trachea and in 
the epithelium that lines the developing lung branches distally as well as punctuate 
points of expression throughout the mesenchyme. CaR mRNA expression is also 
detected in the epithelium lining the developing branches of lungs at El 1.5, E l2.5 
and E14.5 (Fig. 3.2C, D and E).
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Figure 3.2: Whole mount in situ hybridization of CaR RNA in developing lungs.
P F A - f i x e d  l u n g s  w e r e  s u b j e c t e d  t o  w h o l e  m o u n t  in situ h y b r i d i s a t i o n  w i t h  C a R -  
s p e c i f i c  R N A  p r o b e s .  A). N e g a t i v e  c o n t r o l ,  s e n s e  C a R  p r o b e  a p p l i e d  t o  E10.5 l u n g  
s h o w s  n o  s i g n i f i c a n t  b i n d i n g  t o  C a R  m R N A .  A n t i s e n s e  C a R  p r o b e  d e t e c t s  
d e v e l o p m e n t a l  C a R  m R N A  e x p r e s s i o n  ( p u r p l e )  i n  m o u s e  l u n g s  a t  e m b r y o n i c  d a y s  
10.5 ( B . ) ,  11.5 (C.), 12.5 ( D . )  a n d  14.5. S c a l e  b a r  =  200 j a m .
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3.4 CaR protein expression
Several antibodies were tested for their ability to specifically detect CaR in 
PFA-fixed, paraffin embedded lung tissue. The first antibodies tested were antiserum 
733 (733), a rabbit polyclonal directed against amino acids 217-235 in the amino- 
terminus of the CaR (Riccardi et al., 1998) and IMG-71169 (Imgenex, San Diego, 
CA, USA) also detecting a region in the N-terminus of the CaR protein, between 
amino acids 370-420. Figure 3.3 shows that both antibodies detected CaR expression 
in the same areas of serial E l2.5 lung sections, mainly in the epithelium of the 
developing lung buds, with faint scattered staining in the mesenchyme. Negative 
controls, performed using pre-immune serum for 733 or omission of the primary 
antibody for the antiserum IMG-71169, detected no immunoreactivity.
Imgenex also produce another antiserum, IMG-71168, which is in the region 
of amino acids 200-250 of the N-terminus of the CaR. This antibody was not used 
initially due to the probability that it was directed toward the same amino acid 
residues as 733. However, in the interest of further validating the staining pattern for 
CaR in E l2.5 lungs it was tested and yielded similar results to IMG-71169 (Fig. 3.4) 
with immunoreactivity mainly in epithelium and some scattered detection in the 
mesenchyme of E l2.5 lung tissue.
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Figure 3.3: CaR protein detection by immunohistochemistry using IMG-71169 and 733 antisera on E12.5 mouse lung. E l 2 . 5  l u n g s  w e r e  d i s s e c t e d  
f r o m  t h e  e m b r y o ,  f i x e d  i n  4 %  P F A ,  e m b e d d e d  i n  p a r a f f i n  a n d  s e c t i o n e d  t o  5  m i c r o n s  t h i c k .  I m m u n o h i s t o c h e m i s t r y  w a s  p e r f o r m e d  w i t h  I M G -  
7 1 1 6 9  ( C )  a n d  7 3 3  (D) t o  d e t e c t  C a R  p r o t e i n  e x p r e s s i o n ,  v i s u a l i s e d  w i t h  D A B  ( b r o w n  p i g m e n t )  a n d  c o u n t e r s t a i n e d  w i t h  H a r r i s ’ s  h e m a t o x y l i n  
( b l u e  p i g m e n t ) .  N e g a t i v e  c o n t r o l s  w e r e  p e r f o r m e d  i n  t a n d e m  b y  o m i t t i n g  t h e  p r i m a r y  a n t i b o d y  ( A )  a n d  b y  a p p l y i n g  p r e - i m m u n i z a t i o n  s e r u m  
f r o m  7 3 3  p r o d u c t i o n  (B). T h e  t o p  r o w  s h o w s  l o w  m a g n i f i c a t i o n  i m a g e s  o f  t h e  w h o l e  m o u s e  l u n g  s e c t i o n .  T h e  b o t t o m  r o w  o f  i m a g e s  s h o w s  
g r e a t e r  d e t a i l  o f  C a R  i m m u n o r e a c t i v i t y  i n  t h e  d i s t a l  e p i t h e l i u m  a s  w e l l  a s  i n  t h e  m e s e n c h y m e  o f  t h e  E l  2 . 5  m o u s e  l u n g .  T o p  r o w  s c a l e  b a r s  = 1 0 0  
j i i m ,  b o t t o m  r o w  s c a l e  b a r s  =  5 0  p m
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Figure 3.4: CaR protein detection by immunohistochemistry using IMG-71169 and -  71168 antisera on E12.5 mouse lung. E l 2 . 5  l u n g s  w e r e  
d i s s e c t e d  f r o m  t h e  e m b r y o ,  f i x e d  i n  4 %  P F A ,  e m b e d d e d  i n  p a r a f f i n  a n d  s e c t i o n e d  t o  5  m i c r o n s  t h i c k .  I m m u n o h i s t o c h e m i s t r y  w a s  p e r f o r m e d  
w i t h  I M G - 7 1 1 6 9  (B) a n d  I M G - 7 1 1 6 8  ( C )  t o  d e t e c t  C a R  p r o t e i n  e x p r e s s i o n ,  v i s u a l i s e d  w i t h  D A B  ( b r o w n  p i g m e n t )  a n d  c o u n t e r s t a i n e d  w i t h  
H a r r i s ’ s  h e m a t o x y l i n  ( b l u e  p i g m e n t ) .  N e g a t i v e  c o n t r o l  w a s  p e r f o r m e d  i n  t a n d e m  b y  o m i t t i n g  t h e  p r i m a r y  a n t i b o d y  ( A ) .  S c a l e  b a r s  =  5 0  p m .
I l l
There are several other commercially available polyclonal antibodies for the 
detection of the CaR. Two of these detect antigenic regions at opposite ends of the 
CaR protein (either the NH2- or COOH-terminus) and were tested for validation of 
the CaR expression in E12.5 lungs; the ABR antibody detects amino acidsl2-27 at 
the end of the N-terminus and is commonly used for detection of the CaR by western 
blotting (Oda et a l,  1998), the USB antibody detects 20 amino acids near the C- 
terminus of the protein. Both antibodies, when used in reactions in tandem with 733 
show the same patterns of immunoreactivity in the lung, with strong detection of 
CaR in the epithelium and some scattered detection of CaR in the mesenchyme (Fig. 
3.5).
All of the antibodies tested on El 2.5 gave a similar staining pattern in the 
lung which is a positive indicator that CaR protein is being detected by these 
antibodies regardless of the epitope against which the antibody is directed. Antisera 
733 and IMG-71168 were tested at E16.5 to ensure that the same protocols were still 
applicable to larger tissue samples and that staining patterns remained the same for 
separate antibodies. Figure 3.6 shows that at this time point there is still 
immunoreactivity although the localisation is less concentrated in the epithelium, 
and more spread throughout the lung tissues as a whole.
The ontogeny of the CaR was determined on sections of whole embryo at 
embryonic stages, E10.5, El 1.5, E12.5, E13.5, E14.5, E16.5 and E18.5. P0 and adult 
lung samples were used as negative controls, as previous PCR experiments indicated 
that CaR mRNA expression was decreased by E l8.5 and undetectable in P10 or 
adult lungs. Using the 733 antibody, expression of the CaR can be seen in the 
epithelium of E10.5 -  E16.5 lungs (Fig. 3.7A-F). At earlier time points, (El 1.5- 
El 3.5) slight expression is also detected in the mesenchyme of the lung which
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increases through E16.5. By E18.5 CaR immunostaining is extremely faint (Fig. 
3.7G) and is completely gone by PO (Fig. 3.7H). The lack of CaR positive 
immunostaining is maintained in adult lung tissue (Fig. 3.71).
There have been previous reports of CaR expression decreasing as cells are 
cultured (Mithal et a l , 1995). In order to ensure that the lung explant cultures 
maintained CaR expression in both low and high [Ca2+]0 culture conditions after 48 
h, antiserum IMG-71169 was applied to sections from both 1.2 mM and 1.7 mM 
cultures. Results shown that in both experimental conditions CaR expression is 
maintained for 48 h (Fig. 3.8).
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Figure 3.5: CaR protein detection by immunohistochemistry using 733, ABR and USB antisera in E12.5 mouse lungs. El 2.5 embryos were 
fixed in 4% PFA, embedded in paraffin and sectioned to 5 microns thick. Immunohistochemistry was performed with antisera 733 (B), 
ABR (C) and USB (D) to detect CaR protein expression, visualised with DAB (brown pigment) and counterstained with Harris’s 
hematoxylin (blue pigment). Negative control was performed in tandem by omitting the primary antibody (A). The top row shows low 
magnification images of the mouse lung in the context of the embryo. The bottom row of images shows greater detail of CaR 
immunoreactivity in the distal epithelium as well as in the mesenchyme of the El 2.5 mouse lung. Top row scale bars = 100 jum, bottom 
row scale bars = 50 pm.
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Figure 3.6: CaR protein detection by immunohistochemistry using 733 and IMG -  71168 antisera in E16.5 mouse lungs. E16.5 embryos 
were fixed in 4% PFA, embedded in paraffin and sectioned to 5 microns thick. Immunohistochemistry was performed with 733 (B) and 
IMG-71168 (C) antisera to detect CaR protein expression, visualised with DAB (brown pigment) and counterstained with Harris’ 
hematoxylin (blue pigment). Negative control was performed in tandem by omitting the primary antibody (A). The top row shows low 
magnification images of the mouse lung at E l6.5. The bottom row of images shows greater detail of CaR immunoreactivity in the distal 
epithelium as well as in the mesenchyme of the El 2.5 mouse lung. Top row scale bars = 100 pm, bottom row scale bars = 50 pm.
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Figure: 3.7: CaR protein ontogeny in the developing mouse lung. Mouse lungs were 
fixed in 4% PFA, embedded in paraffin and sectioned to 5 microns thick. CaR 
protein was detected with 733 antiserum, a CaR N-terminal specific antibody, and 
developed with DAB substrate (brown pigment). Slides were counterstained with 
Harris’ haematoxylin (blue pigment). Panel shows the lung at different stages of 
development. A). E10.5, B). El 1.5, C). E12.5, D). E13.5, E). E14.5, F). E16.5, G). 
E l8.5, H). PO, I). Adult. Red arrowheads refer to an area of lung mesenchyme in 
each section. Black arrows refer to an area of the lung epithelium in each section. 
Scale bars = 200pm.
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A.
Figure 3.8 CaR expression is retained in culture for 48 h. After 48 h in culture, lung 
explants were fixed in 4% PFA, embedded in paraffin and sectioned to 5 microns 
thick. CaR protein expression was detected using IMG-71169 antiserum on lungs 
cultured in 1.2 mM Ca2 + 0  (A, right panel) and 1.7 mM Ca2 + 0  (B, right panel). 
Negative control was performed by omission of the primary antibody (A and B, left 
panels). Scale bars = 100 jitm.
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3.5 Chapter Discussion
Detection of CaR transcripts have not been previously reported in the lung 
when Northern blot analysis was performed on adult samples (Brown et a l, 1993; 
Riccardi et a l, 1995). The results presented in this chapter confirm previous findings 
showing a lack of CaR expression in adult tissue, but show that both RNA and 
protein are detected in the developing lung from E10.5 through E l8.5. This detection 
was accomplished using a variety of methods in order to ensure that the results were 
genuine. A summary of the results is presented in Figure 3.9.
Initial RT-PCR results using CD1 embryonic lung total RNA indicated that 
the CaR was expressed in at least El 1.5, E l2.5 and E16.5 samples. Further 
experimentation using total RNA from C57/BL6 embryonic lungs subjected to 
quanitiative real-time PCR by my collaborator, Pierre delMoral PhD, in Los Angeles 
confirmed that CaR RNA was indeed expressed at El 1.5, and that this expression 
peaked at El 2.5, then tapered off through the remainder of development. By P10, 
there was no CaR mRNA detectable by this method. One further method of RNA 
detection, whole mount in situ hybridisation, detected CaR expression earlier, in 
E10.5 lungs, as well as El 1.5, 12.5 and 14.5 lungs. Later time points were not 
attempted due to the limitations of the whole mount method on larger specimens.
This set of results shows that, by a combination of RNA detection 
techniques, CaR mRNA is indeed expressed in the developing mouse lung.
However, mRNA expression does not necessarily translate into protein expression 
within a tissue, and aside from the whole mount in situ method, these modes of 
detection cannot show exactly what cell type is expressing the CaR at a certain time 
point. Therefore CaR protein detection was accomplished using standard 
immunohistochemical techniques.
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One classic problem with immunohistochemistry is the specificity of the 
antibody used to detect the protein of interest. In order to ensure that the detection of 
CaR in the developing lung by immunohistochemistry was valid, different control 
applications, as well as several different antibodies were used. For the 733 antibody 
produced by Dr. Riccardi, a specific negative control was employed; the application 
of the pre-immune serum collected from the rabbit used to produce the polyclonal 
antibody prior to immunization with the 733 antigenic peptide. This negative control 
proves that any immunoreactivity seen is not due to an inherent antibody in the 
serum of the rabbit which was immunised to produce the 733 antiserum. Another 
way in which to confirm that the protein expression pattern detected is genuine, is to 
use antibodies produced to detect the same protein, but directed against different 
antigenic regions. In this study I used a total of 5 different CaR antibodies, all of 
which, when applied to E l2.5 lung or whole embryo samples, gave a similar CaR 
staining pattern although with different intensities. CaR protein was mainly detected 
in the epithelium at early developmental time points, E10.5-12.5. At E13.5 and 
beyond CaR protein was detected in the mesenchyme as well.
Importantly after 48 h in culture, lungs removed at E l2.5 still express CaR 
protein in their epithelium. This is probably due to the maintenance of the tissue 
structure instead of dispersing the cells for culture, as dispersed parathyroid cells 
lose CaR expression within 18 h of culture (Mithal et a l , 1995) whereas parathyroid 
cells cultured as pseudoglands maintain CaR expression and activity for much longer 
(Ritter et a l, 2004). It can therefore be assumed that any responsiveness to CaR 
agonists should be maintained throughout the length of the lung explant cultures 
used in the experimental program contained in this thesis.
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What is the implication of this pattern of CaR expression within the 
developing lung? CaR is mostly expressed during the embryonic and 
pseudoglandular stages of lung development, E10.5-E16.5. During these stages the 
lung is undergoing branching morphogenesis, a process that involves the elongation 
and dichotomous branching of the lung epithelia, which over several branching 
generations forms the respiratory tree (Cardoso & Lu, 2006). As discussed in Section 
1.10, this process requires the coordination of many signalling processes as well as 
the correct environmental stimuli in order to occur properly. Expression of the CaR 
during this time could be one factor which helps to coordinate the effects of 
environmental stimuli, i.e. [Ca2+]0, into cellular signalling responses; CaR activation 
has been previously shown to affect diverse cellular processes like proliferation and 
apoptosis, ion channel activity and secretion (Brown & MacLeod, 2001).
In early development, CaR expression appears to be maximal in the 
epithelium of the developing lung with faint detection in the mesenchyme, possibly 
reflecting a function for responding to [Ca2+]0 in the fluid of the lung lumen. 
Additionally, when the CaR is expressed in the epithelium at E l2.5, there appears to 
be a fairly equal distribution between the apical and the basolateral membrane. After 
48 h in culture, this distribution appears to shift with greater expression on the apical 
membrane. If this localisation shift is not an artefact of the staining protocol, the 
reason behind this shift remains to be determined. As the fetus continues to develop, 
CaR expression is more robustly detected within the mesenchyme. At these later 
time points (E13.5-E16.5) the lung mesenchyme is becoming vascularised (Colen et 
a l, 1999) and the expression of CaR in this compartment could represent a need to 
detect [Ca2+]0 from the infiltrating blood supply.
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The role of the CaR at this point is purely speculative, but if the results of 
the previous chapter are taken into account, one can propose that changes in the 
branching morphogenesis, as well as changes in proliferation levels, TPD, and gene 
expression could all be mediated by the activation of CaR by high [Ca2+]0. The 
following chapters will focus on testing whether the CaR is indeed active in the 
developing lung and the possible mechanism(s) by which it could exert its effects.
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Figure 3.9: Diagrammatic summary of Chapter 3 results. CaR expression was 
detected using four different methods throughout embryonic development which 
resulted in a profile of developmentally regulated CaR expression in the lung.
122
CHAPTER 4:
EFFECT OF EXTRACELLULAR 
CALCIUM SENSING RECEPTOR 
ACTIVATION ON LUNG 
DEVELOPMENT
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4.1 Methods
4.1.1 Lung Explant Cultures with CaR Agonists
Lungs were isolated from time-pregnant C57/BL6 females as in section 2.1.1. 
The calcimimetic NPS R-467 was a gift from NPS Pharmaceuticals. The 
calcimimetic, AMG R-568 was obtained from Amgen, Inc. An initial stock solution 
of each calcimimetic at 10 mM in DMSO was prepared and stored at -20°C. Prior to 
each experiment, fresh serial dilutions of the calcimimetics were prepared in water 
for addition to the culture medium at time = 0  h to the concentrations listed in figure 
legends. The culture medium was changed daily. Cultures were carried out in the 
same serum-free, chemically defined conditions as in section 2.1.1. The 
aminoglycoside antibiotics, gentamicin and neomycin (Sigma-Aldrich, Gillingham, 
Dorset, UK), were added to the culture medium of the lung explants to the 
concentrations specified in the text at t = 0  h and the medium was changed daily.
4.1.2 Lung Explant Cultures with Signalling Pathway Inhibitors
Lungs were isolated from time-pregnant C57/BL6 females and cultures 
carried out as in section 2 .1.1. EC50 concentrations for signalling inhibitors are only 
available for cell culture models, thus initially inhibitors were added to the culture 
medium at time = 0  h in a range of concentrations for each inhibitor to determine the 
concentration appropriate (i.e. without achieving toxicity) for the explant culture 
method. All signalling inhibitors were obtained from Sigma-Aldrich (Gillingham, 
Dorset, UK) unless otherwise stated.
The following signalling inhibitors (listed with their target molecules) were used:
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PD98059 -  mitogen-activated protein kinase kinase (MEK)l/2 activation blocker; 
applied for 24 h at 25 or 50 pM and then medium replaced with Ca2+0 adjusted 
medium alone at the desired [Ca2+]0 for the final 24 h;
U0126 -  ERK1/2 inhibitor, applied for 24 h at 20, 30 or 40 pM and then medium 
replaced with Ca2+0 adjusted medium alone at the desired [Ca2+]0 for the final 24 h; 
BIRB 796 -  p38 inhibitor (Kind gift of Dr. Mark Bagley, Cardiff University), 
applied for 24 h at lpM and then medium replaced with Ca2+0 adjusted medium 
alone at the desired [Ca2+]0 for the final 24 h.
U73122 -  PLC inhibitor, applied for 24 h at concentrations of 2.5, 5 or 10 pM and 
then medium replaced with Ca2+0 adjusted medium alone at the desired [Ca2+]0 for 
the final 24 h;
U73343 -  Inactive control analogue for U73122, applied for 24 h at concentrations 
of 2.5, 5 or 10 pM and then medium replaced with Ca2+0 adjusted medium alone at 
the desired [Ca2+]0 for the final 24 h;
LY294002 -  PI3K inhibitor, applied for 48 h at concentrations of 5, 12.5 or 25 pM;
4.1.3 Intracellular Calcium Imaging
The mesenchyme was gently removed from the epithelium of E l2.5 lungs 
using forceps and the remaining epithelial buds were cultured for 24 h free floating 
in DMEM/F-12 supplemented with 1% FCS. After 24 h epithelia were loaded with 6 
pM fura-2 acetoxymethyl ester (Fura -  2AM; Molecular Probes, Eugene, OR., 
U.S.A.) for 60 min at 37 °C as described (Ward et al., 2002). The epithelial buds 
were then placed on glass coverslips and covered with Nucleopore filters (Whatman 
Intl. Ltd., Maidstone, Kent, UK) to prevent movement. These were placed in a 
perfusion chamber mounted upon a Nikon Diaphot equipped with a Cairn
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monochromotor-based fluorescence system (Cairn Instruments, Faversham, Kent, 
U.K.) and were continuously superfused with a solution containing (in mM): 135 
NaCl, 5 KC1, 0.8 CaCl2, 0.8 MgCl2, 5 HEPES, 10 glucose, pH 7.4. R-568 and 
carbachol were added to this solution to the final concentrations of 100 nM and 10 
pM, respectively. Fura-2 was alternatively excited at 340 and 380 nm. Images at 510 
nm were acquired at 0.2 Hz by a slow-scan CCD camera (Kinetic Imaging Ltd, 
Nottingham, U.K.). Following background subtraction, ratio of emission results from 
340/380 excitation were calculated off-line using Andor IQ 1.3 software package 
(Andor Technology, UK).
4.1.4 Immunohistochemistry
Epithelial buds not used for intracellular calcium imaging studies were fixed 
in ice-cold methanol for 15 min, then washed in PBS at 4°C for 1 h. The primary 
antibodies, mouse monoclonal anti-smooth muscle actin antibody conjugated to cy3 
(1:200, Sigma-Aldrich, Dorset, UK) co-incubated with a rabbit polyclonal anti- 
laminin antibody (1:200, Sigma-Aldrich, Dorset, UK), were applied to fixed 
epithelial buds overnight at 4°C. The following day the specimens were washed in 
PBS at RT for 1 h and then the secondary antibody, a donkey anti-rabbit conjugated 
to Alexa 488 (1:200, Molecular Probes, Eugene, OR., U.S.A.) was applied for 2 h at 
RT with gentle shaking. The final wash in PBS was done at RT for 1 h. The 
specimens were then mounted on a glass slide in Prolong anti-fade mounting 
medium (Molecular Probes, Eugene, OR., U.S.A.) and allowed to set at RT before 
being imaged by confocal microscopy.
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4.1.5 Statistics
Graphic representations and statistics of the data were prepared with Origin 7 
software. Data are presented as the mean (from multiple pooled experiments where 
indicated) + s.e.m. Significance was determined using one-way ANOVA with 
Tukey post-hoc test and a p-value of < 0.05 was deemed significant.
4.2 Philosophy of Work
The CaR has been previously shown to be activated, in a variety of systems, 
by [Ca2+]0 of 0.5 -  2.5 mM (Brown & MacLeod, 2001). This range is compatible 
with that used for the lung explant cultures in this project. To test the hypothesis that 
CaR activation is involved in the high [Ca2+]0- dependent suppression of lung 
branching morphogenesis, we utilised existing specific positive allosteric modulators 
of the CaR, NPS R-467 and AMG R-568. These compounds increase the sensitivity 
of the CaR to its classic agonist, Ca2+, and they have been used in lung explant 
cultures grown in the presence of 1.05 and 1.2 mM Ca © to try and recapitulate the 
suppressive effect of high [Ca2+]0 on lung branching morphogenesis.
As a pleiotropic G-protein coupled receptor, CaR is known to mediate its 
effects via a number of different signalling pathways. These responses are generally 
dependent upon the G-protein subunits associated with the receptor in cell type or 
system tested (Ward, 2004). It was therefore decided to test a battery of well- 
characterised signalling inhibitors for their ability to rescue the suppressive effect of 
high [Ca2+]0 on lung branching morphogenesis in lung explant cultures, as an index 
for CaR activation. The pathways tested were MEK1/2, ERK1/2, p38, PLC and 
PI3K, all of which are known to be activated by the CaR (Brown & MacLeod, 2001).
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4.3 Lung Branching Morphogenesis is Responsive to Treatment with 
Calcimimetics.
In Chapter 3 it was demonstrated that CaR protein is present in the 
epithelium of El 2.5 lungs. In order to determine if the suppression of branching 
morphogenesis by 1.7 mM Ca2+0is mediated by the CaR, lung explant cultures were 
treated with calcimimetic compounds, NPS R-467 and R-568 in the presence of 
either 1.05 or 1.2 mM Ca2+0. As positive allosteric modulators of the CaR, these 
calcimimetics would be expected to shift the dose response for Ca2+0 to the left, 
thereby mimicking the effects of high Ca2+0 and inhibiting branching morphogenesis.
Treatment with NPS R-467 resulted in a dose-dependent inhibition of 
branching morphogenesis at both 24 and 48 h when used at 100 or 1000 nM (n=3 for 
each concentration of NPS R-467 from a single isolation) in the presence of 1.05 
mM Ca2+0 (Fig. 4.1 A). Branching was significantly decreased from 1.05 mM levels 
of 35.2+2.3% at 24 h and 123.3+4.5% at 48 h (taken from Fig. 2.2A); to 13.9+3.9% 
(p = 0.04) at 24 h and 77.8+7.7% (p=0.02) at 48 h with addition of 100 nM NPS R- 
467; to 14.17+11.8% at 24 h and 51.9+17.8% at 48 h with addition of 1000 nM NPS 
R-467 to culture medium containing 1.05 mM Ca2+0. Both of these concentrations of 
NPS R-467 resulted in branching increases which were not statistically different 
from those observed in lungs grown in 1.7 mM Ca2+0, 19.9+1.7% (24 h) and 
62.2+4.4% (48 h, Fig. 2.2A).
When NPS R-467 was added to culture medium containing 1.2 mM Ca2+0 a 
dose-dependent effect, similar to that in Figure 4.1 A was not detected (Fig. 4. IB). A 
greater range of NPS R-467 concentrations resulted in significant decreases from 1.2 
mM Ca2+0 branching levels (30.4+1.8%+ at 24 h and 109.2+3.1% at 48 h; Fig. 2.2A) 
after 48 h of treatment. The addition of both 10 and 30 nM NPS R-467 resulted in a
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significant decrease from 1.2 mM Ca2+0 levels of branching morphogenesis to 
76.5+17.4% (n=6, p=0.01) and 83.4+12.2% (n=10, p=0.01) at 48 h respectively. The 
addition of 100 nM NPS R-467 resulted in significant decreases at both 24 h, to 
15.5+5.3% (n=9, p=0.01) and at 48 h, 85.4+12.04% (p=0.02). The highest 
concentration of NPS R-467 tested was 1000 nM which only showed a significant 
decrease in branching levels at 48 h to 72.9+13.5% (n=6, p=0.004).
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Figure 4.1: Effect of increasing concentrations of NPS R-467 on lung branching 
morphogenesis. Lungs from E l2.5 mouse embryos were cultured for 48 h in the 
presence of either 1.05, 1.2 or 1.7 mM Ca2+0 with or without the presence of NPS R- 
467. A). Graphic representation of branching morphogenesis induced when cultures 
are treated with 10-1000 nM NPS R-467 in 1.05 mM Ca2+0 for 24 (black bar) and 48 
h (hatched bar). B). Graphic representation of branching morphogenesis induced 
when lung explant cultures are treated with 10-1000 nM NPS R-467 in 1.2 mM 
Ca2+0 for 24 (black bar) and 48 h (hatched bar). Terminal branch number at 24 and 
48 h was normalised to branch number at 0 h and expressed as percent change in 
number of branches. Data shown as mean + s.e.m from > 1 separate experiments, n 
in parentheses above 48 h results, ** = p<0.05 by ANOVA compared to 1.05 mM or 
1.2 mM control values.
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As an alternative positive allosteric modulator of the CaR, the calcimimetic 
Amgen R-568, was tested at 10, 30 and 50 nM in a single culture experiment grown 
in medium containing 1.2 mM Ca2+0 (Fig. 4.2) for its ability to mimic the effects of 
1.7 mM Ca2+0 on lung branching morphogenesis. At all concentrations tested R-568 
reduced the amount of branching although not all values reached statistical 
significance (Fig.4.2, n=3 lungs per condition). After 24 h lungs cultured in the 
presence of 1.2 mM Ca2+0+ 0.1% DMSO (control for the calcimimetic treatment) 
had increased branching by 41.2+18.3%, and after 48 h branching had increased by 
101.2+15.5%, values similar to those observed in the presence of 1.2 mM Ca2+0 
without addition of DMSO in Figure 2.2A (30.4+1.8% and 109.7+3.1%). These 
results indicate that 0.1 % DMSO application had no effect on branching 
morphogenesis. Application of 10 nM R-568 reduced the branching response to 
17.2+8.6% at 24 h and 53.6+10.5% at 48 h, although these values were not 
significant different from control values. 30 nM R-568 evoked an increase in 
branching by 9.9+6.2% at 24 h and 40.2+9.4% (n=3, p=0.02) at 48 h, while 50 nM of 
the compound produced 16.7+5.5% at 24 h and 50+6.3% (n=3, p=0.03) at 48 h.
These values are significantly different from 1.2 mM + 0.1% DMSO, but are not 
significantly different from the values induced by 30 nM R-568. Doses of 1, 10, 30 
and 100 nM R-568 were also used in cultures with a basal [Ca2+]0 of 1.05 mM (Fig. 
4.3). Significant changes in branching morphogenesis resulting in an increase of 
79.6+15.7% (n=3, p=0.03) were seen with 10 nM R-568 and 96.5+9.1% (n=7 from 
two isolations, p=0.04) with 30 nM R-568 after 48 h in culture.
Figure 4.3B shows the results of TPD recordings from Chapter 2 with the 
addition of lungs cultured in the presence of 1.05 mM Ca2+0 + 30 nM R-568 for 48 h. 
When lungs were cultured in the presence of 1.05 mM Ca2+0, their TPD was
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-1.24+0.15 (n=17). This was significantly decreased when they were cultured in the 
presence of 1.7 mM Ca2+c where their TPD is -1.68+0.16 (n=20, p=0.048). The 
negativity of TPD recordings was increased further when 30 nM R-568 was added to 
culture medium containing a basal Ca2+0 of 1.05 mM to -2.18+0.12 (n=4, p=0.007). 
This indicates that the increased negativity, or increases in secretion are mediated by 
activation of the CaR.
From the results of the previous experiments, it appeared that the 
concentration of R-568 needed to induce significant changes in branching 
morphogenesis was lower than that needed to produce a significant effect with NPS 
R-467. Therefore Figure 4.4B and D show the effect of specifically activating the 
CaR with a low dose of R-568 (10 nM) in the presence of 1.2 mM Ca2+0 (n=15 from 
5 separate isolations) on the branching morphogenesis of cultured lung explants. R- 
568 significantly suppressed the branching response at 24 h from 30.4+1.8% in the 
presence of 1.2 mM Ca2+0 to 15.5+2.9% (p=0.001) in the presence of 1.2 mM Ca2+0 
+ 10 nM R-568. This level of branching is not significantly different (p=0.2) from 
the 19.9+1.7% increase in branching seen in the presence of 1.7 mM Ca2+0. The 
suppression of branching by R-568 is maintained at 48 h where there is a 
109.7±3.1% increase in the presence of 1.2 mM Ca2+0, and the branching 
suppression is shown by a branching increase of 72.9+5.9% (p<0.0001) in the 
presence of 1.2 mM Ca2+0 + 10  nM R-568. Again, this value is not significantly 
different (p=0.2) from the 62.2+4.4% branching increase in the presence of 1.7 mM 
Ca2+0 (Fig. 4.4C and D).
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Figure 4.2: Effect of increasing concentrations of R-568 on lung branching 
morphogenesis in the presence of 1.2 mM Ca2+0. Lungs from E l2.5 mouse embryos 
were cultured for a total of 48 h in the presence 1.2 mM Ca2+0. Parallel experiments 
were carried out with the addition of the calcimimetic R-568 in the presence of 1.2 
mM Ca2+0. Terminal branch number at 24 and 48 h was normalised to branch 
number at 0 h and expressed as percent change in number of branches. Data 
presented as mean ± s.e.m. from a single experiment, n=3 for each condition, ** = p 
<0.03, *** = p<0.02 determined by ANOVA with Tukey post-hoc test.
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Figure 4.3: Effect of R-568 on lung branching morphogenesis and TPD in the presence 
of 1.05 mM Ca2+0. Lungs from E l2.5 mouse embryos were cultured for a total of 48 h 
in the presence 1.05 mM Ca2+0 with the addition of the listed concentrations of R- 
568. A). Terminal branch number at 24 and 48 h was normalised to branch number 
at 0 h and expressed as percent change in number of branches. B). TPD was 
measured after 48 h in culture and becomes more negative in cultures with the 
addition of 30 nM R-568 or in the presence of 1.7 mM Ca2+0 for 48 h. Data presented 
are mean ± s.e.m. from > 1 separate experiments, n shown in parentheses 
above/below 48 h results, *** = p<0.048 determined by ANOVA with Tukey post- 
hoc test.
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Figure 4.4: Lung branching morphogenesis is suppressed in the presence of 10 nM R-568 
and high [Ca2+]0. Lungs from E l2.5 mouse embryos were cultured for a total of 48 h in 
the presence 1.2 mM Ca2+0 with 10 nM R-568. A). Representative pictures of lungs 
cultured in the presence of 1.2 mM Ca2+0, 1.2 mM Ca +Q + 1 0  nM R-568 and 1.7 mM 
Ca2+0at 0, 24 and 48 h. B). Terminal branch number at 24 and 48 h was normalised to 
branch number at 0 h and expressed as percent change in number of branches. Data 
presented are mean ± s.e.m., from > 5 separate experiments, n in parentheses above 48 h 
results, *** = p<0.001 in comparison to explants cultured in the presence of 1.2 mM 
Ca2+0 determined by ANOVA with Tukey post-hoc  test. Scale bars = 650 pm.
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4.4 Aminoglycoside Antibiotic Treatment does not affect Branching 
Morphogenesis
As the previous studies have shown the CaR to be expressed in lung explant 
cultures and responsive to calcimimetic treatment, it was decided to test other 
activators of the CaR in this system. Both neomycin and gentamicin have been 
shown to be agonists of the CaR (Ward et al., 2002; Ward et al., 2005) in 
experiments involving homologous (kidney derived) and heterologous (CaR- 
HEK293) cell systems. Since these antibiotics are not routinely used in lung explant 
cultures, several concentrations were tested. Neomycin was used at concentrations 
between 30 and 100 pM in the presence of 1.05 or 1.2 mM Ca2+0 and gentamicin 
was used at 20 -  100 pM at 1.05 mM Ca2+0. Neither aminoglycoside antibiotic 
produced a significant reduction in branching regardless of the concentration applied 
to the cultures.
Figure 4.5A shows that neomycin, applied at either 50 or 100 pM in the 
presence of 1.05 mM Ca2+0 did not affect the amount of branching normally seen in
1.05 mM Ca2+0 cultures where there is a branching increase of 35.7+2.4% at 24 h or 
123.3+4.5% at 48 h (n=54, see Fig 2.2A). Indeed, in the presence of the same 
[Ca2+]0, administration of 50 pM neomycin resulted in branching increases of 
21.7+8.5% at 24 h (p=0.2) and 91.4+25.7% at 48 h (n=3, p=0.12), similarly 100 pM 
allowed for 23.3+1.6% at 24 h (p=0.24) and 117.8+16.3% at 48 h (n=3, p=0.78). In 
the presence of 1.2 mM Ca2+0 (values of 30.4+1.8% at 24 h or 109.2+3.1% at 48 h, 
n=88, see Fig. 2.2A), 30 (n=12) or 60 (n=3) pM neomycin treatment again did not 
produce any significant change in branching resulting in 20.9+3.9% (p=0.06) and 
38.9+2.4% (p=0.37) at 24 h and 97.8+7.4% (0.18) and 89.3+1.8% (p=0.24) at 48 h 
respectively.
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2+Gentamicin treatment was applied in the presence of 1.05 mM Ca 0 at 20, 50 
and 100 pM but produced no significant changes to the level of branching 
morphogenesis normally seen in the presence of 1.05 mM Ca2+0 (Fig. 4.5B). In the 
presence of 20 pM gentamicin (n=3) branching levels were 30.9+4% at 24 h 
(p=0.65) and 109.9+13.4% (p=0.5) at 48 h. Gentamicin concentrations of 50 (n=3) 
and 100 (n=6) pM produced much the same effects with increases in branching of 
25.5+5.5% (p=0.33)or 29.5+5.1% (p=0.41) at 24 h and 122.6+2.5% (p=0.97) or 
123+10.4% (p=0.98) at 48 h respectively.
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Figure 4.5: Aminoglycoside antibiotic treatment does not significantly affect branching 
morphogenesis. Lungs from E l2.5 mouse embryos were cultured for 48 h in the 
presence of 1.05, 1.2 or 1.7 mM Ca2+0 with or without the antibiotic indicated. A). 
Graphic representation of branching morphogenesis induced when cultures are 
treated with 30-100jjM  neomycin for 48 h. B). Graphic representation of branching 
morphogenesis induced when lung explant cultures are treated with 20-100 pM 
gentamicin for 48 h. Terminal branch number at 24 and 48 h was normalised to 
branch number at 0 h and expressed as percent change in number of branches. Data 
shown as mean + s.e.m from multiple pooled experiments, n shown in parentheses 
above 48 h results, ## = p<0.001 by ANOVA compared to both 1.05 and 1.2 mM 
control values; ** = p<0.001 by ANOVA compared to 1.05 mM control values.
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4.5 Inhibition of Signalling Pathways Downstream of CaR Activation
4.5.1 Effect ofMEK and ERK1/2 Inhibition on Lung Branching 
Morphogenesis
In order to test the hypothesis that CaR was mediating its high [Ca2+]0 or 
calcimimetic induced suppression on lung branching morphogenesis via MEK 
signalling, PD98059, a MEK 1/2 activation blocker was added to the culture medium
9+ 9-i-of lung explant cultures containing either 1.7 mM Ca 0 or 1.2 mM Ca 0 + 10 nM R- 
568. Previously, concentrations of 25 and 75 pM PD98059 have been used in whole 
kidney explant culture models (Fisher et a l, 2001). In these experiments we used 
both 25 and 50 pM PD98059, neither of which rescued the branching morphogenesis 
suppression by high [Ca2+]0 or by calcimimetic.
In a single experiment (n=3), lung cultures exposed to 1.2 mM Ca2+0, with 
the addition of 50 pM PD98059 (Fig. 4.6Am) resulted in branching increases of 
31.5+2.8 % at 24 h and 70.1+11.2% at 48 h, which were not significantly different 
from values observed in control cultures of 19.3+3% at 24 h and 78.5+24% at 48 h 
(Fig. 4.6B). When lungs were cultured in the presence of 1.2 mM Ca2+0 + 10 nM R- 
568, the level of branching was decreased slightly in comparison to control cultures, 
to 17.5+6.4% at 24 h and 60+6.6% at 48 h, although this was not statistically 
significant (Fig. 4.6A» and B). Addition of 50 pM PD98059 to 1.2 mM Ca2+0 with 
10 nM R-568 did not significantly change the branching levels resulting in 19+3.4% 
change in branching at 24 h and 54.7+6.6% at 48 h (Fig. 4.6A/v and B).
Similarly, when 25 pM PD98059 was added to medium containing 1.7 mM 
Ca2+0, branching levels did not significantly differ from control cultures resulting in 
increases of 9.8+4.2% (control, n=7 from 2 separate isolations) and 15.1+2.4% 
(PD98059, n=8 from 2 separate isolations, p=0.28) at 24 h and 38.5+8.6% (control)
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and 40.4+4.4% (PD98059, p=0.84) at 48 h (Fig. 4.7B). When 25 pM PD98059 is 
added to 1.7 mM Ca2+0 or 1.7 mM Ca2+0 + 10 nM R-568 (Fig. 4.7 Am), the amount 
of branching morphogenesis still remains similar to that observed in control 
conditions, with values of 9.8+2.3% at 24 h (n=3, p=0.24) and 37.9+15.8% (p=0.84) 
at 48 h.
A second compound, U1026 was used to test the hypothesis that the CaR was 
mediating its calcimimetic or high Ca2+0 induced suppression on lung branching 
morphogenesis by initiating ERK1/2 signalling. U0126 is commonly used for 
inhibition of ERK1/2 activation at concentrations of 10 and 20 pM in both cell and 
organ explant cultures (Kling et al., 2002; Bhagavathula et al., 2005). U0126 was 
applied to E l2.5 mouse lungs cultured in the presence of 1.7 mM Ca2+0 in order to 
test if the diminished branching morphogenesis could be rescued by the inhibition of 
ERK1/2 activation (Fig. 4.8).
Treatment with either 20 or 30 pM U0126 in 1.7 mM Ca2+0 resulted in 
further reductions in the amount of branching morphogenesis (Fig. 4.8An and Hi). 
Lungs cultured in the presence of 1.7 mM Ca2+0 showed branching increases of 
9.5+5.7% at 24 h and 67.6+22.5% at 48 h (Fig. 4.8A/v and B, n=6 from 2 separate 
experiments). Application of 20 pM U0126 for 24 h decreased these values to 
6.4+2.5 % at 24 h and 50.4+19.6% at 48 h (n=6 from 2 separate experiments); 30 
pM U0126 for 24 h decreased these values even further to 2.1+6% at 24 h. At 48 h 
in one lung there was a loss of a branch due to the swelling of the bud, this resulted 
in an overall negative mean of -0.7+4% at 48 h (n=3). A single experiment with 40 
pM U0126 was attempted, but this was toxic as the lungs died within 24 h (not 
shown).
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Figure 4.6: Effect of 50 pM PD98059 on [Ca2+]0- and calcimimetic-regulated branching 
morphogenesis. Lungs from E l2.5 mouse embryos were cultured in the presence of 
1.2 or 1.7 mM Ca2+0 with 0.1% DMSO (negative control); and in the presence of 1.2 
mM Ca2+0 with 50 pM PD98059 (MEK activation blocker). A). Representative 
pictures of lungs cultured for 48 h in: 1. 1.2 mM Ca2+0 + 0.1 % DMSO, ii 1.2 mM 
Ca2+0 + 10 nM R-568, iii. 1.2 mM Ca2+0 + 50pM PD98059, iv. 1.2 mM Ca2+0+ 50 
pM PD98059 + 10 nM R-568, v. 1.7 mM Ca2+0. Inset pictures show each lung at 0 h 
(post-dissection) showing a comparable number of initial terminal branches for each 
condition. B). Terminal branch number at 24 and 48 h was normalised to branch 
number at 0 h and expressed as a percent change in number of branches. Data shown 
are mean ± s.e.m., n=3 for all conditions, from a single isolation. Scale bars = 500 
pm.
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Figure 4.7: Effect of 25 pM PD98059 on [Ca2+]0- and calcimimetic-regulated branching 
morphogenesis. Lungs from E l2.5 mouse embryos were cultured in the presence of 
1.7 mM Ca2+0 with 0.1% DMSO (negative control); or in the presence of 1.7 mM 
Ca2+0 with the addition of 25 pM PD98059 (MEK activation blocker). A). 
Representative pictures of lungs cultured for 48 h at: i. 1.7 mM Ca2+0 + 0.1% DMSO, 
ii. 1.7 mM Ca2+0 + 25 pM PD98059, fit 1.7 mM Ca2+0 + 25 pM PD98059 + 10 nM R- 
568. Inset pictures show each lung at 0 h (post-dissection) showing a comparable 
number of initial terminal branches for each condition. B). Terminal branch number 
at 24 and 48 h was normalised to branch number at 0 h and expressed as a percent 
change in number of branches. Data shown are mean + s.e.m., n in parentheses above 
48 h results, from 2 separate experiments. Scale bars = 650 pm.
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Figure 4.8: Effect of U0126 on [Ca2+]0. regulated branching morphogenesis.
Lungs from El 2.5 mouse embryos were cultured in the presence of either 1.05 or 1.7 
mM Ca2+0 with 0.1% DMSO (negative control); and in the presence of 1.7 mM Ca2+0 
with 20 or 30 pM U0126 (ERK1/2 inhibitor). A). Representative pictures of lungs 
cultured for 48 h in: i. 1.05 mM Ca2+0+ 0.1 % DMSO, ii. 1.7 mM Ca2V  20 pM 
U0126, ii i  1.7 mM Ca2+0 + 30 pM U0126, iv. 1.7mM Ca2+0 + 0.1 % DMSO. Inset 
pictures show each lung at 0 h (post-dissection) showing a comparable number of 
initial terminal branches for each condition. B).Terminal branch number at 24 and 48 
h was normalised to branch number at 0 h and expressed as a percent change in 
number of branches. Data shown are mean ± s.e.m pooled from 2 separate 
experiments, n in parentheses above 48 h results. Significant inhibition of branching 
morphogenesis is induced by application of U0126 is indicated in time matched 
samples by the asterisks (p<0.01). Scale bars = 700 pm.
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4.5.2 Effect ofp38 Inhibition on Lung Branching Morphogenesis
CaR activation can lead to p38 phosphorylation and activity in osteoblastic 
MC3T3-E1 cells (Yamaguchi et a l ,  2000). Therefore to test the hypothesis that the 
CaR was mediating its high Ca 0 induced suppression on lung branching 
morphogenesis by initiating p38 activity, a selective inhibitor for p38 was applied to 
the lung explant cultures. BIRB 796 has been successfully used as a potent and 
selective compound to acutely inhibit p38 MAPK signalling in Werner syndrome 
cells at a concentration of 10 pM (Bagley et al., 2006).
Chronic application of 1 pM BIRB 796 was used due to the potential toxicity 
of 10 pM. Application of BIRB 796 at this concentration to inhibit p38 signalling did 
not rescue the branching responses of 1.7 mM Ca2+0 (Fig. 4.9). If anything, it 
suppressed the branching even further. The control treatment of DMSO did not 
significantly impair branching when compared to previous experiments with 1.7 mM 
Ca2+0 resulting in branching increases of 19.9+7.1% and 66.7+13.1% at 24 and 48 h 
(Fig. 4.9Az and ii). When 1 pM BIRB 796 was applied to lung cultures containing 
1.7 mm Ca2+0, the percentage increases in branching were 20.5+6.5% and 35.9+20% 
at 24 and 48 h (Fig. 4.9 A and B, n=7 from two separate isolations).
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Figure 4.9 Inhibition of p38 signalling does not rescue 1.7 mM Ca2+0 inhibition of 
branching morphogenesis. Lungs from E l2.5 mouse embryos were cultured at 1.7 
mM Ca2+0 with 0.1% DMSO (negative control); and with 1 pM BIRB 796 (p38 
inhibitor). A). Representative pictures of lungs cultured for 48 h in: i. 0.01% DMSO, 
ii. 1 pM BIRB. B). Terminal branch number at 24 and 48 h was normalised to 
branch number at 0 h and expressed as a percent change in number of branches. Data 
shown as mean + s.e.m, n=7 lungs from two separate isolations. Scale bar = 600 pm.
[ C a (m M )
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4.5.3 Effects ofPLC Inhibition on Lung Branching Morphogenesis
Activation of the CaR is linked to a phospholipase C-mediated increase in 
intracellular calcium concentration ([Ca2+]j) in almost every system expressing the 
CaR (Brown & MacLeod, 2001). The PLC inhibitor, U73122, is widely used to 
inhibit the CaR-dependent activation of PLC (Godwin and Soltoff, 2002; Handlogten 
et al., 2001; Huang et al., 2002). Concentrations of U73122 used in previous studies 
range from 1 - 1 0  pM. However, these studies were carried out on isolated cells and 
not whole tissue explants, therefore three different concentrations of U73122 and of 
its inactive analog U73343 were tested (2.5, 5 and 10 pM) in the studies presented 
here. DMSO (0.01-0.2%) was also used as a negative control compound.
When compared to the branching responses detailed in Figure 2.2A 0.1% 
DMSO did not have any significant effects on the level of branching morphogenesis 
at any concentration tested. Unfortunately at every dosage tested, U73343 treatment 
resulted in minimal branching increases (1-4%) at 24 h and by 48 h lung explants 
appeared dark and grainy, which is generally taken as an indicator that the lung has 
died (Fig. 4 .10C, D and E). It was therefore decided that this did not demonstrate an 
applicable negative control and in subsequent cultures a relevant concentration of 
DMSO was added to culture medium.
Branching morphogenesis was sensitive to PLC inhibition by U73122 in a 
concentration-dependent manner (Fig. 4.11) at both 24 and 48 h in culture. At 24 h 
control explants exposed to 1.05 mM Ca2+0 + 0.2% DMSO (n= 8 from 2 separate 
isolations) showed an increase in branching of 28.0+4.7%, at 48 h the number of 
terminal branches had doubled resulting in a 101.4+6.3% increase. There was no 
significant difference in the level of branching morphogenesis when 2.5 pM U73122 
was added to the culture medium at either 24 or 48 h resulting in increases of
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32.1+7.3% (n=3 from a single isolation, p=0.65) and 98.5+8.7% (p=0.81) 
respectively. However, both 5 and 10 pM U73122 caused an increase in branching 
morphogenesis that was significantly higher than that observed in the presence of 
1.05mM Ca2+0+ 0.2% DMSO. Treatment with 5 pM U73122 resulted in an increase 
of 55.6+7.1 % (n= 9 from 2 separate isolations, p<0.001) at 24 h and 165.1+18% at 
48 h (p<0.001). 10 pM U73122 resulted in an even greater increase of 123.4+6% 
(n=l 1 from 3 separate isolations, p <0.001) at 24 h and 246.3+7.6% (p<0.001) at 48 
h.
In the presence of 1.7 mM Ca2+c + 0.2% DMSO branching is suppressed as 
expected from previous experiments (Fig. 2.2A, Fig. 4.12C), with only small 
increases in branch number, 16.1+5.3% at 24 h and 66.6+10.7% after 48 h (n=9 from 
2 isolations). Addition of 2.5 pM U73122 does not significantly change these levels 
resulting in similar increases of 16.9+4.8% (n=4 from single isolation, p=0.94) at 24 
h and 69.2+4.3% (p=0.89) after 48 h. With the addition of 5 pM U73122 the 
branching response is completely rescued to levels not statistically different from 
those observed in the presence of 1.05 mM Ca2+Q(Fig. 4.12D), and were 
88.7+10.08% at 24 h and 171.7+15.11% at 48 h (n=9 from 2 separate isolations, 
p<0.001 compared to 1.7 mM Ca2+0 + 0.2% DMSO). This rescue is made even more 
robust by the addition of 10 pM U73122, which results in branching increases of 
117.5+6.9% (n=l 1 from 3 separate isolations, p<0.001 compared to 1.7 mM Ca2+0 + 
0.2% DMSO) after 24 h and 215.5+5.4% after 48 h (p<0.001 compared to 1.7 mM 
Ca2+0+ 0.2% DMSO).
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Figure 4.10: Effects of U73122 and U73343 on lung branching morphogenesis. The
pictures are exemplar of El 2.5 mouse lungs cultured for 48 h in the presence of 1.7 
mM Ca2+0 + U73122 (A-C) or + U73343 (D-F) at the concentrations indicated 
between the top and bottom row. Pictures are representative of n 3 lungs for each 
condition. Scale bars = 500 pm.
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Figure 4.11: Branching morphogenesis is sensitive to PLC inhibition with U73122.
Lungs from E l2.5 mouse embryos were cultured in the presence of either 1.05 or 1.7 
mM Ca2+0, with or without the addition of DMSO (0.2%) or U73122 (2.5, 5 and 10 
pM). Graphic representation of branching increases seen in response to treatment 
with U73122. Branching responses are significantly increased with the addition of 5 
or 10 pM U73122 at both 24 and 48 h. Terminal branch number at 24 and 48 h was 
normalised to branch number at 0 h and expressed as a percent change in number of 
branches. Data shown as mean + s.e.m, from 1-3 separate experiments (n=3 or 4 then 
single experiment), n is shown in parentheses above 48 h results, *** = p<0.001 by 
ANOVA with Tukey post-hoc test.
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Figure 4.12: Exemplar lungs cultured with U73122. Lungs from E l2.5 mouse 
embryos were cultured in the presence of 1.05mM Ca 0 (A and B) or 1.7mM Ca 0 
(C and D) with 0.1% DMSO (A and C, negative control) or 5 |iM U73122 (B and D, 
PLC inhibitor). Increased branching was visible after 24 h and continued to develop 
through to 48 h. These pictures are representative of two separate experiments where 
n=8 for A and n=9 for all other conditions. Scale bars = 725 (xm.
150
4.5.4 Effect of PI3Kinase Inhibition on Lung Branching Morphogenesis
CaR activation has been shown to induce ERK1/2 activation via PI3 K 
induction in primate OSE cells (Hobson et al., 2003). In order to test the hypothesis 
that the CaR was mediating its calcimimetic or high Ca2+0 induced suppression on 
lung branching morphogenesis via activation of PI3 K, a known inhibitor of PI3 K 
activation, LY294002, was applied to lung explant cultures. Concentrations of both 
10 and 20 pM LY294002 have been previously published for use on lung explant 
cultures (Wang et al., 2005; Metzger et al., 2007). In this study, concentrations of 
LY294002 from 5 - 2 5  fiM were tested on lung explant cultures. The initial and 
highest dosage of LY294002 used was 25 |iM. While this was not immediately toxic 
to the lungs, it did seem to be detrimental to their overall health as little branching 
morphogenesis was achieved and there was a dark, grainy appearance in their 
luminal area (Fig. 4.13Ah' and iv).
In this single experiment, treatment with 25 pM LY294002 did not enhance 
branching morphogenesis at 24 h in the presence of 1.05 mM or 1.7 mM Ca2+0 with 
21.4+4.5% (n=3) and 23.7+7.1% (n=3) branching increases respectively. After 48 h, 
branching of explants incubated in 25 pM LY294002 in the presence of 1.05 mM 
Ca2+0 had increased 38.2+5.9%, while the explants incubated in 25 pM LY294002 
and in the presence of 1.7 mM Ca2+0 remained unchanged from their 24 h increase of 
23.7+7.1%. Both of these values were not statistically different from the amount of 
branching produced in the presence of 1.7 mM [Ca2+]0 + 0.1% DMSO, which was, 
47.6+6.8% after 48 h (p=0.38 for 1.05 mM [Ca2+]c+ 25 pM LY294002 and p=0.062 
for 1.7 mM [Ca2+]0+ 25 pM LY294002). In comparison, the percent change of 
branching morphogenesis in the presence of 1.05 mM (n=5) and 1.7 mM Ca2+0 (n=5) 
containing 0.1% DMSO resulted in an increase in branching of 21.9+4.6% and
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12.7+2.7% at 24 h with increases in branching of 98.1+24.5% and 47.6+6.8% after 
48 h (Fig. 4.13B).
After the above experiment, lower concentrations of 5 and 12.5 pM 
LY294002 were used on lung explant cultures. At these concentrations, LY294002
9 -4-  •application induced recovery from high Ca 0- and calcimimetic- induced depression 
of branching morphogenesis. Figure 4.14 details the response of lung explant 
cultures to the application of 5 pM LY294002. There is no significant change in the 
amount of branching morphogenesis when 5 pM LY294002 is applied to cultures 
containing 1.05 mM Ca2+0 for 48 h. Indeed, in the presence of 1.05 mM Ca2+0 
branching increases were 65.2+8.8% at 24 h and 170.33+23.4% at 48 h (n=3) while 
branching in the presence of 1.05 mM + 5 pM LY294002 (n=2) resulted in 
branching increases of 69.8% at 24 h and 131.3% at 48 h.
When 5 pM LY294002 was applied to cultures containing 1.2 mM Ca2+0 + 
10 nM R-568 there is a significant rise in the % increase in branch number at 24 h 
from 8.3+5.5% (1.2 mM + 10 nM R-568, n=3) to 39.8+5.3% (1.2 mM + 10 nM R- 
568 + 5 pM LY294002, n=4, p=0.01). The increase is maintained at 48 h where 
branching is increased from 66.1+5.1% to 137.6+14.3% (p=0.009). Lung explant 
cultures exposed to 1.7 mM Ca2+0 resulted in the expected amount of branching 
morphogenesis with 9+3.2% at 24 h and 42.5+1.1% at 48 h. Treatment of lungs also 
grown in the presence of 1.7 mM Ca2+0, but with 5 pM LY294002 resulted in a 
robust rescue of the branching inhibition at both 24 h with 42.01+9.1% (n = 6 for 
both conditions from 2 separate isolations, p=0.007) and at 48 h, with a branching 
increase of 133.2+22.5% (n=6, p=0.005).
Experiments performed with 12.5 pM LY294002 did not show a 
concentration-dependent rescue of the branching morphogenesis as did experiments
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with varying concentrations of U73122. However, there was still a rescue of 
branching suppression mediated by both the R-568 calcimimetic and by high (1.7 
mM) Ca2+0 (Fig. 4.15). As in the previous experiments, at 48 h there is no significant 
difference between branching observed in the presence of 1.05 mM Ca2+0 (n=8; 
135.2+19.9%) and that observed in the presence of 1.05 mM Ca2+0 + 12.5 pM 
LY294002 (n=3; 137.9+2.8%). When 30 nM R-568 is added to the culture medium, 
branching morphogenesis decreases at 24 h from 41.2+7.9% in the presence of 1.05 
mM Ca2+0 alone, to 17.6+5.5% (n=7 p=0.03) in the presence of 1.05 mM Ca2+0 + 30 
nM R-568. At 48 h there is suppression from 135.2+19.9% in the presence of 1.05 
mM Ca2+0 alone, to 76.5+12.7% in the presence of 1.05 mM Ca2+0+ 30 nM R-568. 
Branching suppression at both time points is rescued in the presence of 1.05 mM 
Ca2+0 + 30 nM R-568 + 12.5 pM LY294002, branching increased to 64.2+10.5% 
(n=7, p=0.001) at 24 h and 124.5+13.7% (p=0.03) at 48 h (Fig. 4.15 A - D and G). 
High (1.7 mM) Ca2+0 suppression of branching morphogenesis was also abolished by 
co-incubation with 12.5 pM LY294002. Data pooled from 3 separate isolations (n=7 
for each condition) show a rescue of branching rate from 12.9+2.8% to 57.1+5.9% 
(p=0.0002) at 24 h and from 50.6+5.9% to 139.2+14.7% (p=0.002) at 48 h when in 
the presence of 1.7 mM Ca2+0 + 12.5 pM LY294002 (Fig. 4.15E, F and G).
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Figure 4.13: Treatment with 25 pM LY294002 does not rescue high [Ca2+]0 suppression 
of branching morphogenesis. L u n g s  f r o m  E l 2 . 5  m o u s e  e m b r y o s  w e r e  c u l t u r e d  i n  t h e  
p r e s e n c e  o f  1 . 0 5  m M  C a 2+0 w i t h  0 . 1 %  D M S O  ( n e g a t i v e  c o n t r o l ) ;  a n d  1 . 0 5  m M  C a 2+0 
w i t h  2 5  p M  L Y 2 9 4 0 0 2  ( P I 3K  i n h i b i t o r ) .  A). R e p r e s e n t a t i v e  p i c t u r e s  o f  e x p l a n t s :  i.
1 . 0 5  m M  C a 2+0 + 0 . 1  %  D M S O  l u n g  a f t e r  4 8  h ,  iL 1 . 0 5  m M  C a 2 + c  w i t h  2 5 p M  
L Y 2 9 4 0 0 2  a f t e r  4 8  h ,  111.  1 . 7  m M  C a 2 + c  + 0 . 1 %  D M S O  l u n g  a f t e r  4 8  h ,  iv. 1 . 7 m M  
Ca2+0 w i t h  25|liM L Y 2 9 4 0 0 2  a f t e r  4 8  h .  I n s e t  p i c t u r e s  s h o w  e a c h  l u n g  a t  0  h  ( p o s t ­
d i s s e c t i o n )  s h o w i n g  a  c o m p a r a b l e  n u m b e r  o f  i n i t i a l  t e r m i n a l  b r a n c h e s  f o r  e a c h  
c o n d i t i o n .  B ) .  T e r m i n a l  b r a n c h  n u m b e r  a t  2 4  a n d  4 8  h  w a s  n o r m a l i s e d  t o  b r a n c h  
n u m b e r  a t  0  h  a n d  e x p r e s s e d  a s  a  p e r c e n t  c h a n g e  i n  n u m b e r  o f  b r a n c h e s .  D a t a  s h o w n  
a r e  m e a n  +  s . e . m ,  n  i s  s h o w n  i n  p a r e n t h e s e s  a b o v e  4 8  h  r e s u l t s .  S c a l e  b a r s  =  7 5 0  p m .
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Figure 4.14: Effect of 5 pM LY294002 on [Ca2+]0- and calcimimetic-regulated 
branching morphogenesis. Lungs from E l2.5 mouse embryos were cultured in the 
presence of 1.05, 1.2 or 1.7 mM Ca2+0 with 0.025% DMSO (negative control); and 
with 5 pM LY294002 (PI3K inhibitor). Terminal branch number at 24 and 48 h was 
normalised to branch number at 0  h and expressed as a percent change in number of 
branches. Data shown as mean + s.e.m, n is shown in parentheses above 48 h results. 
Rescue by LY294002 of the inhibition of branching which is evoked by either R-568 
or 1.7 mM Ca2+0 is indicated in time-matched samples by the asterisks (p<0 .0 1 ).
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Figure
4.15: Effect of PI3 kinase inhibition on [Ca2+]0- and calcimimetic-regulated branching 
morphogenesis. Lungs from E l2.5 mouse embryos were cultured in the presence of 
1.05 or 1.7 mM Ca2 + 0 with 0.1% DMSO; or with 12.5 pM LY294002. Effect of 1.05 
mM (A, B), 30 nM R-568 (C, D) and 1.7 mM Ca2 + 0  (E, F) in the absence (DMSO 
vehicle control; A, C, E) or presence (B, D, F) of 12.5 pM of LY294002 (LY), on 
branching. G). Terminal branch number at 24 and 48 h was normalised to branch 
number at 0 h and expressed as a percent change in number of branches. Data shown 
are mean + s.e.m. from 3 separate experiments, n is shown in parentheses above 48 h 
results. Significant rescue of branching inhibition is indicated in time-matched 
samples by the asterisks (p<0.01). Scale bars = 750 pm.
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4.6 Increases in Ca2* as a readout of CaR Activation in Isolated Lung 
Epithelium
Downstream of PLC signalling, CaR activation evokes an increase in [Ca2+]j 
due to release of Ca2+ from internal stores (Brown et a l ,  1993). To test the 
hypothesis that the CaR was mediating its calcimimetic or high Ca2+0 induced 
suppression on lung branching morphogenesis by initiating PLC signalling pathways 
and resulting in an increase in [Ca2+h, ratiometric Ca2+ imaging was performed on 
E l2.5 mouse lungs acutely exposed to high [Ca2+]0 and to the calcimimetic R-568.
As CaR expression at E12.5 was shown to be mostly restricted to the epithelia of the 
lung buds (Fig. 3.6) and other studies by our collaborators have shown that isolated 
epithelial buds are viable and adequate for determining responses to externally 
applied stimuli (del Moral et a l ,  2006a), it was decided to use mesenchyme-free 
epithelia for these studies (Fig. 4.16A). One significant difference in the 
methodology of this study to the del Moral et al. study, is that the epithelium for 
calcium imaging were mechanically stripped of their mesenchyme without prior 
enzymatic digestion. This preparation allowed for the epithelium and the lumen to be 
visualised by our microscope system on most samples (Fig. 4.16B). Additionally, a 
small hole was made, using the tip of a pipette normally used in electrophysiology, 
at an adjoining area of the epithelial bud to allow access of the solutions to the 
luminal surface of the epithelium. It should be noted that this preparation did not 
completely remove the smooth muscle cell layer that is closely associated with the 
lung epithelium (Fig. 4.16C) and therefore most of the lung samples still displayed 
contractions of the epithelial buds during Ca2+i recording.
After the lung bud was loaded with Fura -  2AM and mounted on the heated 
stage of the microscope, perfusion of the preparation was started with a pre-warmed
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(32-35°C) physiological solution containing 0.8 mM basal Ca2+0 and allowed to 
acclimatise under the microscope. When adequate visual resolution was achieved,
9+recording of the epithelial bud began by taking initial readings of the basal Ca i 
fluorescence for 1 minute. When [Ca2+]0 was increased from 0.8 to 2 mM, isolated 
epithelia from El 2.5 mouse lung explants demonstrated a mean increase in 340:380 
ratio of 0.18 + 0.04. In the presence of 0.8 mM Ca2+0, 100 nM R-568, evoked a mean 
increase of 0.090 ± 0.02. At the end of each experiment, as a control for viability of 
the preparation, isolated epithelial buds were treated with 10 pM carbachol, an 
activator of muscarinic acetylcholine receptors which have been shown to be 
expressed in the epithelia of the developing mouse respiratory system (Lammerding- 
Koppel et a l ,  1995). When charbachol was applied the mean increase in 340:380 
ratio was 0.16 ± 0.02 (Fig. 4.17B, n=6 for all conditions from three separate 
isolations).
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c.
Figure 4.16: Exemplar photos of lung epithelia used in calcium imaging experiments.
A). Freshly isolated lung epithelial bud, scale bar = 200 pM. B). Higher 
magnification phase contrast image of isolated epithelial bud after 24 h in culture. E 
designates the epithelium and L designates the lumen. Scale bar = 50 pM. C). 
Smooth muscle cells (anti- smooth muscle actin, 1:200 dilution, red) are not 
removed by mechanical dissection of the mesenchyme and remain closely associated 
with the basement membrane of the epithelium (anti-laminin, 1:200 dilution, green). 
Scale bar =150 pm.
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Figure 4.17: Effect of CaR activators on [Ca2+L signalling. A). Representative Fura-2 
trace of epithelial buds loaded with the calcium-sensitive fluorescent dye after 
exposure to CaR activators showing that CaR-expressing epithelial cells exhibit rapid 
and transient increase in [Ca2+h (340:380 fura-2 fluorescence ratio) to acute (1-3 min) 
stimulation with Ca2+0 (2 mM), and with the calcimimetic compound R-568 (100 
nM). Carbachol treatment (Cch, 10 pM) confirms cell viability at the end of the 
experiment. B). Mean increase in fura-2 fluorescence ratio (6 epithelial buds from 
three separate isolations in three different days of experimentation). Only epithelial 
preparations that responded to the final carbachol stimulation have been considered.
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4.7 Chapter Discussion
The purpose of this chapter was to elucidate the mechanism of action by which 
[Ca2+]0 exerts it effects on the branching morphogenesis programme of the lung and to 
test specifically the hypothesis that CaR activation was involved in this process. Results 
in Chapter 2 showed that lung branching morphogenesis is sensitive to changes in 
[Ca2+]0 and Chapter 3 showed that CaR is present in the lung across the pseudoglandular 
stage of lung development, when the majority of branching morphogenesis takes place, 
E10.5 -  E16.5. The results in this chapter show that, by specifically activating the CaR 
using the calcimimetic R-568 in lung explant cultures, the branching suppression 
generally produced by high [Ca2+]0 can be recapitulated in the presence of low [Ca2+]0, 
that TPD increase is mediated by CaR activation, and that CaR activation potentially 
mediates its effects through activation of PLC and PI3 K (Fig. 4.20).
The main pharmacological tools for determining the function of the CaR are the 
calcimimetics, specific positive allosteric modulators of the CaR which shift the 
concentration response curve for Ca2+0 to the left (i.e. lower concentrations of classic 
agonists are needed to instigate signalling; see Section 1.5.2 for review). Most 
importantly, these compounds are specific for the CaR as the application of NPS-R-467 
and Amgen R-568, at the concentrations used in this study, does not affect other GPCRs 
when they are expressed in HEK293 cells (Nemeth et al., 1998).
Concentration response studies with R-568 revealed that the concentration 
required for effective suppression of branching morphogenesis was much lower than 
that needed when using NPS-R-467. This is in agreement with previously published data 
showing that R-568 is approximately twice as potent as NPS-R-467 (Nemeth et al.,
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1998). Therefore, subsequent experiments only used R-568, as the supply of this 
compound was not rate-limiting. In TPD recording experiments, there was a link 
between increased secretion and activation of the CaR. That there is a link between CaR 
activation and Cl" secretion is unsurprising, as a previously published report has shown 
that CaR activation can affect both the expression and current amplitude of volume- 
sensitive outwardly rectifying (VSOR) Cl" channels in an intestinal epithelial cell line, 
Intestine 407 (Shimizu et a l , 2000).
In my hands, the use of alternative membrane-impermeant CaR agonists, the 
aminoglycoside antibiotics neomycin and gentamicin, did not affect the branching 
morphogenesis programme of the lung explant cultures at any concentration tested.
This lack of affect could be ascribed to the phenotypic pharmacology displayed by the 
CaR. A similar lack of response of the CaR to neomycin has been reported in cultured 
human aortic endothelial cells (Ziegelstein et al., 2006). It is possible that these 
antibiotics induce some CaR mediated signalling, but that this does not have an effect on 
the branching morphogenesis readout which I am using.
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Figure 4.20: Diagrammatic summary of Chapter 4 results. High [Ca2+]0, or low [Ca2 + ] 0  
with the addition of calcimimetics, induces CaR activation in lung explant cultures. This 
activation results in the downstream activation of PLC, with resultant increases in 
[Ca2+]j, PI3 K activation and suppression of branching morphogenesis. In these 
conditions, CaR activation does not appear induce the MEK1/2, ERK1/2 or p38 
activation.
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Having determined that CaR is indeed active in the lung’s response to high 
[Ca2+]0 it needed to be determined by which signalling pathway(s) this response was 
occurring. Different G-protein mediated pathways are known to be activated by the CaR 
depending upon the cell type in which the receptor is expressed. As this is a new system 
for CaR expression, several of these pathways were interrupted using commercially 
available signalling inhibitors in order to determine the pathway by which CaR was 
exerting its effects in the developing lung. A summary of inhibitors used is presented in 
Figure 4.21.
Pharmacological inhibition of the MAPK signalling pathway, in the form of 
specific inhibitors of MEK and ERK1/2, activation did not result in an increase in 
branching morphogenesis. Many separate growth factors important within lung 
development induce signalling cascades that converge on the MAP kinases including 
FGFs, EGF and E-cadherin (Cardoso & Lu, 2006; Liu et a l ,  2008). PD98059 has been 
previously used to block activation of MEK 1/2 in whole kidney explant cultures at a 
concentration of 25 pM. In the same study, concentrations of 25 up to 75 pM in lung 
explant cultures were tested. The results of this study show tissue-specific effects, 25 
pM PD98059 inhibits branching in the kidney, but branching still occurs in the lung at 
all concentrations tested (Fisher et a l ,  2001). In this report however, there is no 
quantification of the rate or amount of branching that occurs in the absence of PD98059 
application. Therefore it is possible that an inhibition of the default branching rate in the 
group’s standard culture medium was overlooked. Since minimal branching did still 
occur at the concentrations I tested, it might be assumed that the branching observed by 
Fisher et a l  (2001) was at a similar level.
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In the context of branching morphogenesis, the results obtained from application 
of U0126 were much the same as Kling et al. (2002), where it was used on E l3 rat lung 
explants at a concentration of 20 pM. Similar to my results, U0126 treatment diminished 
branching morphogenesis. This group determined that the suppression of branching 
morphogenesis was due to ERK1/2 inhibition decreasing proliferation, and inducing 
mesenchymal apoptosis (Kling et al., 2002). Something much the same could be 
occurring in the lung explants treated with U0126 in this study.
There does appear to be a differential type of morphological presentation when 
treating lung explants with PD98059 and U0126, which was unexpected due to the fact 
that they both target the same signalling pathway. Lungs treated with U0126 have a 
higher inhibition of branching morphogenesis and qualitative changes in the 
presentation of their mesenchyme after 48 h. This differential morphology could be due 
to the concentrations at which these inhibitors were used in the current study as both 
PD98059 and U0126 can also inhibit ERK5 (Mody et al., 2001). In the current study, 
PD98059 was used below the concentration at which it inhibits ERK5 activation 
(IOOjxM) and U0126 was used at a concentration which would completely inhibit ERK5 
(20 and 30 \lM).
The last MAP kinase inhibitor used was BIRB 796, an inhibitor of p38 (Bagley 
et al., 2006). My results showing that p38 inhibition slightly increases the branching 
inhibition of 1.7 mM Ca2+0 are supported by a previously published report using a 
different p38 inhibitor, SB203580. Application of 10 jiM SB203580 significantly 
impairs branching morphogenesis by impairing cell-cell interactions (Liu et al., 2008).
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Therefore, taking into consideration the results using PD98059, U0126 and BIRB 796, 
CaR activation is not exerting its effects via MEK-ERK1/2 or p38 activation.
Blocking PLC signalling using U73122 on lung explants rescued the suppression 
of branching morphogenesis by high [Ca ]Q back to and above levels seen in the 
presence of 1.05 mM Ca2+0. U73122 is a widely used inhibitor of PLC activity, 
repetitively used for determining if CaR activation results in PLC activity and the 
downstream effects of this for the cell (Ward, 2004).
Unexpectedly, although sold as an inactive compound for use as a negative 
control along side of U73122; U73343 has lethal effects on lung explant cultures. The 
differential effects seen in treating lungs with these compounds could be the result of 
differential activities of the compounds due to the complexity of the system in which 
they are applied. There is some precedent for U73343 having a non-PLC related effect. 
When applied to isolated pyramidal cells expressing G-protein activated inwardly 
rectifying K+ (GIRK) channels, U73122 inhibited PLC but also suppressed channel 
activity. In the same system, application of U73343 did not inhibit PLC but was even 
more effective at blocking GIRK channel activity than U73122 (Sickmann et al., 2008).
Another possibility is that the toxicity of U73343 is a non-specific effect due to 
impurities present in the preparation purchased. The U73343 supplied by Sigma-Aldrich 
is reported to be > 90% pure, where as the U73122 is >98% pure. In the 10% of the 
U73343 preparation unaccounted for there could be a toxic by-product that is producing 
the effect seen. However, the rescue of branching morphogenesis seen when U73122 is 
applied does not appear to mediated by the DMSO in which it is dissolved, therefore the 
effect is most likely due to the inhibition of PLC signalling.
166
The activation of PI3 K is another CaR associated signalling pathway which 
appears to be intimately connected with the CaR mediated suppression of branching 
morphogenesis. LY294002 has been shown to inhibit casein kinase 2 to a similar extent 
as PI3 K (Davies et a l ,  2000) and a second inhibitor of PI3 K, wortmannin, has not been 
used. Therefore, it is not possible to definitively state the involvement of PI3 K in CaR -  
mediated suppression of branching morphogenesis. However, the use of LY294002 
rescued both high [Ca2+]0 and calcimimetic induced suppression of branching 
morphogenesis. As PI3 K inhibition is the most commonly reported affect of LY294002 
application, these results imply that the activation of PI3 K was induced by CaR 
activation.
Not only do the results in this Chapter show the potential involvement of PLC 
and PI3 K, Ca2+i- imaging experiments performed here showed transient activation of 
Ca2+i in response to both Ca2+0 and R-568. Results produced by performing ratiometric 
imaging of Ca2+i release in epithelial buds were much in line with a previous study 
showing that [Ca2+]0 similar to that used in my experiments ( 0 . 8 - 2  mM) resulted in 
transient, small, nanomolar [Ca2+h increases. Additionally, in the dispersed bovine 
parathyroid cells used for that study, the EC50 of Ca2+0 which increases [Ca2+]i was 
1.66+0.34 mM and when 100 nM R-568 was added this decreased to 0.61+0.04 mM, 
values that are in line with the results in Section 4.7 (Nemeth et al., 1998).
While the specific effect of smooth muscle on the response was not investigated 
in this study, it could be argued that, in this preparation smooth muscle cells are not 
removed from interacting with the epithelium. Therefore, any response to Ca2+0 and R-
'J-L568 recorded could be due to Ca 0 influx from outside of the smooth muscle cell. This
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is a possibility however, I would argue that R-568 is a membrane- impermeant agonist 
and therefore must interact with a receptor at the cellular membrane in order to exert its 
effects. Additionally, this compound requires the presence of a type 1 calcimimetic 
(Ca2+0 etc.) to produce any signal within the cell by CaR (McLamon & Riccardi, 2002) 
and therefore cannot be acting independently especially at the relatively low 
concentration used in this study (100 nM).
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Figure 4.21 Diagrammatic summary of the signalling pathways inhibited in lung explant 
cultures. The CaR is known to activate several different signalling pathways dependent 
upon the cell type in which it is expressed. Gq-mediated PLC activation was inhibited 
using U73122. Gq-mediated PI3K signalling was inhibited using LY294002. MEK1/2 
and ERK1/2 activation were inhibited by PD98059 and U0126, while p38 activation 
was blocked by BIRB 796.
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The likely involvement of both PLC and PI3 K with the attendant Ca2+i increases 
in the CaR mediated effects on branching morphogenesis provides a candidate route for 
speculation regarding the mechanism by which CaR exerts its effects. This is due to 
recent publications on Ca2+0and CaR mediated signalling in keratinocytes (Tu et al., 
2008; Xie and Bikle, 2007). In these reports it is shown that CaR activation effects E- 
cadherin mediated intracellular adhesion and signalling through a mechanism which 
involves both PLC and PI3 K. These two publications propose a model of intracellular 
signalling that is based on the Ca2+0-induced activation of CaR which has yet 
undetermined interaction with E-cadherin which then recruits and associates with a 
complex of p-catenin and p-120-catenin. This E-cadherin/p-catenin/p-120-catenin 
complex then recruits and activates PI3 K via P-catenin, generating PIP3 which activates 
PLC ultimately resulting in Ca2+i release. CaR activation also results in the activation of 
Src family tyrosine kinases and culminates in the formation of adherens junctions reliant 
upon the intercellular interactions of the E-cadherin/p-catenin/p-120-catenin complex. 
Both of these processes then result in the differentiation of keratinocytes.
Five pieces of data should be taken into account when considering this possible 
mechanism of CaR action in the context of lung development:
1. E-cadherin is constitutively expressed in lung epithelial cells at the same 
developmental time point as CaR (Hirai et al., 1989), this is also shown in Chapter 6 of 
this report;
2. application of active antibodies to perturb E-cadherin activity results in dismpted 
morphogenesis with deformed tubules (limited luminal space) most likely resulting from 
the reduced efficacy of intracellular connection (Hirai et al., 1989);
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3. ectopic over-expression of E-cadherin in isolated epithelial cultures impairs branching 
(Liu et a l , 2008) and results in large cyst-like epithelial cultures;
4. CaR activation in keratinocytes is related to E-cadherin mediated PI3 K-PLC 
activation (Tu et al., 2008);
5. rescue of high Ca2+0 branching morphogenesis suppression can be promoted by the 
inhibition of both PLC and PI3 K.
In the light of those pieces of data it is possible that CaR is mediating its effects 
in a similar fashion to that which occurs in keratinocytes; although in order to 
definitively elucidate the role of the CaR in lung development it would be useful to 
investigate how the lung develops in its absence. Experiments attempting this are the 
subject of the next chapter.
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CHAPTER 5:
THE EFFECTS OF CALCIUM- 
SENSING RECEPTOR ABLATION 
ON LUNG DEVELOPMENT
172
5.1 Methods
5.1.1 Addition of CaR-specific Oligodeoxynucleotides (ODNs) to Lung 
Cultures
In order to reduce expression of the CaR in cultured lungs, previously 
described ODNs against the CaR (Ritchie et a l,  2001) were added to the culture 
medium to a final concentration of 50(nM and left for 48h, as per section 2.1. The 
antisense sequence was designed to bind specifically to the complementary CaR 
mRNA, which in turn impairs the expression of native CaR protein. As controls, 
both sense and missense sequences were used to show that application of the ODNs 
did not impact on the responses of the lung explant cultures. The missense sequence 
was designed to have no homology to any known sequence in the mouse, but 
contained the same nucleotide components of the antisense sequence in a scrambled 
order. All of these ODNs were phosphorothiolated at the 3’- end to ensure their 
stability in the culture medium.
Antisense ODN sequence; 5’-CCATGCCATGGCTCTGCCTTCTC;
Sense sequence; 5’- GAGAAGGCAGAGCCATGGCATGG;
Missense ODN sequence 5’- CTCCGATCCCAITTCGGTCCGCT.
5.1.2 Genotyping CaR Knockout Mice
Mice heterozygous for CaR deletion on a C57/BL6J background strain were 
maintained in conventional housing, climate controlled environment with a 
laboratory diet. Ear biopsy of mice provided tissue to be used for the genotyping 
adult and weanling animals. DNA for genotyping embryos was isolated from limb 
tissue taken at the time of dissection. DNA isolation was performed using either a
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Wizard SV Genomic DNA isolation system (Promega, Southhampton, UK) or a 
DirectPCR DNA extraction system (Viagen Biotech, Los Angeles, CA, USA).
Isolated DNA was used in two separate PCR reactions. The reaction using 
the CaR6HF and CaR6HR primers resulted in a -215 bp amplicon demonstrating the 
presence of the wild-type (WT) CaR gene. The other set of primers, CaR6HR and 
Neo, resulted in a -280 bp amplicon that indicated the presence of the neomycin 
resistance cassette (NEO) used to produce the CaR knockout.
The PCR primer sequences are as follows:
CaR6HF -5 ’ -TCTGTTCTCTTTAGGTCCTGAAACA 
CaR6HR - 5 ’ -TCATTGATGAACAGTCTTTCTCCCT 
Neo - 5’ -TCTTGATTCCCACTTTGTGGTTCTA
PCR reactions were performed with BioTaq (Bioline, London, UK), in a 
reaction mix containing 2 mM Mg2+as specified by the manufacturer. Reactions 
containing 1 jj.1 genomic DNA, extracted as above, were subjected to the following 
PCR regime: 95°C x 5 min; 95°C x 30 s, 55°C x 30 s, 72°C x 1 min repeated for 35 
cycles; 72°C x 8 min. Resultant PCR products were separated by electrophoresis 
using a 2% agarose gel. Wild-type mice (WT) were designated by the presence of 
the WT band alone, heterozygous mice (HET) produced both the WT and NEO 
bands, and homozygous null mice (NULL) produced only the NEO band (Fig. 5.1). 
In order to confirm the identity of the resultant PCR products, individual bands were 
cut from the agarose gel and purified using a gel extraction kit (Qiagen, Crawley, 
UK) according to the manufacturer’s instructions. Purified PCR products were 
sequenced by Cogenics (Essex, ,UK) and resultant sequences are shown in Appendix 
C.
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5.1.3 Calculation of Lung:Body Weight Ratio
After removal from the uterus, embryos at various developmental stages were 
placed into individual wells of a multi-well tissue culture dish. Embryos were 
weighed in a Petri dish on a Sartorius Series balance (d = lmg, Acculab, Epsom, 
Surrey, UK) and then humanely sacrificed. Tissue was then collected for genotyping 
and the heart and lungs dissected en-bloc from the chest cavity. The heart and 
associated blood vessels were carefully removed from the lungs which were then 
weighed on either the Sartorius balance (for embryos >E14.5) or B1204 balance (for 
embryos < E l4.5; d = 0.1 mg, Analytical Products, Oxford, UK). Lung:body weight 
ratio was calculated as the wet weight of the lungs divided by the wet weight of the 
freshly isolated embryo.
5.1.4 Lung Explant Cultures
Lungs were dissected and cultured as described in Section 2.1.1 and cultured 
in the presence or absence of the calcimimetic R-568 as per Section 4.1.1. Lungs 
from the entire litter were exposed to the same [Ca2+]0, as genotypes were not 
revealed until the end of the study, to reduce experimenter bias. Lungs to be used for 
RNA isolation were immersed in RNAlater (Sigma-Aldrich, UK) and frozen at - 
20°C until a sufficient number was gathered for isolation.
5.1.5 Immunohistochemistry
Immunohistochemical detection and quantification of proliferating and 
apoptotic cells in CaR WT, HET and NULL lungs was performed as in Section 
2.1.3.
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5.1.6 Optimisation of PCR for the detection of CaR Splice Variant 
Expression
As it has been reported that certain tissues of the current mouse model of 
CaR knockout express a functionally active, exon-5- less splice variant of the CaR, 
lung samples used for explant cultures were collected to determine its expression in 
this system. RNA was isolated from pooled lung and kidney samples using RNeasy 
Mini-Prep kits (Qiagen,Crawley, West Sussex, UK) according to manufacturer’s 
instructions. Reverse transcription was performed with either Stratascript QPCR 
cDNA synthesis kit (Stratagene, CA, USA) or BioScript One-step RT-PCR kit 
(Bioline, London, UK). PCR primers previously used in WT samples for the 
detection of CaR RNA can also be used to detect the exon-5-less splice variant of the 
CaR, as they span the sequence which is deleted in the splice variant (Fig 5.2A; See 
Section 3.1.1 for primer sequences).
PCR reactions were performed with Velocity Taq polymerase (Bioline, 
London, UK) in a reaction mix specified by the manufacturer. Annealing 
temperature and Mg2+ concentration gradients were performed with RNA from 
kidney samples to determine the best conditions for the clearest amplification of 
desired bands. Other reaction temperatures were as specified for the Velocity taq 
polymerase and all reactions were carried out for a total of 35 cycles. Two amplicon 
sizes were possible; 584 bp for the full-length CaR and 354 bp for the splice variant 
CaR (Fig. 5.2B). After amplification the resulting products were separated on a 2% 
agarose gel by electrophoresis along with Hyperladder IV (Bioline, London, UK) as 
molecular weight markers for size comparison.
To confirm the presence of bona fide full-length and splice-variant CaR 
transcripts, amplicon bands of each size were cut from the agarose gel and purified 
using a Gel Extraction kit (Qiagen, Crawley, UK) according to manufacturer’s
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instructions. This DNA was then sub-cloned into a pGEM vector (Promega, 
Southhampton, UK) and used to transform Alpha-select competent bacterial cells 
(Bioline, London, UK). Cells which incorporated the vector and produced colonies 
on ampicillin containing agar plates were grown overnight in LB medium (Sigma- 
Aldrich, Dorset, UK). DNA was isolated from the bacterial cultures using a QIAprep 
spin mini-prep kit (Qiagen, Crawley, UK) according to manufacturer’s instructions. 
This DNA was then sent to Cogenics (Essex, UK) for sequencing. The sequencing 
results are presented in Appendix C.
5.1.7 Statistics
Graphic representations and statistics of the data were prepared with Origin 7 
software. Data are presented as the mean (from multiple pooled experiments where 
indicated) ± s.e.m. Significance was determined using one-way ANOVA with 
Tukey post-hoc test and a p-value of < 0.05 was deemed significant.
5.2 Philosophy of Work
The previous chapters have shown that the CaR was expressed in lung 
explant cultures and that activation of the receptor using Ca2+0 and calcimimetic 
suppressed branching via a mechanism involving PLC and PI3 K. Experiments in this 
chapter were designed to test the hypothesis that, by abrogating CaR expression, the 
CaR-mediated suppression of lung branching morphogenesis would no longer occur. 
Any resultant changes would inform further on the role that the CaR may be playing 
in lung development and its modes of action. Two different approaches to abrogate 
CaR expression were used in this chapter;
1. Application of CaR specific ODNs to reduce/ inhibit functionality of the native 
CaR in WT lung cultures;
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2. Lung explant cultures from CaR knockout mice where there is no endogenous 
expression of the full-length CaR transcript.
Due to the maintained responsiveness of the lung explant cultures of CaR 
knockout mice to Ca2+0 and calcimimetic, a PCR reaction to detect the expression of 
the exon-5-less splice variant of the CaR was optimised and employed. Furthermore, 
as a lung phenotype has never been investigated in embryonic CaR knockout mice, 
lung and body weight of embryos were measured to detect any gross physical 
differences between the genotypes. The amount of proliferation and apoptosis 
occurring at different stages of development and in response to culture in 1.7 mM 
Ca2+0 was also investigated to characterize any potential phenotypic differences 
underpinning the different genotypes.
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Figure 5.1: Exemplar CaR mouse genotyping results. After PCR reaction, 10 pi of 
PCR product was mixed with 5x loading buffer and electrophoresed on a 2% agarose 
gel. Resultant bands were visualised on a UV light box and photographed.
Genotypes were recognised as indicated above. Molecular weight markers of 100 -  
1 0 0 0  bp in 1 0 0  bp increments are shown in the first lane on the left.
A.
Full-length CaR
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Transmembrane & 
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Figure 5.2: Schematic representation of full-length and splice variant isoforms of the 
CaR with primer placement and exemplar PCR products. A). Schematic diagram of 
both the full-length CaR and the exon-5-less splice variant CaR. Exon-5 is 
highlighted in red and primer locations are indicated with the red arrows. Exon 1 is a 
non-coding exon, exons 2-6 form the extracellular domain of the protein and exon 7 
comprises the transmembrane and intracellular domains of the CaR protein. B). 
Exemplar PCR products at expected sizes amplified from adult heterozygous kidney 
RNA. (Figure adapted with permission from Dr.Thomas Vizard.)
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5.3 ODN Treatment of Lung Explant Cultures
A synthetic short anti sense ODN that had been previously utilised 
successfully to knock down CaR expression was selected from Ritchie et a l (2001). 
As a functional readout, the authors measured the effect of Ca2+0 on l,25(OH)2D3 -  
responsive Mg2+ entry in mouse distal convoluted tubule cells, which was 
diminished by application of the CaR antisense ODN (Ritchie et a l, 2001). As this 
ODN should inhibit any endogenous expression of the CaR in embryonic lungs, 
experiments treating the lung explants in culture could provide more detailed 
information about the CaR’s role in lung branching morphogenesis.
Application of the ODNs to cultures containing a basal [Ca2+]0 of 1.05 mM 
resulted in a slight reduction of the branching response regardless of the sequence 
applied to the culture (Fig. 5.3A). Pooling the results from 2-3 separate lung 
isolations at 24 h in the 1.05 mM control, I observed an increase in branching of 
38.1+5.6% (n=12). When sense (n=9), missense (n=6) or antisense (n=9) ODNs 
were added to the culture, the branching response decreased to 22+6.5%, 20.6+5.6% 
and 9.8+3.2% respectively. After 48 h all cultures containing ODN’s had a 
significantly decreased branching response (p<0.004) in comparison to 1.05 mM 
Ca2+0 which had a branching increase of 127.9+7%. These values, although different 
from the 1.05 mM Ca2+0 culture, were not significantly different from each other, 
with sense cultures increasing to 86.3+7.3%, missense cultures increasing to 
92.8+3.3% and antisense cultures increasing to 78.8+5.5% (p>0.08). In a single 
experiment (n=4 for each condition) where ODNs were added to cultures containing
1.7 mM Ca2+0) there was only one significant change in the branching response from 
the 16.5+3.1% at 24 h and 53.3+5.9% at 48 h of the 1.7 mM Ca2+0 control (Fig.
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5.3B). There was a significant decrease in the amount of branching morphogenesis 
after 24 h where anti sense ODNs had been applied, with a small branching increase 
of 3.3+3.3% (p=0.03) however this significant reduction was abolished by 48 h when 
the explants had an increase in branching morphogenesis of 63.1+11.2% (p=0.5). 
The sense ODN cultures had increases of 7.9+2.9% (p=0.09) at 24 h and 59.2+4.9% 
(p=0.5) at 48 h; missense ODN cultures had increases of 5+5% (p=0.1) at 24 h and 
59.1+5.5% (p=0.5) at 48 h none of these values were significantly different from 1.7 
mM Ca2+0 control culture values. Although the level of branching morphogenesis in 
the antisense ODN culture was significantly different from the 1.7 mM Ca2+0 control 
culture at 24 h, it was not significantly different from the levels of branching 
morphogenesis in either the sense or missense ODN containing cultures at either 
time point (p=0.7 at 24 h and p=0.9 at 48 h). These results indicate that any changes 
in the branching response of cultures where ODNs have been applied are due to an 
ODN treatment effect, not due to the specificity or binding of the ODN to the target 
CaR sequence.
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Figure 5J: CaR ODN treatment is not sufficient to change [Ca2+]0 dependent 
branching responses. Lungs from E l2.5 mouse embryos were cultured for a total of 
48 h in the presence 1.05 or 1.7 mM Ca2+0 with the addition of CaR specific ODNs 
applied to a 50 |nM final concentration in culture medium. Percent change in 
branching is defined as the number of branches in each explant at 24 and 48 h 
divided by number branches at 0 h. Data presented are mean + s.e.m., from >2 
pooled experiments at 1.05 mM Ca2+c (n>6 for each condition) and a single 
experiment at 1.7 mM Ca2+0 (n=4), ** = p=0.03 by ANOVA.
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5.4 Effect of [Ca2+]0and Calcimimetic on Lung Explant Cultures from 
CaR Knockout Mice
As there was a DNA-toxicity effect when treating lung explant cultures from 
C57/BL6 mice with ODNs, the next logical step was to look at the branching 
responses of lungs from mice genetically engineered to lack CaR expression. The 
hypothesis was that, as the lungs of these mice must lack CaR expression, then the 
branching morphogenesis responses in lung explant cultures would be similar to the 
branching morphogenesis responses observed when PLC and PI3K signalling are 
inhibited, regardless of the [Ca2+]0 in which the knockout lungs are cultured. 
Therefore, CaR knockout lung explants were cultured for 48 h in the presence of 1.2 
mM or 1.7 mM Ca2+0.
For many of the CaR knockout experiments, C57/BL6 mice were used as a 
control for the culture conditions as this is the background strain on which the CaR 
knockout line is kept. When grown in the presence of 1.2 mM Ca2+0j all three 
genotypes responded with similar percentage branching increases after 48 h to those 
observed in E l2.5 lungs from C57/BL6 (Fig. 5.4A). WT lungs from CaR knockout 
litters had branching increases of 111.2+10.5% (n=l 1) while HET lung branching 
increased by 113.3+11.9% (n=18) and NULL lungs kept up with their counterparts 
with an increase in branching of 106.3+16.7% (n=6). The C57/BL6 column in Figure 
5.4A is from a separate experiment (n=6) and for reference only showing that 
C57/BL6 lungs in 1.2 mM Ca2+0 double their branch number after 48 h (See also 
Fig.2.2A).
When grown in the presence of 1.7 mM Ca2+0, none of the genotypes 
branches significantly more than C57/BL6 lungs grown in the same conditions 
(p>0.06). In this experiment, C57/BL6 lungs had a branching increase of 57.9+7.7%
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(n=3, similar to that seen in Fig. 2.2A) after 48 h, while WT lungs increased by 
74.5+22.1% (n=4), HET lungs increased 53.5+11.7% (n=8) and NULL lungs 
increased 45.1+15.6% (n=5, Fig. 5.4B).
Since the genotype (and therefore CaR expression) of the lungs did not seem
9 - i-to contribute to a differential branching morphogenesis response evoked by Ca 0 
than that of normal C57/BL6 mice, CaR knockout and littermate lungs were treated 
with the calcimimetic R-568. By exposing the lungs to this CaR specific positive 
allosteric modulator, the hypothesis that there was a functional CaR still present in 
these lungs, despite their genetic status, could be tested. This does indeed appear to 
be the case from the results detailed in Figure 5.5.
In two separate experiments, four separate CaR knockout litters were used. 
C57/BL6 lungs grown for 48 h in the presence of 1.2 mM Ca2+0 increase their 
branching by 102.4+8.1% (Fig. 5.5A, n=6), when grown in the presence of 1.7 mM 
Ca2+0 for 48 h this is decreased to 56.7+8.8% (Fig. 5.5E, n=3). When CaR knockout 
and littermate lungs were cultured in the presence of 1.2 mM Ca2+c with 10 nM R- 
568, all of the genotypes showed a branching response reduced from that of 
C57/BL6 lungs grown in the presence of 1.2 mM Ca2+0 alone. WT lungs responded 
with a decrease in branching morphogenesis to 85.4+6.9% (Fig. 5.5B, n=8) which 
although showing a shift, was not statistically different from that of 1.2 mM Ca2+0 
lungs alone. However, both HET and NULL lungs responded to R-568 with 
statistically significant decreases in the amount of branching morphogenesis at 48 h, 
indicating the residual presence of a functional CaR. After 48 h of R-568 treatment, 
HET lungs responded with an increase in branching of 69.7+8.03% (Fig. 5.5C, n=14, 
p=0.0030). In the same conditions, NULL lungs had an increase in branching 
morphogenesis of 72.6+4.6% (Fig. 5.5D, n=7, p=0.04) after 48 h.
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Although branching morphogenesis levels do not vary between embryos of 
different genotypes, it was thought that perhaps the response seen would have 
differential effects on the amount of proliferation and apoptosis within lungs from 
knockout litters. Therefore the amount of proliferation and apoptosis was determined 
as in Section 2.1.3 on lung explants after culture for 48 h in the presence of 1.7 mM 
Ca2+0. It was thought at one point early in this analysis that the genotype of the 
mother might have been influencing the proliferation and apoptosis of the response, 
therefore both WT pups and HET pups from C57/BL6 mothers were also tested for 
comparison against WT, HET and NULL embryos from a HET mother (Fig. 5.6).
No changes in proliferation or apoptosis resulted from the differences in either 
maternal or fetal genotype.
The percentage of proliferating cells in WT embryos from a C57/BL6 
mother, used as control values, was 5.3+0.7% (n=7, similar to the value presented in 
Figure 2.6), HET pups, also from a C57/BL6 mother, had 4.4+0.5% proliferating 
cells, a value not statistically different from their WT littermates (n=5, p=0.37). 
These values did not change significantly when embryos were bom from a HET 
mother with the percentage of proliferating cells in WT lungs at 3.9+0.6% (n=6, 
p=0.16), HET lungs at 3.8+0.5% (n=8, p=0.1) and NULL lungs at 4.6+0.3% (n=4, 
p=0.5).
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Figure 5.4: Lung explants with partial or complete knockout of CaR show similar 
[Ca2+]0-mediated branching responses to wild-type C57/BL6 lungs. Lungs from E l2.5 
mouse embryos were cultured for 48 h in the presence of 1.2 or 1.7 mM Ca2+0. A). 
The branching response of CaR knockouts, littermates and C57/BL6 controls was 
comparable in the presence of 1.2 mM Ca2+0 after 48 h in culture. B). The branching 
response of CaR knockouts, littermates and C57/BL6 controls was comparable in the 
presence of 1.7 mM Ca2+0. Total number of terminal branches was counted at 0 and 
48 h, normalized to 0 h, and the change expressed graphically as a percentage 
increase over 48 h. Data shown are the mean + s.e.m., n numbers shown above each 
result in parentheses from pooled experiments.
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F i g u r e  5 . 5 :  L u n g  e x p l a n t  c u l t u r e s  w i t h  p a r t i a l  o r  c o m p l e t e  k n o c k o u t  o f  C a R  r e s p o n d  t o  
R - 5 6 8  t r e a t m e n t .  Lungs from E l2.5 mouse embryos were cultured for 48 h in the 
presence of 1.2 or 1.7 mM Ca2+0, with or without the addition of 10 nM R-568. A). 
Representative pictures of explants after 48 h: i. C57/BL6 lung, 1.2 mM Ca2+0, if.
WT lung, 1.2 mM Ca2+0 + 10  nM R-568, iii. HET lung, 1.2 mM Ca2+0 + 10 nM R- 
568, iv. NULL lung, 1.2 mM Ca2+0 + 10 nM R-568, v. C57/BL6 lung, 1.7 mM Ca2+0. 
Inset pictures present each lung at 0 h (post-dissection) showing a comparable 
number of initial terminal branches for each genotype and culture condition. B). 
Graphical presentation of the branching response of CaR knockouts, littermates and 
C57/BL6 controls in the presence of 1.2 mM Ca2+0, with or without 10 nM R-568, 
and 1.7 mM Ca2+0 after 48 h in culture. Total number of terminal branches was 
counted at 0 and 48 h, normalized to 0 h, and the change expressed graphically as a 
percentage increase over 48 h. Data shown are the mean + s.e.m from 2 pooled 
experiments, n shown in parentheses above results, *** = p<0.04 in comparison to 
time-matched samples cultured in 1.2 mM Ca2+0, determined by ANOVA. Scale bars 
= 800 pm.
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Apoptosis levels showed a large degree of variability in the amount of cells 
detected between samples and no significant differences were achieved. WT lungs 
from a C57/BL6 mother had 3.7+3% (n=4) apoptotic cells while WT lungs from a 
HET mother had 3.7+1.7% (n=3, p=0.1) apoptotic cells. These values were not 
significantly different from HET and NULL lungs from a HET mother, where the 
percentage of apoptotic cells was 2.0+1.6% (n=3, p=0.9) for HET lungs, and 
4.7+4.1% (n=3, p=0.1) for NULL lungs (Fig. 5.6).
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Figure 5.6: Levels of proliferation and apoptosis in lung explants cultured in the 
presence of 1.7 mM Ca2+0 are not dependent upon fetal or maternal genotype. Lungs 
from El 2.5 mouse embryos were cultured in the presence of 1.7 mM Ca2+0 for 48 h. 
After culture the lungs were fixed in 4% PFA and embedded into paraffin. 5 pm 
sections were subjected to immunohistochemistry to detect proliferation (phospho- 
histone H3) and apoptosis (TUNEL assay as described in Chapter 2). The number of 
cells detected is expressed as a percentage of the total number of cells counted. Data 
presented are the mean + s.e.m from 3 separate litters for proliferation and a single 
litter for apoptosis.
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5.5 Physical Measurements of Development in CaR Knockout Mice
As the gross physical appearance (i.e. size and shape) of CaR NULL 
knockout mice is not overtly different to that of their WT and HET counterparts at 
birth, no investigation has been done to determine if there may be any phenotypic 
differences during development. With an aim to increase the knowledge base of how 
these mice and their lungs develop in utero, the body and lung weight of each 
embryo was measured at the time of dissection. These values are informative in their 
own right, but also can be used to produce the lung:body weight ratio which is 
commonly used as an indication of hypoplastic lung development (Bratu et al., 
2001).
At early developmental time points, El 1.5-12.5, only the embryo’s total 
weight was recorded as the individual lungs proved to be below the capability of the 
available balances to measure accurately. Therefore it is impossible to provide a 
lungibody weight ratio for these time points. However, body weights show no 
significant difference between the genotypes with El 1.5 embryos weighing on 
average between 37.6 and 41.3 mg (Fig. 5.7A) and E l2.5 embryos weighing on 
average between 79.2 and 87.2 mg (Fig. 5.7B). At E l3.5, WT embryos weigh 
147.5+6.7 mg, HET embryos weigh 158.4+6.6 mg and NULL embryos weigh 
164.2+10.6 mg (p>0.05). As the embryos continue to develop, the lack of a 
statistically significant weight difference between the genotypes is maintained 
(p>0.05, Fig 5.8A). At P0, WT embryos weigh 1402+67.8mg, HET embryos weigh 
1298.8+37.3 mg and NULL embryos weigh 1302.6+70.8 mg (Fig. 5.8A).
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Figure 5.7: Body Weight comparison of WT, HET and NULL CaR mice at E11.5 and 
E12.5. Embryos were removed from time-mated females, washed in HBSS and 
weighed immediately before lung dissection. A). Weights of embryos harvested at 
El 1.5. B). Weights of embryos harvested at E12.5. Data shown are mean ± s.e.m 
pooled from at least 3 different litters.
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Figure 5.8: Body and lung weight comparisons of WT, HET and NULL CaR mice at 
E13.5, E15.5 and PO. Embryos were removed from time-mated females, washed in 
HBSS and weighed immediately before lung dissection. Lungs were weighed post­
separation from the heart. A). Body weight of embryos removed at El 3.5, E l5.5 and 
PO. B). Lung weights from E l3.5, E15.5 and PO embryos. Data shown are mean + 
s.e.m pooled from > 3 different litters, *** = p=0.03 in comparison to HET 
littermate samples by ANOVA.
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Figure 5.9: Lung:Body weight ratio comparisons of WT, HET and NULL CaR mice at 
E13.5, E15.5 and PO. Embryos were removed from time-mated females, washed in 
HBSS and weighed immediately before lung dissection. Lungs were weighed post­
separation from the heart. Ratio was calculated as the wet lung weight divided by the 
body weight of each embryo. Data shown are mean ± s.e.m pooled from >3 different 
litters, *** = p = 0.003 in comparison to HET littermate samples by ANOVA.
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The weight of individual lungs was also measured at E13.5, 15.5 and PO. 
There is no significant difference in the lung weights between the genotypes at E l3.5 
or E15.5. At E15.5 WT lungs weigh 12.2+2.2 mg and NULL lungs weigh 11.3+0.9 
mg. At PO there is a statistically significant shift between HET lungs at 41.5+1.1 mg 
and NULL lungs weighing 36+2.6 mg (p=0.03), although there is no significant 
difference between NULL and WT lungs, which weigh 39.5+3.3 mg (Fig. 5.8B).
Lung:body weight ratios can be directly linked with lung growth and are used 
to determine whether a lung is to be considered hypoplastic (DiFiore et al., 1994). 
The lower the lung:body weight ratio, the more likely that the lung is hypoplastic. At 
the earliest time point measured, E l3.5, the NULL ratio was 0.027±0.005 and the 
HET ratio was 0.022+0.002, their WT littermates had a ratio of 0.017+0.02 but this 
was not statistically significant (p>0.05, Fig. 5.9). At E15.5 all of the genotypes have 
similar ratios with WT at 0.028+0.004, HET at 0.029+0.003 and NULL at 
0.027+0.002. At P0 WT lungs have a ratio of 0.032+0.0003 and their HET 
littermate’s lung:body weight ratio is 0.035+0.0006 (p=0.14). However, NULL 
embryos have a significantly lower lung:body weight ratio than their HET 
counterparts, with a value of 0.0296±0.001 (p=0.003). This indicates that, at P0, the 
lighter lung weight measured in NULL embryos does not completely correspond 
with a decrease in total body weight (Fig. 5.9), and therefore the lungs are more 
likely to be hypoplastic than the lungs of their HET littermates.
The amount of cellular proliferation was determined by 
immunohistochemical detection of cells expressing phosphorylated Histone H3 in 
order to elucidate any differences in the developmental programme of the genotypes 
(Fig. 5.10A). No statistically significant differences were detected at any stage 
tested. El 5.5 lungs all had similar levels of proliferation when compared with WT, at
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2.39+0.4% (n=5) cells proliferating, HET at 2.65+0.5% (n=6, p=0.68) and NULL at 
2.39+0.7% (n=4, p=0.99) cells proliferating. E17.5 lungs also had similar levels of 
proliferation with WT at 2.86+0.57% (n=8) cells proliferating, HET at 2.19+0.3% 
(n=8, p=0.34) and NULL at 2.82+0.05% (n=8, p=0.8) cells proliferating. At P0 
levels of proliferation were reduced across all genotypes by approximately 50%, but 
levels were not statistically different across the genotypes. At this time point, the 
percentage of proliferating cells out of the total cell number counted in WT lungs 
was 1.04+0.5% (n=7), in HET lungs this was 1.25+0.5% (n=5, p=0.78) and in NULL 
lungs was 0.4+0.1% (n=3, p=0.4).
Apoptosis levels were quantified at both E l5.5 and P0 by TUNEL 
immunohistochemistry (Fig. 5.10B). At E15.5 there was significantly more apoptosis 
(50-100%) detected in HET and NULL lungs than in their WT counterparts. At this 
time point WT lungs had 1.0+0.2% (n=5) apoptotic cells while HET lungs had 
2.56+0.6% (n=6, p=0.035) apoptotic cells and NULL lungs had 1.61+0.1% (n=4, 
p=0.025) apoptotic cells. This trend looks likely to continue as the lungs develop, 
although at P0 due to the large variability, in HET and NULL samples there is no 
statistical difference between genotypes. At this time point WT lungs had 1.78±0.5% 
(n=7) apoptotic cells while HET lungs had 2.85+1.2% (n=5, p=0.38) apoptotic cells 
and NULL lungs had 2.86+1.5% (n=3, p=0.4) apoptotic cells.
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Figure 5.10: Proliferation and apoptosis levels in the developing lungs of WT, HET and 
NULL CaR mice. A). Proliferating cells were detected in paraffin sections of El 5.5, 
E l7.5 and P0 lungs from WT, HET and NULL CaR mice by immunohistochemical 
detection of phosphorylated Histone H3. B). Apoptotic cells were detected in 
paraffin sections of E l5.5 and P0 lungs from WT, HET and NULL CaR mice by 
TUNEL immunohistochemical detection. Data presented are mean ± s.e.m. from 2 
separate litters of mice. *** = p<0.04 by ANOVA.
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5.6 CaR Knockout Lungs express the Exon-5-Less CaR Splice Variant
The existence of a CaR splice variant, lacking exon-5 (SPV) has been 
previously reported in epidermal keratinocytes (Oda et a l , 1998; Oda et al ,  2000), 
chondrocytes (Rodriguez et a l ,  2005) and aortic endothelial cells (Ziegelstein et al ,  
2006). Therefore, the lungs from CaR knockout litters that had been cultured were 
screened for the presence of the SPV by RT-PCR. The developmental pattern of 
splice variant and full-length CaR expression, at two time points, was also 
investigated.
5.6.1 Splice Variant PCR Optimization
While the primers used for splice-variant CaR have been previously used on 
RNA from neuronal cell preparations (Vizard et a l ,  2008), they were used in 
different experimental conditions. Therefore, the preliminary experiment optimising 
the experimental conditions using Velocity Taq polymerase (Bioline, London, UK) 
was done with kidney RNA samples from adult HET and E l5.5 WT, HET and 
NULL CaR mice. This PCR reaction resulted in amplicons of the expected sizes, of 
584 bp for the full-length CaR and 354 bp for the SPV CaR, but also superfluous 
products of a larger size than those expected (Fig. 5.11). Non-specific binding of the 
primers, due to an inadequate annealing temperature, or genomic contamination of 
the RNA samples, could cause the production of non-specific PCR products seen in 
this reaction. Therefore the next PCR used a broader temperature gradient, as well as 
a gradient of [Mg2+] within the PCR reaction mix. This PCR showed that the optimal 
reaction conditions were 2 mM Mg2+ in the reaction mix with 68°C annealing 
temperature (Fig. 5.12).
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Figure 5.11: Initial temperature gradient for optimisation of PCR conditions for the 
detection of the CaR SPV. Total RNA was isolated from an adult HET kidney (B), 
E15.5 WT (C), E15.5 HET (D) and E15.5 NULL (E) pooled kidney samples and 
reverse transcribed. The resulting cDNA was used in PCR reactions with varying 
annealing temperatures. DNA ladder (A) 100 -  1000 bp in 100 bp increments 
indicates size of products. Top row- solid line is annealing temperature = 56°, Top 
and bottom row- dotted line is annealing temperature = 58.4°, Bottom Row- dashed 
line is annealing temperature = 60°. Full-length CaR expected size of the amplicon = 
584 bp, red arrowheads, SPV CaR expected size of the amplicon = 354 bp, green 
arrowheads.
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Figure 5.12: Temperature and [Mg2+] gradient for optimal detection of CaR SPV by 
PCR. Total RNA was isolated from each of the following: adult HET kidney (C),
E l5.5 WT (D), E l5.5 HET (E) pooled kidney samples and reverse transcribed, the 
resulting cDNA was used in PCR reactions with varying annealing temperatures and 
[Mg2+]. Negative control was performed with water replacement of cDNA (B). DNA 
ladder (A) 100 -  1000 bp in 100 bp increments indicates size of products. Full-length 
CaR amplicon expected size = 584 bp (red arrowhead), SPV CaR amplicon expected 
size = 354 bp (green arrowhead), [Mg2+] of 2, 3 and 4 mM were tested and are 
indicated above products. Annealing temperature sets, 60 °C, 64.8 °C, 66 °C and 68 
°C are indicated below the products. The clearest amplicons were produced by 2 mM 
Mg2+ and 68°C annealing temperature (red circles).
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5.6.2 Developmental detection of SPV CaR expression by RT-  PCR
As branching morphogenesis studies using WT, HET and NULL CaR mouse 
lung showed that sensitivity to high [Ca2+]0 and calcimimetics is maintained 
regardless of genotypic status, I performed a PCR reaction to detect expression of a 
CaR splice-variant lacking exon 5. This exon-5-less splice-variant could result in a 
functionally active protein mediating the branching response to [Ca2+]0 and R-568.
As a positive control, a PCR reaction for p-actin was also performed (Fig. 5.13A).
Total RNA was isolated from WT, HET and NULL lungs which had been 
cultured in 1.2 mM Ca2+0+ 10 nM R-568 for 48 h. The RNA was reverse transcribed 
and the resulting cDNA was used in the PCR reaction optimised in Section 5.7.1 for 
detecting both full-length and SPV CaR. The products of this reaction were 
separated on a 2% agarose gel by electrophoresis and visualised. This reaction 
showed that cultured WT CaR lungs continue to express the CaR after 48 h in 
culture, while HET CaR lungs express both the full-length and SPV CaR and NULL 
CaR lungs only express the SPV CaR after 48 h (Fig. 5.13B).
Developmental expression of SPV RNA was also investigated to determine if 
SPV expression was maintained across the genotypes at different time points. Full- 
length CaR expression was confirmed in E l 1.5 and E l5.5 WT lung samples while 
SPV CaR expression was detected in HET and NULL lungs of the same time points 
(Fig. 5.14).
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Figure 5.13: Full-length CaR, SPV CaR and P-actin expression in cultured WT, HET 
and NULL CaR mouse lungs determined by RT-PCR. Total RNA was isolated from 
pooled lung samples and subjected to RT-PCR. A), p-actin expression in WT, HET 
and NULL (also used in B), amplicon size = 180 bp (blue arrow). B). Full-length and 
SPV CaR expression in WT (single lung), HET (3 lungs pooled) and NULL (3 lungs 
pooled) littermates after culture in 1.2 mM Ca2+0+ 10 nM R-568 for 48 h. Expected 
amplicon size for full-length CaR = 584 bp (red arrow). Expected amplicon size for 
SPV CaR = 354 bp (green arrow).
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Figure 5.14 Full-length and SPV CaR expression in E11.5 and E15.5 WT, HET and 
NULL CaR mouse lungs determined by RT-PCR. A). Total RNA was isolated from 
pooled (8 lungs each) samples of E l 1.5 WT, HET and NULL CaR knockout 
littermate lungs and subjected to RT-PCR for detection of full-length and SPV CaR 
expression. B). Total RNA was isolated from pooled E l5.5 WT (3 lungs), HET (8 
lungs) and Null (4 lungs) CaR knockout littermate lungs and subjected to RT-PCR 
for detection of full-length and SPV CaR expression. Expected amplicon size for 
full-length CaR = 584 bp (red arrow). Expected amplicon size for SPV CaR = 354 
bp (green arrow).
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5.7 Chapter Discussion
The experiments in this chapter were designed to elucidate the effects of 
abrogating CaR expression and activity within lung development. It was expected 
that, by using two different approaches, ODN application and mice genetically 
modified to lack CaR, I would be successful in removing CaR activity from my 
culture model and determine any effects this had on lung development. However, 
ODN application resulted in decreases in branching morphogenesis regardless of the 
sequence applied, implying that this effect was due to application of the ODN, not 
due to specific interactions with the target CaR. Additionally, lungs harvested from 
CaR knockout mice responded to both changes in [Ca2+]0 and the specific positive 
allosteric modulator of the CaR, R-568. Proliferation levels, as well as embryo size, 
did not differ between the genotypes regardless of the time-point investigated. Subtle 
differences between WT/HET and NULL embryos were detected in lung weight and 
lungrbody weight ratios, apoptosis levels mid-gestation (E15.5) were also 
significantly higher in both HET and NULL embryos in comparison to their WT 
littermates. The lack of a robust phenotypic difference between the genotypes 
implies that CaR HET and NULL embryonic lungs either have a redundant 
mechanism with which to respond to CaR agonists, or they are incomplete knockouts 
for the CaR. One possible component of the response of the knockout lungs, 
expression of the exon-5-less splice variant of the CaR, was detected in both cultured 
and in vivo lung samples using RT-PCR.
The lack of response to ODN application may be due to technical difficulties 
in applying the ODN sequence to the locality of CaR expression. Previously, 
Rothenpieler and Dressier (1993) used FITC-labelled ODNs to determine how they 
are distributed in several cultured organs, including the lung. Their study showed
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that after 48h with ODNs in the culture medium, there was high expression of their 
labelled ODN in the mesenchyme of the lung, but very little in the epithelium 
(Rothenpieler & Dressier, 1993). Therefore lack of ODN access to the epithelium, 
where the majority of CaR protein is expressed at El 2.5, could be causing the results 
in Figure 5.3. Further experiments could improve the method of ODN delivery to the 
lung epithelium, including direct injection into the lung lumen of the ODN alone 
and/or use of surfactants to promote ODN uptake or application of ODNs to isolated 
epithelial bud cultures.
After the lack of success with the CaR ODN knockdown experiments, it was 
thought that using the CaR knockout mice would be more informative in 
conclusively determining the role of CaR in lung development. The logic being that, 
by using a model where CaR expression had been completely removed from the 
embryo, the technical issues surrounding exogenous knockdown of CaR expression 
would be overcome. Therefore it was surprising that lungs hetero- and homo-zygous 
for CaR knockout branched to the same extent as their WT counterparts in culture, 
regardless of the [Ca2+]0 and application of R-568. Data obtained from the physical 
measurement of body weight, as well as developmental measurements such as 
proliferation and apoptosis, also did not differ between the genotypes at the stage 
(E l2.5) used for lung explant culture.
Significant differences were never detected in the body weight of embryos, 
and it was not until later in development that differences in lung weight and 
lung:body weight ratio were noted. These differences were again subtle, with the 
HET embryos remaining more similar to the WT, while the NULL embryos showed 
reductions in both lung weight and lung:body weight ratios in comparison to their 
HET littermates. The lack of statistical significance between the lung:body weight
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ratios of WT and NULL embryos is possibly due to the large variability in the data 
obtained for the WT embryos. For an unknown reason, measurements of both HET 
and NULL embryos was within a more consistent range, especially in the body 
weight measurements despite a fairly large sample size (WT n=10, HET n=23, 
NULL n=9).
Although there were no overt differences in the physical aspects of CaR 
knockout mice aside from slightly smaller lungs, Appendix B details the numbers of 
each genotype that were harvested for a period in 2007. This information was 
gathered because; during the process of harvesting embryos I noted that there 
seemed to be an abnormally large number of aborted fetuses within the uterus of 
each HET mother. Additionally it seemed to take a large number of litters to obtain 
sample sizes large enough for each genotype. After compilation of the genotyping 
data, embryos aged E l4.5 and younger resulted in the expected Mendelian 
genotyping ratio of approximately 1 WT: 2 HET: 1 NULL. However, there were a 
large number of aborted fetuses within this group and almost invariably they were 
either HET (19 to 1 WT) or NULL (7 to 1 WT) embryos. This implies that embryos 
with disrupted activity of the CaR may be more susceptible to death than those 
which maintain normal CaR activity.
HET and NULL embryos that are not aborted begin to show signs of a 
phenotypic difference in their lungs at E15.5. At this time point HET and NULL 
lungs have significantly increased levels of apoptosis in their lungs. Although it is at 
a low level, 2-2.7% of cells counted, apoptosis is still 50-100% more in these 
embryos than their WT counterparts. It is possible that the decrease in lung size 
noted in NULL lungs at P0 could be the result of increased apoptosis through the 
latter stages of development. Indeed the trend towards a higher level of apoptosis in
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HET and NULL lungs seems to be preserved at PO, however at this point is not 
significant, potentially due to high variability and could be improved by the addition 
of several samples for each genotype. However, what the increase in apoptosis does 
not explain is that the greatest difference at PO is between HET and NULL embryos, 
not NULL and WT embryos. Therefore, if apoptosis is increased in both genotypes 
why are they different from each other?
The answer could be as simple as the fact that HET embryos have at least one 
copy of a functioning CaR. This allows for at least partial control of calcium 
homeostasis with a phenotype of greatly reduced severity in HET pups after birth 
(Ho et al., 1995) and could be compensating in the developing lung as well, reducing 
the severity of any phenotype induced by disrupted CaR expression. There could 
also be a compensation effect within the in vivo developmental situation, by the 
exon-5 less splice variant of CaR. This has been recently suggested by the increased 
severity of hyperparathyroidism in a conditional CaR knockout which removes both 
full-length and SPV CaR from the targeted tissues (Chang et al., 2008) in 
comparison to the hyperparathyroidism in the CaR knockout mouse used in this 
study.
Compensatory mechanisms could also be a part of the reason why lungs 
NULL for CaR still respond to R-568 application. WT lungs were expected to 
present with a lower amount of branching in 1.2 mM Ca2+0 when R-568 was applied, 
some decrease could also be expected in the HET lungs as they too express some 
CaR, however NULL lungs should have responded as if R-568 was not present, with 
a doubling of branching morphogenesis in 48 h. El 2.5 HET and NULL lungs after 
48 h in culture express RNA for the exon-5 less SPV of the CaR as do El 1.5 and 
E l5.5 lungs. Presumably expression of the SPV in HET and NULL lungs
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corresponds to the same expression pattern as full length CaR, E10.5-E18.5, and 
experiments to determine this definitively are ongoing.
While in some systems of the CaR knockout mouse the SPV is not 
expressed, such as SCG neurons (Vizard et a l ,  2008), expression has been detected 
in others including keratinocytes (Oda et a l ,  1998), chondrocytes (Rodriguez et al ,  
2005) as well as both E15.5 and adult kidney (Fig. 4.11-12). Studies using 
heterologous systems to express the SPV, such as HEK293 cells, have shown that it 
is not trafficked to the membrane, whereas in native systems, such as chondrocytes, 
it is expressed at the membrane and is functional (Rodriguez et a l ,  2005). 
Functionality was determined in this study by treatment of NULL chondrocytes with 
Ca2+, Mn2+ and Sr2+, as well as neomycin, all of which resulted in the production of 
inositiol phosphates in a similar fashion to full length CaR. Indeed, embryos with 
complete ablation of CaR expression in their chondrocytes die by E l3, implying not 
only a vital role for CaR activity during development, but that the SPV can 
functionally compensate for loss of the full-length CaR in this tissue (Chang et al ,  
2008).
That this SPV CaR receptor is functional in the developing lung is supported 
by the response of the NULL lungs to both high [Ca2+]0 and R-568. R-568 should be 
able to modulate allosterically the SPV in the same fashion as the full-length CaR 
because, studies using site-directed mutagenesis have shown that one of the primary 
residues for binding R-568 is Glu837 at the junction between extracellular loop 3 
and the seventh transmembrane domain of the protein (Hu et a l ,  2002; Petrel et al,  
2004). The loss of exon-5 does not affect this area of the protein, but removes only a 
small part of the large extracellular domain (Oda et a l , 2000). Indeed, long term 
application of R-568 has been shown to rescue plasma membrane expression and
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function of several loss-of-function CaR mutants in HEK293 cells (Huang & 
Breitwieser, 2007).
It may be interesting for the CaR research field as a whole to determine in 
which systems the SPV is active and whether the lung compensation effects are by 
other receptors or the involvement of the SPV, but how relevant this information 
would be to the research of lung branching morphogenesis is unclear. Studies may 
pursue the [Ca2+h signalling behaviour of isolated epithelial buds from these mice, 
but presumably they would respond in a similar way to their WT counterparts as they 
did with branching. Overall, the major drawback to using this particular mouse 
model for lung branching morphogenesis studies is that any phenotype is going to be 
very subtle, and clear, timely results are not going to be provided by its continued 
use.
Therefore several other options are to be considered for the progression of 
elucidating the role of CaR in lung development. Nuf mice, with constitutively active 
CaR, have been characterised for their ectopic calcification and hypocalcaemia, but 
specific morphology of their lungs, except in the context of calcification, has never 
been studied (Hough et a l ,  2004). The hypothesis to be tested with these mice would 
be, that their developing lungs should have lower levels of branching morphogenesis 
at lower [Ca2+]0 than their WT counterparts, i.e. in 1.05 mM Ca2+0for 48 h, their 
level of branching should be more like WT lungs in 1.7 mM Ca2+0. Experiments to 
characterise the [Ca2+]0 response of the Nuf  mouse background strain, Balb/C, have 
begun in order eventually to test the hypothesis that reduced branching results from 
constitutive CaR activation in Nuf mice.
There is also the possibility of injecting WT lungs with an adenoviral 
dominant negative CaR, such as, the dominant negative CaR construct that was
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transfected into WT SCG neurons in order to successfully knockdown activity of the 
receptor in a native system (Vizard et al., 2008). While having technical issues of its 
own, such as titration of viral dose etc., an adenoviral dominant negative construct 
would remove the technical difficulty of transfecting the lung epithelium in a whole 
lung explant based culture system. Also as mentioned earlier in this section, CaR 
ODNs could be applied to isolated epithelial buds, where the access to the epithelium 
would be much less restricted than in the whole lung explant system. The dominant 
negative CaR construct could also be applied to this system.
By far the most effective means of removing CaR expression from the 
developing lung would be to use the recently published floxed CaR mouse (Chang et 
al,  2008). The use of this transgenic mouse line would allow for lung specific 
knockdown of both the CaR and the SPV CaR. This could be achieved by crossing 
the floxed CaR mouse with a mouse containing Cre-recombinase linked to a SP-C 
promoter, producing CaR knockout in the developing epithelium, or other promoters 
could be used to generate mesenchyme-specific or total lung knockout of CaR. 
However, due to potential difficulties with Intellectual Property arrangements, this 
mouse may not be widely available for some time.
In summary, the results presented within this chapter have not as yet 
conclusively demonstrated a specific role of the CaR in lung development due to the 
inability to successfully knockdown CaR expression. Therefore, until a complete 
CaR knockout mouse becomes available, other modes of interfering with natural 
CaR expression and activity, by using knockdown strategies in native CaR 
expressing lung tissue or by use of a mouse model with constitutively active CaR 
should be attempted in order to help determine the specific role of CaR in lung 
development.
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CHAPTER 6: 
PRELIMINARY EXPERIMENTS FOR 
PROGRESSION OF THE PROJECT
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6.1 Methods
6.1.1 Lung Explant Cultures
Embryos at day 12.5 of development (E l2.5) were removed from time-mated 
females for gene expression studies from 3 different lines of transgenic mice:
1. MlclvnLacz~v24 mice, hereafter referred to as FgflO+/LacZ (Kelly et a l ,  2001), 
contain an Mlcv-nLacZ gene encoding for p-galactosidase 114 kb upstream of FGF-10 
and are reporters for FGF-10 expression. Confirmation that the pattern of p- 
galactosidase expression is specific for FGF-10 in the lung has been previously 
demonstrated (Mailleux et a l ,  2005). FGF-10 protein is expressed throughout lung 
development and has been specifically localised to the mesoderm where it induces 
budding and growth o f lung endoderm (Bellusci et a l ,  1997b).
2. TOPGAL mice (DasGupta & Fuchs, 1999) are used as a reporter line for p- 
catenin and LEF/TCF transcription factor activation. These mice have been used as a 
reporter for canonical Wnt signalling; canonical Wnts inhibit glycogen-synthase kinase- 
3P (GSK-3P) from phosphorylating p-catenin, which then accumulates in the cytoplasm, 
translocates to the nucleus and activates transcription o f LEF/TCF target genes. 
TOPGAL expression in lung at E l2.5 is present in the distal epithelium (De Langhe et 
a l ,  2005).
3. F lk -l+/LacZ mice (Shalaby et a l ,  1995) are a reporter line for Flk-1 marking 
vasculogenesis. Flk-1, also known as VEGF-R2, is a receptor for VEGF-A which is 
exclusively expressed in the mesenchyme o f the developing lung (Del Moral et a l ,  
2006b) and is an early marker o f endothelial cell precursors with very high expression 
during vasculogenesis and angiogenesis (Yamaguchi et a l ,  1993).
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The morning o f plug was considered E0.5, all females were humanely sacrificed 
in accordance with Home Office or Children’s Hospital Los Angeles Institutional 
Animal Care and U se Committee regulations. E l2.5 lungs from each transgenic line 
were cultured in the presence o f either 1.05 mM Ca2+0 or 1.7 mM Ca2+0 for 48 h as in 
section 2.1.1. The level o f branching morphogenesis was counted at 0, 24 and 48 h to 
ensure that the effect of [Ca2+]0 on branching morphogenesis was maintained despite 
their transgenic status.
6.1.2 X-gal Staining o f  Cultured LacZ Positive Lungs
After 48 h in culture, the lung explants from reporter mice (Section 6.1.1) were 
washed briefly in PBS and fixed in 4% PFA for 3 minutes at RT. Freshly prepared X-gal 
solution (0 .1M phosphate buffer (pH 7.3) with 2 mM MgCE, 5mM C6N6FeK4, 5mM 
C6N6FeK3, and 1 mg/ml X-gal [5-bromo-4-chloro-3-indolyl-P-D-galactoside]) was 
applied to the lungs and they were stained in the dark for 2-48 h with rocking at 37°C. 
After sufficient staining was achieved the tissue was washed briefly in PBS and then 
post-fixed and stored in 4% PFA at 4 °C.
6.1.3 Immunohistochemistry
E l 1.5 lung buds and isolated epithelium were fixed in ice-cold methanol for 15 
min, then washed in PBS at 4°C for 1 h. Specimens were exposed to the following 
primary antibodies; mouse monoclonal anti-smooth muscle actin antibody conjugated to 
cy3 (1:200, Sigma-Aldrich, Dorset, UK), or rat monoclonal antibody to E-cadherin 
(1:200, Abeam, Cambridge, UK), both antibodies were co-applied with a rabbit 
polyclonal anti-CaR antibody (1:200, US Biologicals, Massachusetts, USA ). Primary
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antibodies were incubated overnight at 4°C. The following day the specimens were 
washed in PBS at RT for 1 h and then the secondary antibodies, goat anti-rat conjugated 
to CY3 (1:200, Jackson Laboratories, Pennsylvania, USA) or donkey anti-rabbit 
conjugated to Alexa 488 (1:200, Molecular Probes, Eugene, OR., U.S.A.) was applied 
for 2 h at RT with gentle shaking. The final wash in PBS was done at RT for 1 h. The 
specimens were then mounted on a glass slide in Prolong anti-fade mounting medium 
(Molecular Probes, Eugene, OR., U .S.A.) and allowed to set at RT before being imaged 
by confocal microscopy.
6.2 Philosophy o f Work
The contents of this chapter address two separate lines of experimental inquiry. 
Firstly, changes in [Ca2+]0 and CaR activation have been previously shown to affect 
gene expression (Brown & MacLeod, 2001; Peterlik & Cross, 2005). Therefore, in order 
to test the hypothesis that gene expression patterns are differentially regulated by [Ca2+]0 
in the lung explant culture model, transgenic LacZ-expressing reporter mice were used 
to demonstrate global changes in FGF-10, (3-catenin and Flk-1 expression. Secondly, as 
a preliminary investigation into the possible mechanism of CaR action, I also performed 
immunofluorecent detection o f CaR in conjunction with a-smooth muscle actin, or E- 
cadherin on E l 1.5 lungs to determine if  there was any co-localisation between these 
proteins.
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6.3 Effects o f [Ca2+]0 on Gene Expression
2+
The effects o f [Ca ]0 on gene expression during lung development were tested 
using three different transgenic mice which express P-galactosidase under the control of 
a gene specific promoter. For all three strains, branching morphogenesis increased 
approximately 100% after culture for 48 h in the presence of 1.05 mM Ca2+0, while 
branching morphogenesis in the presence of 1.7 mM Ca2+0 for 48 h was approximately 
60%. These levels o f branching morphogenesis were comparable to the levels 
previously obtained from C57/BL6 lung explant cultures.
In preliminary experiments (n=3 lungs per Ca2+0 condition), lung explants from 
FgflO+/LacZ mice cultured in the presence of 1.7 mM Ca2+0 showed an increase in FGF- 
10 expression in their distal mesenchyme, without an attendant increase in branching 
morphogenesis (Fig. 6.1). Lung explants from TOPGAL mice, cultured for 48 h in the 
presence of 1.05 mM Ca2+0 (n>l 1) show a substantial amount of staining in their distal 
epithelium and main bronchi (Fig. 6.2B and C, left panels). When cultured in the 
presence of 1.7 mM Ca2+0, this expression appears decreased in the distal epithelium, 
although the levels o f P-galactosidase staining in the main bronchi appear unchanged 
(Fig. 6.2B and C, right panels).
Lung explants from Flk-1+/LacZ mice, cultured for 48 h in the presence of 1.7 mM 
Ca2+0 had greatly increased expression of Flk-1 in comparison to the staining present in 
lungs cultured in the presence of 1.05 mM Ca2+0 (n = 7, Fig. 6.3) for 48 h. In the 
presence of 1.7 mM Ca2+0the localisation o f Flk-1 also changes, with strands of 
vasculature criss-crossing over and around the developing branches (Fig. 6.3C, right
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panel) while expression in the presence o f 1.05 mM Ca2+0 is limited to the mesenchymal 
spaces between the developing branches (n = 7, Fig. 6.3C, left panel).
6.4 Immunofluorescent Detection o f CaR, a-sm ooth muscle actin and E- 
cadherin in E l 1.5 M ouse Lung.
In order to begin the experimental programme to define definitively the 
mechanism by which the CaR is mediating its effects, preliminary detection of CaR in 
conjunction with a-smooth muscle actin and E-cadherin was performed using a protocol 
for whole mount immunofluorescence in freshly isolated E l 1.5 lungs and isolated 
epithelium. CaR expression was visualised using the USB antibody which detects a 
region in the C-terminal portion o f the protein. In all whole mount samples there was 
robust detection o f the CaR in both the epithelium and the mesenchyme (Fig. 6.4-6.7). 
CaR and a-smooth muscle actin expression did not appear to co-localise, with a-smooth 
muscle actin expression restricted to the proximal airways (Fig. 6.4). CaR expression in 
the mesenchyme appeared stellate with the strands o f expression following the contours 
of the developing branches (Fig. 6.4-6.7). CaR expression in the epithelium was 
adjacent to areas o f E-cadherin expression at the plasma membrane (Fig. 6.6-6.8) and 
appeared to be fairly uniform in distribution between the luminal and basolateral 
membranes.
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1.05 mM Ca2+0 1.7 mM Ca2+0
Figure 6.1: FGF-10 expression is [Ca2+]0-sensitive. E l2.5 lungs were removed from 
FgflO+/LacZ mice and cultured in the presence o f 1.05 mM (left panel) or 1.7 mM Ca2+0 
(right panel) for 48 h and responded with expected levels of branching morphogenesis 
relative to [Ca2+]0 (A). FGF-10 expression was visualised with p-galactosidase staining 
(B and C) showing increased expression in lungs cultured in 1.7 mM Ca2+0. Lungs 
shown are representative of 3 lungs per condition from a single isolation. Scale bars = 
300 pm.
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1.05 mM Ca2+0 1.7 mM Ca2+0
Figure 6.2: P-Catenin-LEF/TCF complex expression is [Ca2+]0-sensitive. E l2.5 lungs were 
removed from TOPGAL mice and cultured in 1.05 mM (left panel) or 1.7 mM Ca2+0
(right panel) for 48 h and responded with expected levels of branching morphogenesis 
relative to [Ca2+]0 (A). p-Catenin-LEF/TCF complex expression was visualised with P- 
galactosidase staining (B and C higher magnification) showing decreased P-Catenin- 
LEF/TCF complex expression in lungs cultured in 1.7 mM Ca +0. Lungs shown are 
representative of >11 lungs per condition from 3 separate isolations. Scale bars = 300
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1.05 mM Ca2+„ 1.7 mM Ca2+„
Figure 6.3: 1.7 mM Ca2+0 induced vasculogenesis shown by an increase in Flk-1 expression.
E l2.5 lungs were removed from Flk-1+/LacZ mice and cultured in 1.05 mM (left panel) or 
1.7 mM Ca2+0 (right panel) for 48 h and responded with expected levels of branching 
morphogenesis relative to [Ca2+]0 (A). Flk-1 expression was visualised with p- 
galactosidase staining (B and C higher magnification) showing increased vasculogenesis 
in lungs cultured in 1.7 mM Ca2+0. Lungs shown are representative of 7 lungs per 
condition from 2 separate isolations. Scale bars = 500 pm.
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Figure 6.4: CaR and a-smooth muscle actin localisation in E l 1.5 mouse lung.
Lungs from E l 1.5 mouse embryos were fixed in ice-cold methanol and exposed to 
antibodies for detection o f CaR (green) and a-smooth muscle actin (red) expression, a- 
smooth muscle actin is expressed in the proximal airway and CaR is expressed in both 
the epithelium and mesenchyme throughout the lung. Scale bar = 1 5 0  pm.
2 1 9
■>• •-* y / ■*'>., . V v ■ :■*,.' - * . } . * ■  \ :... f l i  *  V-W :. r'
5:.'i t!X  f -
•  ; • ’ , -  *  * ' V  -  >  L  "V i '• “ ' V L ' ' S ? ' ^  i  ' • • > ;  ■'
1 *  . . • ’’ •S . « -'i.. V;£*"it ■*,..> *.. V.v3P®ft«'**J
I-----------------------1
150 Mm
> •'< !>  is . ' 3 ? ' *  • -: - ^ ’f  *u 5 V i - i - J ' I U  • - v>'av.V>i. - • •:*■£• • * - 5 f f . - x ^  _____
Figure 6.5: CaR and E-cadherin localisation in E11.5 mouse lung. Lungs from E l 1.5 
mouse embryos were fixed in ice-cold methanol and exposed to antibodies for detection 
of CaR (green) and E-cadherin (red) expression. E-cadherin is expressed throughout the 
developing epithelium and CaR is expressed in both the epithelium and mesenchyme 
throughout the lung. Scale bar = 150 jam.
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Figure 6.6: CaR and E-cadherin localisation in E l 1.5 mouse lung terminal bud. Lungs 
from El 1.5 mouse embryos were fixed in ice-cold methanol and exposed to antibodies 
for detection of CaR (green) and E-cadherin (red) expression. E-cadherin is expressed 
throughout the developing epithelium and CaR is expressed in both the epithelium and 
mesenchyme throughout the lung. Scale bar = 75 pm.
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Figure 6.7: CaR and E-cadherin localisation in E11.5 mouse lung terminal buds and 
proximal airway. Lungs from E l 1.5 mouse embryos were fixed in ice-cold methanol 
and exposed to antibodies for detection of CaR (green) and E-cadherin (red) expression. 
E-cadherin is expressed throughout the developing epithelium and CaR is expressed in 
both the epithelium and mesenchyme throughout the lung. Scale bar = 75 jam.
Figure 6.8: CaR and E-cadherin localisation in E11.5 mouse lung isolated epithelial buds.
Epithelial buds from E l 1.5 mouse embryos were stripped of their mesenchyme, fixed in 
ice-cold methanol and exposed to antibodies for detection of CaR (green) and E- 
cadherin (red) expression. E-cadherin is expressed throughout the epithelium as is CaR. 
Scale bar = 30 jam.
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6.5 Chapter Discussion
While preliminary, the results presented in this chapter show that [Ca2+]0, 
possibly acting through the CaR, can affect gene expression levels of two 
developmentally important proteins, FGF-10 and p-catenin, as well as influence the 
quantity and locality of vascularisation in the developing lung. Also, using 
immunofluorescence on freshly isolated tissue has allowed for a clearer localization of 
the CaR protein, and demonstrated its proximity to a-smooth muscle actin and E- 
cadherin in freshly isolated E l 1.5 lungs.
The possibility of [Ca2+]0 affecting the cellular processes occurring in lung 
development is supported by the changes in gene expression seen in the studies with the 
LacZ reporter mice. Although still preliminary, the results suggest that there is increased 
and diffuse FGF-10 expression in lungs cultured in the presence of 1.7 mM Ca2+0. These 
results would fit into a model where increased [Ca2+]0 is linked to airway expansion. 
Indeed, mice which lack expression of Shh, a negative regulator of FGF-10 expression, 
have lungs with greatly dilated airways (Pepicelli et a l ,  1998). It is also possible that 
increased FGF-10 expression could cause the differentiation of epithelial cells and 
impede branching due to a change in cellular identity. This possibility is supported by 
data from cultures of human skin keratinocytes, where exogenous FGF-10 application, 
in conjunction with increased [Ca2+]0 promotes differentiation (Marchese et a l ,  2001).
A further indication that high [Ca2+]0 may be impacting the differentiation o f the 
high Ca2+0 lung explant cultures is the decrease in TOPGAL expression seen when lungs 
are cultured in the presence of 1.7 mM Ca2+0. TOPGAL expression is dependent upon 
stabilisation of p-catenin and is also responsive to TCF3/LEF1 transcription factor
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activation (DasGupta & Fuchs, 1999). In the mouse lung, TOPGAL expression is strong 
in the distal epithelium at E12.5, but by E14.5 it is restricted to the proximal epithelium 
(De Langhe et a l ,  2005). Therefore it is possible that the decrease in TOPGAL 
expression seen in mouse lungs cultured in the presence of 1.7 mM Ca2+0 correlates to 
these lungs moving on to a later point of development. It is also possible that Wnt5a 
secretion and signalling is interfering with canonical Wnt activity in the stabilisation of 
p-catenin, as it does in the intestine (MacLeod et a l , 2007; Pacheco et a l ,  2007), 
although this possibility remains to be tested.
The most convincing and complete experiment from these preliminary data 
shows that physiological fetal [Ca2+]0 induces vascular development, as shown by the 
results using reporter mice expressing LacZ under the control of the Flk-1 promoter. 
Flk-1 expression, and therefore the amount of developing vasculature, is greatly 
increased in cultures exposed to 1.7 mM Ca2+0. The increase in Flk-1 expression 
correlates with a larger quantity of endothelial cell precursors. In 1.7 mM Ca2+0, instead 
of being concentrated only in the proximal mesenchyme and between branches, as these 
precursors are in 1.05 mM Ca2+0, they surround the branches with a diffuse, net-like 
pattern. This induction o f vascular development by high Ca2+0 could be important in the 
developing fetus to ensure optimal matching between branches and vasculature for 
eventual gas exchange surfaces.
Not only may high Ca2+0 change the expression patterns of these proteins, but it 
may also impact on the cellular structure of the epithelial sheet by activating CaR 
interaction with E-cadherin (See Chapter 4). To begin investigating if the interaction 
between CaR and E-cadherin occurs in the developing lung, I performed
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immunofluorescence on E l 1.5 lungs in order to determine the baseline localisation of 
these two proteins. The results presented here show that CaR and E-cadherin are located 
in the same cellular compartment, the epithelium, and are closely associated, but not 
over-lapping (using this antibody for detection), at the cellular membrane. Using this 
detection protocol, mesenchymal expression of CaR is also robust at this time point. 
Previous immunohistochemistry o f CaR did not show a robust mesenchymal presence 
until E l3.5, however, as the prior detection was performed on 5 pM thick sections it 
may not have been possible to appreciate fully the stellate expression pattern seen in this 
chapter.
Finally, the results o f this chapter show that by using transgenic mouse models 
and improved immunohistochemistry protocols, I have started the programme of work 
to carry this project forward. The potential implications of the results of this project and 
the continuation o f this programme of work are discussed in the following chapter.
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CHAPTER 7: 
GENERAL DISCUSSION
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7.1 [Ca2+]0 in Culture Conditions and the Developing Fetus
Currently many laboratories that routinely perform lung explant cultures do 
not consider [Ca2+]0 as an important factor within their culture conditions. This may 
be a mistake, because different types of culture media contain [Ca2+]0 that differ 
greatly. As seen within the results from Chapter 2, variations in the [Ca2+]0 of the 
culture medium used can alter the amount of lung growth within explant cultures 
quite dramatically. For instance, the routinely used BGJb medium contains 2.5 mM 
calcium, as calcium lactate (www.invitrogen.com. catalogue number 12591038), a 
concentration which this study has shown to be an inhibitory [Ca2+]0 for the 
branching morphogenesis of lung explants.
One study that has published results using this medium, supplemented their 
explants with serum (Nogawa & Hasegawa, 2002). Indeed, when BGJb medium is 
used alone, the airways of lung explants develop poorly without any definable acinar 
structure (Chinoy et al. , 1998). The addition of a combination of growth factors 
(EGF and TGF-|3l, as may be present in serum) to this preparation results is a 
normal pattern of branching and differentiation (Chinoy et a l, 1998). Therefore, at 
least some inhibitory effects of culture conditions could be overcome by the addition 
of serum and/or growth factors. In conjunction with this idea, the results of the 
experiments in Chapter 2 imply that branching morphogenesis can be rescued by 
reducing the [Ca2+]0 in the culture medium, without adding growth factors or serum. 
How this rescue occurs is currently unknown, but it could be due to an effect on the 
composition of the luminal fluid within the lung.
It is accepted that the fluid within the developing lung is important for the 
formation of an optimally functioning lung (Hooper & Harding, 1995). The exact 
composition of the mouse’s lung fluid, and therefore the exact [Ca2+]0 to which the
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developing lung is exposed, remains unresolved. Classic studies done on late 
gestation sheep fetuses (Adamson et al., 1969) showed that alveolar fluid is of a 
distinctly different composition to either amniotic fluid or blood plasma. Total 
[Ca2+], [phosphates], and [HCO3 ] were all lower in alveolar fluid, regardless of the 
age at which the samples were collected. Total [Ca2+] was 0.8 mM in alveolar fluid, 
as opposed to 1.6 mM in amniotic fluid and 3.3 mM in plasma.
The composition of alveolar fluid has not yet been confirmed in the 
developing mouse for practical reasons of sample size or in human subjects for 
ethical reasons. If these values could be obtained, it would go some way to putting 
the responses observed in this study into the physiological context. In the absence of 
these data, it might be inferred from the above sheep studies, that the [Ca2+]0 of the 
lung lumen is substantially lower than that of plasma, providing a low [Ca2+]0 
environment ideal for branching morphogenesis. Until the practicalities of 
determining [Ca2+]0 from scant microlitres of alveolar fluid can be overcome, it is 
best that research is focused on understanding the phenomena as they are witnessed 
in vitro.
Considering Kovacs et al. (1998), it was assumed that the developing mouse 
and human lung, at the early pseudoglandular phase (in mice, El 1.5-12.5), develops 
in a relatively hypercalcaemic environment. Therefore, it was assumed that the 
serum [Ca2+]0 of the developing embryos is approximately 1.7 mM, as previously 
published for late gestation (E l8.5) mice (Kovacs et al., 1998).
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7.2 Mechanisms of Ca2+0 effects on Lung Development
Taking the results presented in this study into consideration with previously 
published observations, there are potentially two different mechanisms by which the 
CaR can be exerting its influence on the branching morphogenesis of the lung. It is 
entirely possible that the physiological condition of the developing lung is a 
combination of these two mechanisms. However, for clarity the following two 
possibilities will be discussed separately:
1. A CaR and E-cadherin mechanism (Fig. 7.1);
2. A CaR and Wnt5a mechanism (Fig. 7.2).
At the end of Chapter 4, there are listed five pieces of data that need to be 
considered to interpret the mode of CaR activation in lung explant cultures. These 
are:
1. E-cadherin is constitutively expressed in epithelial cells at the same developmental 
time point as CaR (Hirai et a l ,  1989);
2. application of active antibodies to perturb E-cadherin activity results in disrupted 
morphogenesis with deformed tubules (limited luminal space) most likely resulting 
from the reduced efficacy of intracellular connection (Hirai et a l, 1989);
3. ectopic over-expression of E-cadherin in isolated epithelial cultures impairs 
branching (Liu et a l,  2008) and results in large cyst-like epithelial cultures;
4. CaR activation in keratinocytes is related to E-cadherin mediated PI3K-PLC 
activation (Tu et a l ,  2008);
5. rescue of high Ca2+0 branching morphogenesis suppression can be instigated 
through the inhibition of both PLC and PI3K.
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In addition to these five points, the TPD data from Chapter 2 and 4 should also be 
considered. These data showed that Cl' secretion increases in response to CaR 
activation by high [Ca2+]0 and R-568, but without a concurrent increase in branching.
Considering all of these factors, one possible model for the mode of CaR 
exerting is effects on lung branching morphogenesis is that CaR activation increases 
Cl' secretion in response to high [Ca2+]0 (possibly via ion channel activity in the 
epithelial cell membrane, Fig. 7.1). In conjunction with this activation, if similar to 
skin epithelial keratinocytes (Xie & Bikle, 2007; Tu et a l,  2008), then the following 
two pathways are also activated.
1. CaR interacts with E-cadherin, through an as yet unidentified mechanism, which 
associates with (3-catenin and p-120-catenin. This complex recruits and associates 
with PI3K, produces PIP3, which in turn causes the activation of PLC. This 
ultimately results in an increase in [Ca2+]j which could affect the cell cycle and 
differentiation programme of the developing lung.
2. Activation of CaR promotes the formation of E-cadherin mediated intercellular 
adherens junctions by activation of Src family tyrosine kinase signalling. This 
change in the epithelial cell-cell interaction alters the ability of the epithelium to 
respond to the increase in C f secretion with an increase in branching, as has been 
previously reported in other situations of increased pressure (Blewett et al., 1996). 
Therefore, the terminal buds swell, in a similar manner to epithelium where E- 
cadherin is over-expressed (Liu et al., 2008).
This inability to respond to increased secretion/pressure with branching is 
possibly due to a difference in the physics of the branching situation, as described by 
Fleury and Wantanabe (2002). That is, the increase in intercellular junctions 
increases the viscosity/rigidity of the developing epithelium. Therefore, there are no
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positions of reduced viscosity/rigidity from which the cells can protrude and form 
branches.
The second possible mode of CaR action involves the CaR-mediated 
secretion of Wnt5a, a non-canonical Wnt protein that can negatively impact 
canonical Wnt signalling (Fig. 7.2). CaR activation has been shown to up-regulate 
Wnt5a secretion in both adenocarcinoma cells (MacLeod et a l ,  2007; Pacheco et a l, 
2007) and colonic myofibroblasts (Pacheco & MacLeod, 2008). In the lung, Wnt5a 
over-expression increases the expression of FGF-10. The ability of the epithelium to 
respond to the signalling activity of FGF-10 is reduced, possibly by direct effects on 
FGF-10, and/or interfering with the interaction of FGF-10 and Shh signals (Li et a l, 
2005). Within lung explant cultures exposed to high [Ca2+]0, CaR activation could 
lead to secretion of Wnt5a. Wnt5a antagonises the interactions between FGF-10 and 
Shh, as well as the activity of Bmp4, all of which are vital for inducing branching 
morphogenesis in the distal bud tips. It is also possible that Wnt5a secretion could be 
involved in the suppression of branching morphogenesis by high [Ca2+]0 by 
decreasing the stabilisation of p-catenin. However, there is, as yet, no published data 
to support this idea.
Both of these models provide possible mechanisms of action for the CaR 
mediated suppression of branching morphogenesis. Further experimentation will 
help determine if either, or a combination, of these models is a viable representation 
of the in vivo developmental situation. By continuing to investigate the role of the 
CaR in lung development, it may be possible to determine if manipulations of these 
pathways can result in better developmental outcomes in situations of lung hypo- or 
hyper-plasia.
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Mesenchyme
Figure 7.1: Proposed model for the signalling pathway and mechanism of CaR- 
mediated effects on branching morphogenesis. C a R  a c t i v a t i o n  c a u s e s  E - c a d h e r i n  t o  
a s s o c i a t e  w i t h  P I 3K  a n d  i n d u c e  P L C  a c t i v a t i o n  r e s u l t i n g  i n  i n c r e a s e s  i n  [ C a “+] 1 a n d  
c e l l  d i f f e r e n t i a t i o n  ( 1 . ) .  C o n c u r r e n t l y  C a R  a c t i v a t i o n  i n i t i a t e s  S r c  t y r o s i n e  k i n a s e  
p h o s p h o r y l a t i o n  c a u s i n g  E - c a d h e r i n  a n d  i t s  a s s o c i a t e d  c a t e n i n s  ( p - 1 2 0  a n d  |3 -  
c a t e n i n )  w i t h  P I 3 K  t o  f o r m  a d h e r e n s  j u n c t i o n s  w i t h  n e i g h b o u r i n g  c e l l s  ( 2 . ) .  T h e s e  
c e l l - c e l l  i n t e r a c t i o n  c h a n g e s  d e c r e a s e  t h e  a b i l i t y  o f  t h e  e p i t h e l i u m  t o  b r a n c h  i n  
r e s p o n s e  t o  t h e  C a R - m e d i a t e d  i n c r e a s e  i n  C l '  s e c r e t i o n  w h i c h  i s  t h e  r e s u l t  o f  
a c t i v a t i o n  o f  i o n  c h a n n e l s  ( r e d  b a r s ,  3.).
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Figure 7.2: Second proposed model for the signalling pathway and mechanism of CaR- 
mediated effects on branching morphogenesis. C a R  a c t i v a t i o n  c a u s e s  t h e  s e c r e t i o n  o f  
W n t 5 a  w h i c h  t h e n  a n t a g o n i s e s  t h e  FGF-10, S h h  a n d  B m p 4  s i g n a l l i n g  a c t i v i t i e s  
w h i c h  a r e  v i t a l  f o r  b r a n c h i n g  m o r p h o g e n e s i s .  T h e r e f o r e  t h e  l u n g  d o e s  n o t  r e s p o n d  t o  
t h e  i n c r e a s e  i n  C L  s e c r e t i o n  b y  i o n  c h a n n e l s  ( r e d  b a r s )  a c t i v a t e d  b y  C a R  w i t h  a n  
i n c r e a s e  i n  b r a n c h i n g  m o r p h o g e n e s i s .
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7.3 Progression of the Project
To progress beyond these initial findings, experiments should be undertaken 
to elucidate definitively the mechanism by which CaR is exerting its effects on lung 
explant cultures. A similar progression of experiments could be used to inform as to 
which mechanism was occurring. The expression levels of both E-cadherin and 
Wnt5a mRNA and protein should be determined in response to CaR activation in the 
lung. Knockout studies, either with transgenic models or dominant negative 
constructs, for both of these proteins should also be undertaken to determine the 
lung’s response to CaR activation while lacking principle parts of the potential 
mechanisms.
Determining the exact mechanisms of CaR mediated effects on branching 
morphogenesis is important for understanding the pharmacology of this receptor 
within the context of the lung development. There are also possible downstream 
effects by both CaR activation and direct actions of Ca2+0 alone, on gene expression 
and the formation of the vascular network. Definitive distinction between the role of 
Ca2+0 and the role of CaR action in lung development requires two separate lines of 
enquiry to be undertaken. Firstly, test the hypothesis that Ca2+0, acting through CaR 
activation, is responsible for changes in gene expression. This can be accomplished 
by using transgenic reporter mouse lungs for explant culture, as in Chapter 6 . The 
repetition of lung explant cultures on FGF-10+/LacZ and TOPGAL mouse strains will 
improve the robustness of the data for the observed effects of [Ca2+]0 on their 
expression levels and localities. Along with this, lung explants from these mice 
should be used in cultures with R-568 application to determine if any of the observed 
changes in expression are mediated by the activation of the CaR.
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Further explant culture studies with lung explants from Flk-1+/LacZ mice 
should be performed in the presence of R-568 to determine if the increase in 
vascularisation observed in the presence of high [Ca2+]0 is due to CaR activation. 
These studies could provide an underlying role for CaR in lung development. This 
role could be that CaR activation is a physiological brake to control the level of 
branching morphogenesis, so that optimal matching occurs between branch 
development and vasculogenesis.
The level and locality of Wnt5a expression in lung explant cultured should be 
determined to test the hypothesis that Wnt5a secretion and/or signalling are activated 
in response to CaR activation. This should be determined in response to both low 
and high [Ca2+]0, as well as in response to specific activation of CaR by R-568. 
Transgenic models, PCR, western blotting and immunohistochemistry techniques 
could all be used to test this hypothesis. Possible downstream constituents of Wnt5a 
activities include Bmp4 and Shh. Their expression levels and localisation should also 
be determined under the same conditions (i.e. in response to Ca2+0 and CaR 
activation), with or without the presence of Wnt5a. These studies would inform on 
changes, resulting from activation of CaR and Wnt5a, in their patterns (of expression 
or localisation) that could be affecting the lung developmental programme.
Finally, in order to demonstrate conclusively the role of CaR in lung 
development, without the complicating factor of CaR splice variant activity, there 
are two other mouse models with aberrant CaR expression or activity. These 
transgenic mouse lines are:
1. Mice with an activating mutation of CaR, i.e. Nuf mice (Hough et a l, 2004);
2. Mice with a tissue-specific, conditional CaR knockout due to loxP sites flanking 
exon 7 of CaR gene (Chang et al., 2008).
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Lungs from both of these transgenic mouse lines should be used for explant cultures 
to determine the branching response to [Ca2+]0 and R-568 application. Additionally, 
the investigation for lung pathology should be undertaken in adult animals. This 
could lead to the discovery of post-natal consequences after developmental 
perturbation of CaR activity.
7.4 Implications for the Advancement of Medicine
While specific effects of CaR on the lung have not been reported, there is 
some circumstantial evidence to suggest that patients with FHH or NSHPT may be 
pre-disposed to having lung pathology. Section 1.11 detailed two case studies that 
reported severe respiratory complications resulting in the death of two NSHPT 
babies, despite intervention to resolve their hyperparathyroidism. Additionally, in a 
familial cohort study of FHH patients, there were several instances of early death 
from respiratory problems (Auwerx et al., 1985b). In these circumstances it is 
impossible to perform retrospective studies to inform on the role of CaR mutation in 
their respiratory mortality. It may be possible to look longitudinally at cohorts of 
FHH families and determine if there is a higher instance of infant mortality due to 
respiratory pathology, and/or predisposition to respiratory conditions, than in the rest 
of the population. The link has already been made between FHH and interstitial lung 
disease in these cohorts, but perhaps other respiratory pathologies (such as a 
predisposition to asthma or recurrent respiratory infection) have been overlooked due 
to the symptoms from which these patients suffer. If a positive link can be made 
between these cohorts and an increased instance of neo-natal mortality, interventions 
could be taken for monitoring in early pregnancy and delivery in order to prevent 
mortality from FHH expectant mothers.
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The potential for medical intervention in cases of lung hypo- or hyper-plasia 
is another reason for determining the role of the CaR in lung development. 
Advantageously for this possibility, the calcimimetics such as Cinacalcet are already 
proven, have been approved by the FDA and EMEA, and are commercially 
available. If the findings of this report hold true in human lung development, with 
CaR expression and activity playing a role in branching morphogenesis and possibly 
vasculogenesis, it presents a unique opportunity to quickly develop early pre-natal 
interventions without having to start clinical trials ex novo.
7.5 Final Thoughts
“Bodies are not jigsawed together as mosaics of phenotypic pieces, each one 
contributed by a different gene. There is no one to one mapping between genes and 
units of anatomy or behaviour. Genes ‘collaborate’ with hundreds of other genes in 
programming the developmental processes that culminate in a body, in the same 
kind of way as the words of a recipe collaborate in a cookery process that culminates 
in a dish.”
Richard Dawkins The God 
Delusion (Dawkins, 2006)
For the first time this project has shown that the CaR is expressed and is 
active during fetal lung development. It can be therefore be hypothesized that Ca2+0 
and CaR activation are two pieces of the jigsaw puzzle that represents the 
coordination of intrinsic and extrinsic factors, resolving into an organ that is 
responsible for the gas exchange that keeps us all alive.
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APPENDIX A:
PRODUCTION OF A CaR SPECIFIC IN  SITU  
HYBRIDIZATION PROBE
Methods:
JM109 E. Coli (Promega, Southhampton, UK) containing previously cloned full 
length CaR tagged with GFP (Maldonado-Perez et al., 2003) were grown overnight in 
200ml o f LB medium and DNA  purified using a maxi-prep protocol (Qiagen, Crawley, 
West Sussex, UK). This D N A  was then digested using Sph 1 and Sac 1 restriction 
enzymes. The resulting 484 bp fragment was subcloned into pGem-T vector (Promega, 
Southhampton, UK). Once the CaR fragment was cloned into the pGem-T vector 
(Fig. 1), RNA probes could be generated from the SP6 and T7 promoter regions on either 
side of the multiple cloning sites. Where transcription of either sense or antisense 
digoxigenin-labelled RNA probes were produced from the SP6 and T7 promoters 
respectively. Initially, the plasmid was linearised using Sph 1 (for SP6/sense probe) or 
Sac 1 (for T7/antisense probe; Fig. 2 A). The linearised vectors were then transcribed 
with DIG-11-UTP with SP6 and T7 RNA polymerases using a DIG T7/SP6 kit (Roche 
Applied Science, Burgess Hill, UK) according to the manufacturer’s instructions. 1 pi of 
resulting product was then checked via electrophoresis on a 1% agarose gel stained with 
ethidium bromide. According to the product insert, using lp g  of plasmid DNA under 
standard reaction conditions should result in approximately lOpg of labelled product, 
however this was not the case for this particular probe, initially there was not enough 
labelled probe to use in subsequent experiments (Fig. 2B).
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In order to resolve the lack o f sufficient probe, purification and cleaning (PCR 
Purification kit, Qiagen, Crawley, West Sussex, UK) was added post linearization but 
this did not result in any additional probe labelling. However, the control DNA provided 
within the kit resulted in a significant amount of labelled RNA probe; therefore the kit 
components were all working properly (Fig. 2C). The reaction was then scaled up to 
use double the amount o f reagents on the same starting amount (l|Xg) of plasmid DNA. 
Scaling up the reaction resulted in an appropriate amount of labelled RNA probe for the 
lp g  o f starting DNA  (Fig. 2D). This was then purified using Quick Spin Columns 
(Roche Applied Science, Burgess Hill, UK). Quantification and determination of 
labelling efficiency was performed as in the DIG labelling kit package insert. Briefly, 
the amount o f resultant probe was assumed to be 10pg per lp g  of starting material. This 
was diluted to lOng/pl, as was the control labelled RNA provided within the kit. A set of 
serial dilutions was performed on the control RNA from 10ng/pl down to O.Olpg/pl 
using a 5:3:2 mix o f water: 20x SSC: 10% formaldehyde as the RNA dilution buffer. 
lOpl o f each o f the probes and dilutions was applied to a small piece of Hybond N+ 
nylon membrane (GE Healthcare, Chalfont St. Giles, Buckinghamshire, UK) and dried 
at 60°C for 1 hour. The membrane was then washed, blocked and exposed to the DIG 
antibody for 30 minutes at room temperature. After the excess antibody was washed 
from the membrane, it was equilibrated in detection buffer for 5 minutes. The color 
reaction was performed at room temperature using BM purple (Roche Applied Sciences, 
Burgess Hill, UK) as a colour substrate. This reaction took approximately 45 minutes, 
after which it was stopped by washing with distilled water and the membrane was 
allowed to dry for storage.
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T h e  m e m b r a n e  s h o w e d  t h a t  b o t h  p r o b e s  h a d  i n d e e d  l a b e l l e d  t o  a  h i g h  
c o n c e n t r a t i o n  o f  l O n g / j a l  i n  t h e  d i l u t e d  s a m p l e ,  m e a n i n g  t h a t  t h e r e  w a s  a p p r o x i m a t e l y  
l O p g  t o t a l  o f  l a b e l l e d  R N A  i n  t h e  p u r i f i e d  s a m p l e  ( F i g .  2 E ) .
Sph1
T7
CaR in situ y  
fragment in 
pGem-T vector
3416 bp total
SP 6
Appendix A, Figure 1: Schematic diagram of CaR fragment for in situ probe in pGem-T 
vector.
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1 Ong/ul 1 ng/ul 10pg/ul 3pg/ul 1 pg/uI 0.3pg/ul 0.1 pg/ul 0.03pg/ul
Appendix A, Figure 2: Optimization of RNA probe DIG- labelling. MW= molecular weight markers A, C, D=Hyperladder I; 
B=Hyperladder IV (Bioline), U=undigested plasmid, T7=probe labelling with T7, SP6 =probe labelling with SP 6  A). 
Linearization digests using Sacl and Sphl of pGEM-T vector containing CaR. B). Initial RNA probe labelling with faint 500 
base band (arrow). C). Test of labelling kit with Control (CT7, CSP 6 ) and Experimental (ET7, ESP 6 ) CaR RNA 500 base 
band (arrow). D). Increased amount of probe labelling with scaling up of the labelling reaction with 500 base band (arrow). 
E). Quantification and determination of labelling efficiency with Antisense and Sense probes matching 10 ng/pl dilutions of 
control probes.
C a R -G F P  P l a s m i d  s e q u e n c e  -  f r o m  D a v i d  M a l d o n a d o - P e r e z
C aR  in situ p r o b e  s e q u e n c e
H um an P a r a t h y r o i d  C a R ,  mRNA, U 2 0 7 5 9
YELLOW -  R e s t r i c t i o n  e n z y m e  s i t e s
SAC I  -  CTCGAGAGGATGGAGGAGGAGAAGAGGGACGAGACGAGACGACGAAGA
C T C G A-AGG AT GGAGGAGG AGAAGAGGGAC GAGAC GA—  C GA------------
2 3 3 2 -  GAGGAGAAGAGGGACGAGACGA— CGA— AAGA
GGTCGAGGGACAAGAAGTAGCCCCTCGGGGTCCTGACCTGCACGGCGGACGCGGTC
GGTCGAGGGACAAGAAGTAGCCCCTCGGGGTCCTGACCTGCACGGCGGACGCGGTC
GGTCGAGGGACAAGAAGTAGCCCCTCGGGGTCCTGACCTGCACGGCGGACGCGGTC
GGCCGGAAACCGTAGTCGAAGCACGAGACGTAGAGTACGTAGGACCACTTTTGGTT
GGCCGGAAACCGTAGTCGAAGCACGAGACGTAGAGTACGTAGGACCACTTTTGGTT
GGCCGGAAACCGTAGTCGAAGCACGAGACGTAGAGTACGTAGGACCACTTTTGGTT
GGCACAGGAGGACCACAAACTCCGGTTCTAGGGGTGGTCGAAGGTGGCGTTCACCA
GGCACAGGAGGACCACAAACTCCGGTTCTAGGGGTGGTCGAAGGTGGCGTTCACCA
GGCACAGGAGGACCACAAACTCCGGTTCTAGGGGTGGTCGAAGGTGGCGTTCACCA
CCCCCGAGTTGGACGTCAAGGACGACCAAAAGGAGACGTGGAAGTACGTGTAACAG
CCCCCGAGTTGGACGTCAAGGACGACCAAAAGGAGACGTGGAAGTACGTCTAACAG
CCCCCGAGTTGGACGTCAAGGACGACCAAAAGGAGACGTGGAAGTACGTCTAACAG
TAGACACACTAGACCGAGATGTGGCGCGGGGGGAGTTCGATGGCGTTGGTGGTCGA
TAGACACACTACACCGAGATGTGGCGCGGGGGGAGTTCGATGGCGTTGGTCCTCGA
TAGACACACTACACCGAGATGTGGCGCGGGGGGAGTTCGATGGCGTTGGTCCTCGA
CCTCCTACTCTAGTAGAAGTAGTGCACGGTGCTCCCGAGGGAGTACCGGGACCCGA
CCTCCTACTCTAGTAGAAGTAGTGCACGGTGCTCCCGAGGGAGTACCGGGACCCGA
CCTCCTACTCTAGTAGAAGTAGTGCACGGTGCTCCCGAGGGAGTACCGGGACCCGA
AGGACTAGCCGATGTGGACGGACGACCGACGGTAGACGAAGAAGAAACGGAAGTTC
AGGACTAGCCGATGTGGACGGACGACCGACGGTAGACGAAGAAGAAACGGAAGTTC
AGGACTAGCCGATGTGGACGGACGACCGACGGTAGACGAAGAAGAAACGGAAGTTC
AGGGCCTTCGACGGCCTCTTGAAGTTACTTCGGTTCAAGTAGTGGAAGTC-SPHI 
AGGGCCTTCGACGGCCTCTTGAAGTT-CTTC-GTTCAAGTAGTG-AAGTC 
AGGGCCTTCGACGGCCTCTTGAAGTTACTTCGGTTCAAGTAGTG - 2  7 9 5
Appendix A, Figure 3: Sequencing line-up of CaR in situ probe with CaR-GFP and CaR 
mRNA from human parathyroid. Sequencing of linearized pGem-T vector containing 
CaR fragm ent for in situ  shows high sequence homology with original cloned fragment 
and published sequences for CaR mRNA.
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APPENDIX B:
CAR KNOCKOUT EMBRYO GENOTYPE RATIOS
Methods:
D NA  isolation and Genotyping PCR was performed as in Section 5.1.2. For 
abortuses, D NA  was isolated from any tissue remaining in an intact amniotic sac that 
could be distinguished from the placenta. The graph is representative of a sample of 
embryos harvested at E14.5 and younger. Ratio of HET and NULL genotypes were 
calculated as the number o f HET or NULL embryos divided by the number of WT 
embryos.
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Appendix B, Figure 1: Numbers of each genotype harvested from CaR HET mothers.
Mendelian ratios o f genotypes maintained in viable embryos with 1 WT: 2.2 HET: 1.2 
NULL, but higher numbers o f heterozygotes (19 HET: 1WT) and null (7 NULL: 1 WT) 
embryos are aborted.
244
APPENDIX C:
SEQUENCING OF GENOTYPING AND SPLICE 
VARIANT PCR PRODUCTS
Methods:
After PCR amplification of genomic or cDNA the products were 
electrophoresed on a 2% agarose gel. Once separated and photographed the products 
of the desired sizes were cut from the agarose gel and purified using a Gel Extraction 
kit (Qiagen, Crawley, UK) according to the manufacturer’s instructions. PCR 
products from the genotyping PCR were sent for sequencing after this purification. 
SPV PCR products were subcloned into a p-GEM vector (Promega, UK) and E.coli 
were transformed to produce this vector. After plating on agar-ampicillin plates, one 
resultant colony for each PCR product was sent for sequencing.
Sequencing reactions were performed by Cogenics, Essex, UK. When sequences for 
genotyping PCR products were returned a Nucleotide BLAST search was performed 
on the NIH, NCBI website.
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A. The sequence for the CaR6HF-CaR6HR PCR product (Wildtype CaR)
corresponded to the genomic sequence NT_ 039624.7 Mus Musculus chromosome 
16 genomic contig, strain C57BL/6J as well as the transcript NM_013803.1 Mus 
Musculus, calcium-sensing receptor, mRNA. Shown below is the PCR product 
sequence in RED and the genomic (NT_039624.7) CaR sequence from BLAST 
search in black.
ACAACATGGGGGAGCAGGTGACCTTCGATGAGTGCGGTGACCTGGTGGGGAACTACTCCA
3 3 5 0 0 4 6 9 -
ACAACATGGGGGAGCAGGTGACCTTCGATGAGTGCGGTGACCTGGTGGGGAACTACTCCA
TCATCAACTGGCACCTCTCCCCAGAGGACGGCTCCATTGTGTTCAAGGAAGTTGGGTACT
TCATCAACTGGCACCTCTCCCCAGAGGACGGCTCCATTGTGTTCAAGGAAGTTGGGTACT
ACAATGTGTATGCCAAGAAGGGAGAAAGACTGTTCATCAATGA  
A C A A T G TG TATG CCAAG AAG G G AG AAAG ACTG TTCA TCAATG A-3 3 5 0 0 2 9  7
B .  The sequence for the Neo-CaR6HR PCR product (Neo Cassette containing CaR)
corresponded to both cloning vector sequences as well as Car sequences. The initial 
bases 1-111 correspond to several different types of cloning vectors, for simplicity 
only one vector sequence is shown below.
The Neo PCR product sequence to base 111 is in GREEN and the cloning vector, 
pEFBos-IRESGFPNEO, sequence is in BLUE.
GGTTT-CNAATG TG TCAG TTT-NTAG CCTG AAG AACG AG ATCAG CAG CCTCTG TTC CACA  
4 2  7 8 -GGTTTCCAAATGTGTCAGTTTCATAGCCTGAAGAACGAGATCAGCAGCCTCTGTTCCACA
TACACTTCATTCTCAG TA TTG TTTTG CCAAG TTCTAATTCCATCAG AAG CTG
T A C A C T T C A T T C T C A G T A T T G T T T T G C C A A G T T C T A A T T C C A T C A G A A G C T G -4389
246
From base number 112 onwards the Neo-PCR product sequence corresponded to the 
genomic sequence NT_ 039624.7 Mus Musculus chromosome 16 genomic contig, 
strain C57BL/6J as well as the transcript NM_013803.1 Mus Musculus, calcium- 
sensing receptor, mRNA. Neo PCR product sequence is in GREEN and the genomic 
(NT_039624.7) CaR sequence from BLAST search in black.
GTGACCTGGTGGGGAACTACTCCATCATCAACTGGCACCTCTCCCCAGAGGACGGCTCCA
3 3 5 0 0 4 2 3 -
GTGACCTGGTGGGGAACTACTCCATCATCAACTGGCACCTCTCCCCAGAGGACGGCTCCA
TTGTGTTCAAGGAAGTTGGGTACTACAATGTGTATGCCAAGAAGGGAGAAAGACTGTTCA
TTGTGTTCAAGGAAGTTGGGTACTACAATGTGTATGCCAAGAAGGGAGAAAGACTGTTCA
TCAATGA
T C A A T G A -3 3 5  0 0 2  9 7
247
C. S e q u e n c e  f o r  E n s e m b l  T r a n s c r i p t  ID  E N Z M U S T 0 0 0 0 0 0 6 3 5 9 7  
E x t r a c e l l u l a r  C a l c i u m —s e n s i n g  r e c e p t o r ,  M u s  M u s c u l u s
EXON 4
ATGGTTTTGCCAAAGAGTTTTGGGAAGAAACATTTAATTGCCACCTGCAAGACGGCGCA  
AAAGGACCTTTACCCGTGGACACCTTCGTGAGAAGTCACGAGGAAGGCGGCAACAGGTTA  
CTCAATAGCTCCACTGCCTTCCGACCCCTCTGCACGGGGGATGAAAACATCAATAGTGTC  
GAGACCCCTTACATGGACTACGAACATTTACGGATATCCTACAACGTGTACTTAGCCGTC  
TACTCCATTGCGCACGCCCTGCAAGATATATACACCTGCTTACCCGGAAGAGGGCTTTTC  
S P V  PC R  P r o d u c t  S e q u e n c e  : ACCTGCTTACCCGGAAGAGGGCTTTTC  
WT PC R  P r o d u c t  S e q u e n c e  : ACCTGCTTACCCGGAAGAGGGCTTTTC
ACCAACGGGTCCTGTGCAGACATCAAGAAGGTTGAGGCCTGGCAG
ACCAACGGGTCCTGTGCAGACATCAAGAAGGTTGAGGCCTGGCAG
ACCAACGGGTCCTGTGCAGACATCAAGAAGGTTGAGGCCTGGCAG
EXON 5
GTCCTGAAACACCTACGGCACCTGAATTTCACCAACAACATGGGGGAGCAGGTGACCTTC
GTCCTGAAACACCTACGGCACCTGAATTTCACCAACAACATGGGGGAGCAGGTGACCTTC
GATGAGTGCGGTGACCTGGTGGGGAACTACTCCATCATCAACTGGCACCTCTCCCCAGAG
GATGAGTGCGGTGACCTGGTGGGGAACTACTCCATCATCAACTGGCACCTCTCCCCAGAG
GACGGCTCCATTGTGTTCAAGGAAGTTGGGTACTACAATGTGTATGCCAAGAAGGGAGAA
GACGGCTCCATTGTGTTCAAGGAAGTTGGGTACTACAATGTGTATGCCAAGAAGGGAGAA
AGACTGTTCATCAATGAGGGGAAGATCTTGTGGAGTGGGTTCTCCAGAGAG
AGACTGTTCATCAATGAGGGGAAGATCTTGTGGAGTGGGTTCTCCAGAGAG
EXON 6
GTGCCCTTCTCCAACTGCAGCCGGGACTGTCAGGCAGGGACCAGGAAGGGCATCATTGAG
GTGCCCTTCTCCAACTGCAGCCGGGACTGTCAGGCAGGGACCAGGAAGGGCATCATTGAG
GTGCCCTTCTCCAACTGCAGCCGGGACTGTCAGGCAGGGACCAGGAAGGGCATCATTGAG
GGAGAGCCCACCTGCTGTTTTGAGTGTGTGGAGTGTCCTGACGGCGAGTACAGTGGTGAG
GGAGAGCCCACCTGCTGTTTTGAGTGTGTGGAGTGTCCTGACGGCGAGTACAGTGGTGAG
GGAGAGCCCACCTGCTGTTTTGAGTGTGTGGAGTGTCCTGACGGCGAGTACAGTGGTGAG
ACAG
ACAG
ACAG
EXON 7
ATGCGAGTGCCTGTGACAAGTGCCCGGATGACTTCTGGTCCAATGAGAACCACACTTCCT
ATGCGAGTGCCTGTGACAAGTGCCCGGATGACTTCTGGTCCAATGAGAACCACACTTCCT
ATGCGAGTGCCTGTGACAAGTGCCCGGATGACTTCTGGTCCAATGAGAACCACACTTCCT
GCATTGCCAAGGAGATTGAGTTCCTGGCGTGGACTGAGCCCTTTGGAATCGCTCTCACTC
GCATTGCCAAGGAGATTGAGTTCCTGGCGTGGACTGAGCCCTTTGGAATCGCTCTCACTC
GCATTGCCAAGGAGATTGAGTTCCTGGCGTGGACTGAGCCCTTTGGAATCGCTCTCACTC
TCTTTGCGGTGCTGGGCATTTTCCTGACCGCCTTTGTGCTGGGCGTCTTCATCAAGTTCC
TNTTTGCGGTGCTGGGCATTTTCCTGACCGCCTTTGTGC
TCTTTGCGGTGCTGGGCATTTTCCTGACCGCCTTTGTGC
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